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Abstract                                                                                                                                                                                           
 
Background: An unbalanced diet and a sedentary lifestyle are the main 
determinants of obesity and the related metabolic and cardiovascular (CV) 
diseases. Quality of dietary fat, beyond the quantity, can influence CV risk profile 
and in particular omega-3 fatty acids (PUFA) have been proposed as beneficial in 
this setting. The aim of the first study was to evaluate the associations between 
erythrocyte membrane FA, markers of average intake, and individual CV risk 
factors, characterizing the metabolic syndrome (MetS), in a group of 70 obese 
children. In the second study we focused especially on omega-3 and omega-6 
PUFA and their metabolites via CYP450/soluble Epoxide Hydrolase (sEH) in 
relation to blood pressure (BP) and markers of vascular function in the same 
sample of obese children. The aim of the third school-based study was to assess 
the association between body fat distribution, BP and vascular function also in 
relation to erythrocytes membranes PUFA in 309 children aged 8-10 years. 
Results:  Omega-3 Index was low (about 4%) in all children included in the 
studies. In study 1, we found that omega-6 PUFA, especially arachidonic acid 
(AA), were inversely related to most of the characteristics of the MetS: waist 
circumference, triglycerides, insulin, SBP and Fatty Liver Index (FLI), whereas 
saturated FA (SFA) and in particular palmitic acid (PA) were directly related to the 
same features. In the second study, AA was inversely correlated with SBP and 
DBP in the whole population and in normotensive (n: 53/68), whereas in 
hypertensive linoleic acid (LA) was inversely related to SBP and DBP. Omega-3 
PUFA were inversely related to the Reflection Index (RI), an indirect marker of 
relative vasoconstriction, whereas eicosapentaenoic acid (EPA) to the z-score of 
carotid intima-media thickness (cIMT). DiHOMEs, metabolites of LA via 
cytochrome P450/soluble Epoxide Hydrolase (CYP450/sEH), showed a direct 
correlation with office-DBP and nighttime-DBP in the whole sample, but 
especially in normotensives. Only in the hypertensive subgroup, 
epoxyeicosatetraenoic acids (EEQs), metabolites derived from EPA, and 
epoxydocosapentaenoic acids (EDPs), derived from docosahexaenoic acid 
(DHA), were inversely correlated to BP and vascular structure.  In the third study, 
we found a high prevalence of overweight and obesity (19% and 13%, 
respectively). BP was directly related to several anthropometric characteristics and 
indexes of central adiposity showed stronger association in obese children than in 
normal weight subjects. Obese children had higher BP and z-score of PWV in 
comparison to normal-weight children. Omega-6 PUFA inversely correlated with 
triglycerides, whereas omega-3 PUFA with glucose and triglycerides.  
Conclusions: Taken together, our data show a high impact of weight excess on BP 
homeostasis and on arterial stiffness, detectable also in early childhood. Omega-6 
PUFA could exert a beneficial effect on most of the features of MetS, at least in 
obese, whereas the role of omega-3 PUFA, whose assumption appeared very low, 
and of their metabolites via CYP450 resulted of minor importance or confined to 
specific subgroups. Further investigations are needed to better clarify the role of 
omega-6/omega-3 PUFA and their derived metabolites via CYP450/sEH in BP 
homeostasis and MetS in children as well as in adults. 
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Introduction 
Definition and prevalence of obesity in children 
 
Since the last 90s, the Word Health Organization (WHO) has started to claim that 
overweight and obesity were representing an increasing epidemics not only in 
adults but even in children. Since the 70s, the prevalence of obesity and its 
associated comorbidities, including type 2 diabetes, has been rising[1]. Anyhow, 
the different definitions of obesity and different national reference values make it 
difficult to quantify the real prevalence and incidence of obesity worldwide[2]. In 
adults, the cut-off points for the definition of overweight and obesity, namely a 
body mass index (BMI) higher than 25 and 30 kg/m2 respectively, are generally 
accepted[3]. In children, BMI changes with age and therefore the International 
Obesity Task force (IOTF) suggested to link the adult cut-off points to the BMI 
centiles for children, thus identifying specific values for each age and sex[4]. 
To date two international datasets are used to define overweight and obesity in 
children: the IOTF reference and the WHO standards, which present some 
discrepancies due to the different populations and the choice of cut-off points. 
Some comparison studies have shown that WHO standards tend to overestimate 
the body weight excess as compared to IOTF reference[5]. 
According to current guidelines, the 85th percentile of BMI is the threshold for 
overweight and obesity is defined over the 95th percentile[6,7]. 
Regarding adulthood, it has been estimated that the prevalence of obesity in 2014 
was 10.8% in men and 14.9% in women and severe obesity (i.e.  BMI> 35 Kg/m2) 
was 2.3% and 5.0%, respectively[8]. 
Large surveys have collected data for children aged 0 to 5 years old, whereas the 
studies in children older than 5 years and in adolescents are smaller. The available 
data indicate that in the last three decades the prevalence of obesity has risen not 
only in industrialized Countries but also in low and middle-income Countries. 
In 2004, the prevalence of overweight and obesity worldwide was 10% and 2-3%, 
respectively[9]. 
In the U.S.A. the prevalence of weight excess in school-aged children in 2003–
2004 was 35% and obesity accounted for 13%[9]. In eight European countries 
between 2007 and 2010, 18,745 children participated in the IDEFICS Study that 
reported a combined prevalence of overweight and obesity of more than 40% in 
southern Europe and less than 10% in Northern Countries. The prevalence of 
overweight was, overall, higher in girls (21.1%) than in boys (18.6%)[10]. 
In Italy, the data collected in 8-9 years-old children from the national surveillance 
system "Okkio alla salute" reported a prevalence of overweight and obesity of 
23.3% and 12.0%, respectively, in 2008-2009, which slightly decreased to 22.2% 
and 10.6%, in 2012. As in Europe, even in Italy a North-South gradient was 
detectable, showing higher prevalence of weight excess in southern regions. The 
estimated prevalence of severe obesity in 2010 in children aged 8-9 year-old was 
4.5% according to the WHO definition and 2.7% with IOTF reference[11]. 
A few studies investigated the prevalence of obesity in school children. 
In a Chinese sample of 88,974 adolescents from 49 middle schools, 14.6% of 
male and 8.6% of girls were overweight, 7.0% of boys and 2.9% of girls were 
obese, according to Chinese reference data. The prevalence of pre-hypertension 
and hypertension was 7.2% and 3.1%, respectively[12]. Similar results of 
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overweight/obesity prevalence were found also in another large school-based 
study in Shanghai, China[13]. A large multicentric study reported the prevalence 
of overweight in school-aged children of 13 European countries, which ranged 
from 7% to 23% across the different countries[14]. In Italy a cross-sectional 
survey of childhood obesity was performed on 3923 children aged 6-11 years 
from 19 schools. 26.7% of boys and 25.2% of girls were overweight, 21.1% of 
boys and 20.7% of girls were obese. The prevalence of hypertension was 9.9% in 
boys and 13.9% in girls[15]. 
 
 
 
Figure 1. Reproduced from Lobstein T et al., Lancet 2015[16] 
Trend in obesity and overweight prevalence in USA and in 8 low-income and middle –income 
countries 
 
 
Comorbidities associated to obesity 
 
Obesity is associated with a wide range of metabolic and hemodynamic 
alterations in children as well as in adults. Atherosclerotic process begins in early 
childhood, as documented in autoptic studies that identified atherosclerotic lesions 
in the aorta and in coronary artery in 3 years-old children[17] and the extent of the 
lesions was associated with obesity degree and others cardiovascular risk 
factors[18].  
Previous studies in obese children have documented an impairment of vascular 
function tests, like an increase in intima-media thickness, impairment of 
endothelial function, higher arterial stiffness[19,20] leading to higher blood 
pressure levels[21]. Some data suggest that weight excess during childhood is 
associated with dyslipidemia in adulthood[19]. Moreover, obesity in adolescents 
is associated with glucose intolerance and insulin resistance[22,23]. Obesity, and 
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in particular central distribution of the fat, is associated with higher cardiovascular 
risk profile through the clustering of CV risk factors that lead to the metabolic 
syndrome. Non-alcoholic fatty liver disease (NAFLD) can be considered the 
hepatic manifestation of MetS because of the common risk factors and in 
particular insulin sensitivity. MetS in adults has been defined as the cluster of 
abdominal obesity, high triglycerides and low HDL-cholesterol levels, high blood 
pressure and type 2 diabetes or impaired fasting glucose, whose cut-off points are 
clearly stated[24]. In children, there is not yet a consistent set of cut-off points and 
the definition of MetS is still under evaluation.  
Hypertension in children and adolescents 
Elevated blood pressure is often detected in childhood due to the raise in the 
incidence of obesity and to the major attention on the detection of this condition 
also in children. Indeed, longitudinal studies demonstrated that children and 
adolescent with elevated blood pressure often become hypertensive adults[25]. 
Diagnostic criteria for hypertension in children are based on the influence of age 
and anthropometric characteristics on blood pressure, thus needing individualized 
cut-off points for the different ages and growth development. The current 
European guidelines suggest the adoption of normative values based on data 
collected from more than 70,000 children of United States using auscultatory 
method, with cut-off calculated for age, sex and seven height percentile[26]. 
Hypertension in children aged 1 to 16 years is defined as SBP and/or DBP 
persistently at least 95th percentile measured in three separate occasions, whereas 
high-normal BP is defined for SBP and/or DBP between 90th and 95th percentile. 
For older adolescents instead, current European guidelines suggest to use the 
absolute cut-off used for adult, thus defining high-normal blood pressure for SBP 
and/or DBP 130-139/85-89 mmHg and hypertension for SBP and/or DBP higher 
than 140/90 mmHg[26]. Very recently, the American Academy of Pediatric 
recently published new clinical practice guidelines for screening high BP in 
children and adolescents, proposing significant changes as compared to the 
European guidelines[27]. In particular, different cut-off points for children above 
and below 13 years were suggested and new normative tables based on normal-
weight children were proposed, beside other important modification in performing 
screening BP measurements and target organ damage evaluation.  
Lifestyle and obesity 
Sedentary habits and an unhealthy diet are the main determinants of obesity. In 
high-income Countries and in several developing countries lifestyle changed in 
the last few decades determining a reduction in energy expenditure ad an increase 
in caloric intake due to a higher amount of fat and carbohydrates. Increasing 
evidence have shown that not only a rich fat diet, but also the quality of fat, can 
influence the onset of obesity. In particular, a high amount of saturated fatty acids 
and a lower amount of unsaturated fatty acids contribute to the onset and 
maintenance of body weight excess[28]. Indeed, in the last century the Western 
Countries diet increased the total amount of fat and in particular of saturated fatty 
acids and shifted the ratio between omega-6 PUFA and omega-3 PUFA from 1-
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2:1 to 15-20:1, which is thought to increase the susceptibilities to cardiovascular 
disease and other chronic inflammatory disease[29,30]. 
In the following paragraphs it will be discussed the biochemical and clinical 
characteristics of omega-3 and omega- 6 PUFA and pointed out the evidence in 
children. 
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Biochemical characteristics and dietary sources of Omega-3 PUFA 
 
Fatty acids are a wide family of compounds with important and manifold 
biological activities. The difference in chain length and saturation status 
determines their biochemical characteristics and their biological role. Omega-3 
(omega-3) fatty acids are a family of long-chain fatty acids containing more than 
one carbon-carbon double bond (polyunsaturated fatty acids, PUFA). The main 
members of this family are α-linolenic acid (ALA, C 18:3), eicosapentaenoic acid 
(EPA, C 20:5) and docosahexaenoic acid (DHA, C 22:6)[31]. ALA is an essential 
nutrient for mammals because they lack enzymes where to insert the double bond 
in omega-3 position; the main dietary sources are plants and plant oils, such as 
soybean oil, flaxseed oil, canola oil and walnuts[32]. 
In mammals ALA can be converted to EPA, but only in small percentage, and the 
conversion of EPA to DHA, if any, is very limited[33]. Accordingly EPA and 
DHA are considered essential fatty acids, deriving mainly from sea-food, 
especially high-fat cold-water fish, such as salmon, mackerel, herring and 
trout[32]. 
Most of the clinical trials carried out to investigate the potential benefits of 
omega-3 PUFA in adults and in children have used fish oil as supplements of 
omega-3 PUFA, however in the last few years the attention was focused also on 
alternative sources of omega-3 fatty acids, like krill oil, vegetable oils, nuts and 
algae[34,35]. 
EPA and DHA enter the food chain trough marine phytoplankton, proceeding 
through marine mammals and fish, which represent the main dietary source for 
humans[32]. 
In natural fish oil EPA and DHA are bond in triacylglycerides (TG). Fish oil 
capsules are concentrates of marine oils, containing 30-90% of EPA and DHA 
generally bond in ethyl-ester (EE) or re-esterified TG (rTG)[36,37]. 
Because of the reported health benefits of EPA and DHA, there is an increasing 
demand for products rich in marine Omega-3 PUFA and krill oil is an effective 
sources of these fats. 
Krill are small red-coloured crustaceans (Euphausia superba) representing the 
most dominant members of Antarctic zoo-plankton[35]. They are rich in long-
chain polyunsaturated fatty acids, 40% of which are EPA and DHA, in form of 
phospholipids (PL). In addition to Omega-3 PUFA, krill oil contains carotenoid 
astaxanthin, a potent antioxidant, vitamins A and E, and other fatty acids[38]. 
The American Food and Drug Administration has classified krill oil as Generally 
Recognized as Safe and previous clinical and pre-clinical trials have shown that it 
is safe and well tolerated[38]. Only a few studies have tested the efficacy of krill 
oil compared with fish oil and the results go in the direction of a possible stronger 
effect in raising plasma and red blood cell membrane EPA and DHA[35,37,38]. 
10 
 
ALA occurs in vegetable food such as nuts, flaxseeds and vegetable oils like 
canola oil and soy-bean oil, which represent the main sources of Omega-3 in 
vegetarian diets. However the bioavailability of vegetable Omega-3 FA remains a 
matter of debate and seems to limit their use as supplements[34]. Indeed, most 
studies using vegetable sources of Omega-3 (mainly flaxseed oil) report an 
increase in plasma and red blood cell membranes content of ALA and partially of 
EPA but not of DHA[39–42]. Moreover findings from short and long-term trials 
with ALA supplements do not show clear evidence of a protective action in 
cardiovascular risk and therefore the question whether ALA supplements could be 
important for cardiovascular health remains unanswered[43]. 
Observational studies and clinical trials suggest a protective effect of nuts 
consumption on coronary heart disease and some intermediate biomarkers, such 
as blood cholesterol and blood pressure[44–46]. The beneficial effect of nuts can 
be mediated through several mechanisms: nuts are rich in PUFA, with a different 
content of Omega-6 and Omega-3 in the various types, and in addition they 
contain fiber, vitamin E, magnesium, potassium and arginine that can contribute 
to the blood pressure and lipid lowering effect[47].   
In the last few years increasing interest was focused on algal DHA-rich oil 
supplementation: clinical trials reported an increase in plasma and red blood cell 
DHA content after algal oil supplements, but not of EPA or ALA[34] and, even if 
in small number, indicate comparable efficacy to fish oil in potential beneficial 
changes in some markers of cardiovascular risk, in particular on plasma lipid 
profile [43]. 
 
Mechanism of action of omega-3 PUFA 
Omega-3 PUFA exert their biological activities through three main classes of 
mechanisms: some biological effects depend on their incorporation into cell 
membranes, other effects derive from a direct interaction with ion channels and 
other cellular components and, finally, EPA and DHA are the parental compounds 
of bioactive lipid mediators[32]. The exact mechanisms are not yet completely 
understood, especially it is not clear whether EPA and DHA share the same 
pathways or not[48].  
Omega-3 PUFA  can attenuate the response of T-cells and macrophages through 
cell surfaces receptors, not yet identified, perhaps by changing the composition of 
membrane microdomains[49]. A direct interaction with some cellular components 
can mediate some short-term effects such as the antiarrhythmic effect, which 
depends on a steric interference with ion channels[50], for example the inhibition 
of the fast, voltage-dependent sodium and L-type calcium currents[49]. Non-
esterified Omega-3 PUFA can also directly interact with peroxisome proliferator-
activated receptors (PPARs) and others transcription factors, thus modulating 
gene transcription[48]. Recently a role of GPR120 has been discovered, a member 
of the family of fatty acid sensing G-protein-coupled receptors (GPCR), 
mediating the anti-inflammatory and insulin-sensitizing effects of Omega-3 
PUFA[51]. 
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Other proteins that can be directly activated by AA and Omega-3 FA, and 
consequently probably influenced by their ratio, are protein Kinase C, NADPH-
oxidase and a two-pore domain K+ channel[49]. 
Incorporation of EPA and DHA into cell membranes can modulate the properties 
of lipid rafts and thus alter the membrane fluidity, affecting hormone receptor 
binding and the function of membrane-associated proteins[32]. 
Moreover, EPA and DHA, mostly incorporated into the second position of 
membranes phospholipids, can be released by phospholipase A2 (PLA2) and 
converted to a variety of eicosanoids and other lipid mediators through three 
different metabolic pathways. The first two pathways involve cyclooxygenase 
(COX) and lipoxygenase (LOX), leading to the formation of prostaglandins, 
thromboxanes, and leukotrienes; the third branch is catalyzed by cytochrome P 
450 (CYP450) leading to the formation of eicosanoids.  
Therefore EPA and DHA share the same metabolic pathways of arachidonic acid 
(AA) and, moreover, it has been shown that they compete with AA for binding 
with these enzymes, thus inducing profound changes in metabolites biosynthesis 
that could in part explain the beneficial actions of Omega-3 compared to Omega-6 
FA[48]. The competition of EPA and DHA with AA may determine the synthesis 
of TXA3, almost inactive, instead of TXA2, which has pro-aggregatory 
properties. Furthermore, starting from Omega-3 FA the metabolism via COX lead 
to the formation of PGI3 that share the antiaggregatory effect of the AA-derived 
PGI2. The metabolism of EPA via LOX determine the biosynthesis of LTB5, less 
potent than the pro-inflammatory AA-derived LTB4. 
Moreover, Omega-3 PUFA are also the precursors of novel families of 
compounds, the so-called resolvins, protectins and maresins, with anti-
inflammatory and pro-resolving properties[52]. In particular EPA and DHA, 
through the complex metabolism involving COX-2 and aspirin-dependent 
formation of intermediate metabolite, followed by a conversion via LOX, are 
metabolised to the E-series of resolvins, starting from EPA, and to D-series of 
resolvins, protectins and maresins from DHA, which counteract the excessive 
inflammatory while regulating the trafficking of leukocytes and stimulating non-
inflammatory phagocytosis of apoptotic neutrophils by macrophages[53].  
CYP enzymes accept EPA and DHA as efficient substrates alternative to AA. 
CYP epoxygenases produce epoxyeicosatrienoic acids (EETs) from AA, 
epoxyeicosatetraenoic acids (EEQs) from EPA and epoxydocosapentaenoic acids 
(EDPs) from DHA. CYP hydroxygenases lead to the biosynthesis of 20-
hydroxyeicosatetraenoic acid (20-HETE) from AA, 20-hydroxyeicosapentaenoic 
acid (20-HEPE) from EPA and 22-hydroxydocosahexaenoic acid (22-HDoHe) 
from DHA[48]. The role of epoxy- and hydroxy-metabolites of AA in 
cardiovascular function is well known: EETs are mainly involved in 
antihypertensive and organ-protective mechanisms, in particular they determine 
vasodilatation in the systemic vascular system, natriuresis in the kidney and act as 
endothelium-derived hyperpolarizing factors. 20-HETE is involved in both anti- 
and pro-hypertensive mechanisms, depending on the site of formation and action. 
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It shares with EETs the natriuretic effect but determines vasoconstriction in the 
vessels[52]. 
The evidence shows that LOX, COX and CYP enzymes have the ability to 
metabolize EPA and DHA instead AA, but the relative efficiencies are not well 
understood. EPA and DHA are generally considered as poor substrates for LOX 
and COX, compared with AA, whereas they are efficiently metabolized by CYP 
enzymes with similar or higher rates, compared with AA[48]. A recent study on 
20 healthy volunteers indicate that CYP epoxygenases metabolize EPA with an 
8.6-fold higher efficiency and DHA with a 2.2-fold higher efficiency than AA, 
whereas the effects on leukotriene, prostaglandin E, prostacyclin, and 
thromboxane formation remained rather weak[54]. The evidence of the clinical 
significance of EPA/DHA metabolism via CYP450 under in vivo conditions is 
still rare and further investigation is needed.  
In animal models, the biological activities of these compounds are partially 
overlapped to the AA-derived counterparts and partially specific: EEQs and EDPs 
can be as strong as EETs in vasodilation or even stronger in some vascular beds 
like cerebral and coronary vessels[55,56]. In an animal model of angiotensin II-
dependent hypertension it has been shown a possible role of one EDP isomer as a 
mediator of the antihypertensive effect of DHA[57]. Some EPA-epoxydes exert 
anti-inflammatory properties like some EETs regioisomers[58]. Moreover some 
regioisomers of EEQs and EDPs modify the contractility of neonatal 
cardiomiocytes, indicating a possible antiarrythmic effect[59]. 
The suggested hypothesis is that CYP-dependent epoxy-metabolites of EPA and 
DHA may contribute to the vasodilatory and cardioprotective effects of Omega-3 
fatty acids and could also serve as biomarkers of EPA/DHA supplementation. 
Finally, the results of a recent randomized controlled trial on patients with 
peripheral vasculopathy suggest another possible mechanism: after 6 months 
flaxseed oil supplementation, rich in ALA, plasma eicosanoid profile changed 
with a decrease in soluble epoxide hydrolase products compared with controls and 
these subjects exhibited a significant decrease in systolic BP. The authors’ 
conclusion is that flaxseed oil may inhibit soluble epoxide hydrolase thus 
modifying the lipid mediator concentrations that can contribute to the 
antihypertensive effect[60].  
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Figure 2. Reproduced with permission from De Caterina R, NEJM 2011, Copyright Massachusetts 
Medical Society [32] 
Metabolic pathways involve reactions catalyzed by conversion through cyclooxygenase-1 (COX-
1), cyclooxygenase-2 (COX-2), and lipoxygenases to eicosanoids, which include prostaglandins, 
thromboxanes, and leukotrienes in different cell types. When released from membrane 
phospholipids, n–3 fatty acids can give rise to a host of novel eicosanoid derivatives through 
metabolism catalyzed by several lipoxygenases, modified cyclooxygenases, and the cytochrome 
P450 system, producing hydroxy- and hydroperoxy-derivatives, as well as lipoxins, maresins, 
protectins.  
COX-2 denotes cyclooxygenase-2, cPLA2 cytosolic phospholipase A2, EET epoxyeicosatrienoic 
acid, GSH glutathione, HPETE hydroperoxy-eicosatetraenoic acid, LT leukotriene, PAF platelet-
activating factor, PG prostaglandin,  DHA docosahexaenoic acid, DiHDHA dihydroxy-
docosahexaenoic acid, DiHp-ETE dihydroperoxy-eicosatetraenoic acid, EPA eicosapentaenoic 
acid, HETE hydroxy-eicosatetraenoic acid, HpDHA hydroperoxy-docosahexaenoic acid, HpEPE 
hydroperoxy-eicosapentaenoic acid, HPETE hydroperoxy-eicosatetraenoic acid, LOX 
lipoxygenase, NPD1 neuroprotectin D1, and RV resolvin.  
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Clinical effects of omega-3 PUFA 
Omega-3 FA have a wide range of actions as follows: they may act on the vessels 
by improving the endothelial function and elastic properties of the arteries [61], 
exerting a favorable effect on the autonomic system and reducing platelet 
aggregation [62], exerting anti-arrhythmic action by increasing the arrhythmic 
thresholds [63] and playing an important role in the modulation of the 
inflammatory response [64]. Finally, they may improve the serum lipid profile 
[65]. In summary, the rising interest in omega-3 FA is due to their pleiotrophic 
effects and to the possible eventual protective effect on cardiovascular disease, 
although the available data are not always consistent. In fact, despite 
observational studies that have mostly shown a protective effect, the results from 
randomized controlled trials (RCT) have not always been uniform and successive 
meta-analyses have questioned the presence of a large omega-3-FA effect in at-
risk populations. 
For example, a recent large prospective study conducted on healthy older adults 
investigated the role of omega-3 FA consumed through the typical diet in primary 
prevention. The results showed that plasma omega-3 FA, considered as single FA 
(EPA, DHA and DPA) and total omega-3 FA, were associated with lower total 
mortality, largely dependent on fewer cardiovascular deaths and in particular 
fewer arrhythmic deaths [66]. Moreover, total mortality was inversely associated 
with EPA and DHA in a linear fashion, whereas the inverse association with total 
omega-3 FA was not linear, in accord with previous studies [67]. However, it 
should be considered that circulating FA are influenced by short-term fluctuations 
in dietary FA consumption, which probably affects the true relationship between 
plasma FA and mortality.  
Additionally, some large interventional trials supported the beneficial effect of 
omega-3 FA in cardiovascular disease as follows: in the GISSI-Prevenzione trial, 
the treatment by omega-3 FA lowered the risks of death, non-fatal myocardial 
infarction and stroke in a sample of 11,324 patients surviving a recent myocardial 
infarction [68]. Another trial, investigating the effect of EPA supplementation in 
primary prevention in 14,981 hypercholesterolemic subjects on statin therapy, 
indicated a reduction in the incidence of coronary artery disease, particularly in 
the patients with a high-risk dyslipidemic pattern (high triglyceride level and low 
HDL-cholesterol level) [69]. Regardless, recent meta-analyses, including a large 
number of primary studies, have not demonstrated unequivocal results concerning 
cardiovascular risk [70–72]. In a systematic review and meta-analysis, including 
20 studies with a total of 68,680 patients, omega-3 FA supplements were not 
associated with a lower risk of all-cause mortality, cardiac or sudden death, 
myocardial infarction or stroke [70]. Another meta-analysis, including 14 
randomized placebo-controlled trials involving 20,485 patients with a history of 
cardiovascular disease, reported insufficient evidence of a beneficial effect of 
omega-3 FA supplements in secondary cardiovascular prevention [72]. However, 
it is worth considering that the trials included in the meta-analysis had a short 
follow-up period (2 years or less) and that the above-mentioned large trials 
[68,69] with positive findings were excluded from some meta-analyses because 
they were not placebo-controlled, suggesting a cautious interpretation of the 
results. The most recent meta-analysis on the same topics arrived at the same 
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conclusion when considering the association between coronary risk and fatty acids 
from dietary intake, assessed by questionnaire or using dietary records, or by 
circulating levels of fatty acids. Comparing the participants in the top third to 
those in the bottom third, dietary long-chain omega-3 FA and plasma levels of 
EPA and DHA were associated with a nearly 13% lower coronary risk[73]. When 
assessing the effect of omega-3 FA supplements in RCT, no significant reduction 
in coronary risk was found[73]. 
Uncertainty also remains regarding the relationship between fish or omega-3 FA 
consumption and cerebrovascular disease. A systematic review and meta-analysis 
of 26 prospective cohort studies and 12 RCT, which investigated the relation 
between the risk of cerebrovascular disease and omega-3 FA and fish 
consumption in primary and secondary prevention, showed the presence of a 
moderate, inverse association [74]. The analysis of the prospective trials indicated 
a protective effect of fish intake with regard to the risk of cerebrovascular disease 
in the general population and showed that an increment of fish intake (at least 2 
servings per week) reduced cerebrovascular risk by 4%. Interestingly, the analysis 
of the different type of fish consumed showed a possible favorable effect of fatty 
fish, whereas such findings were not significant for white fish. Conversely, the 
RCT analysis of omega-3 FA supplementation did not indicate any significant 
correlation with cerebrovascular risk [74].  
The evidence concerning the beneficial effect of EPA/DHA on BP appears clear 
as follows: many interventional studies with fish oil have suggested a beneficial 
effect of omega-3 supplements on BP control, particularly in hypertensive 
subjects, with a possible threshold effect. The first meta-analysis to show a 
positive antihypertensive action of omega-3 FA in hypertensive patients, 
compared to normotensive subjects, was reported by Morris et al. in 1993 [75]. 
These results were consistent with a subsequent meta-analysis of 36 studies 
evaluating a total sample of 2,114 subjects receiving high doses of fish oil (mean 
dose 4.1 g/day) as follows: fish oil significantly reduced BP (SBP - 2.1 mmHg 
and DBP - 1.6 mmHg), with a stronger effect in hypertensive and older (> 45 
years) subjects. Interestingly, no dose-response relationship was observed and the 
effect of low doses (< 500 g/day) of omega-3 supplements remains unclear [76]. 
They observed a dose-response effect when the studies were grouped by Omega-3 
FA dose; however, it should be emphasized that the omega-3 dose was relatively 
high in the group receiving the lowest dose (up to 3 g/day).  
The most recent meta-analysis examined 70 randomized controlled trials with 
EPA + DHA supplements in hypertensive and normotensive subjects [77]. The 
mean dose of EPA and DHA was 3.8 g/day, deriving mostly from fish oil and also 
from EPA- and DHA-fortified foods, seafood and algal oil. Omega-3 supplements 
provided a reduction in systolic BP (SBP) of 1.52 mmHg and diastolic BP (DBP) 
of 0.99 mmHg in the meta-analysis of all studies with hypertensive and 
normotensive subjects, compared with placebo (mostly olive oil and other 
vegetable oils). The analysis of untreated hypertensive subjects showed the 
strongest effect for EPA+DHA in lowering BP, compared to normotensive 
subjects [77].  
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Prospective cohort studies have also examined the impact of the omega-3 FA 
dietary content on the development of hypertension in normotensive subjects, 
with some finding an inverse association [78,79] and others no association[80,81]. 
A meta-analysis, including 8 of these studies with approximately 56,000 subjects 
followed up for 3 to 20 years, showed that the subjects with the highest dietary 
consumption of omega-3 FA, as determined by plasma or erythrocyte fatty acid 
content, had a lower risk of developing hypertension compared to subjects with 
the lowest intake[82]. Interestingly, this finding supports the hypothesis of a 
stronger protective effect for DHA in primary prevention. 
A recent study on 312 subjects, evaluating the impact on BP of lower doses of 
EPA + DHA (0.7 and 1.8 g/day, respectively), which are more easily achievable 
through dietary modification, showed that only patients with isolated systolic 
hypertension exhibited a significant reduction in SBP (- 5 mmHg)[83]. 
Current guidelines by the American Heart Association Nutrition Committee 
suggest the consumption of at least 2 servings of fish per week for primary 
cardiovascular prevention and Omega-3 supplements for secondary prevention 
[84,85]. Regarding BP, the European Society of Hypertension (ESH) and of the 
European Society of Cardiology (ESC) guidelines published in 2013 recommend 
that patients with hypertension eat fish at least twice a week[86], without 
specifying the type of fish, whereas the 7th and 8th Joint National Project reports 
mention neither fish nor omega-3 FA[87,88]. 
In addition to the actions of EPA and DHA, recent studies found a BP-lowering 
effect of flaxseed oil, which is rich in ALA as follows: in a double-blind, placebo-
controlled RCT (FlexPAD trial) in 110 patients with peripheral artery disease 
(PAD), the treated group (30 g/day of flaxseed) showed an increase in plasma 
ALA, which was inversely associated with BP, and they exhibited a decrease in 
SBP and DBP after 6 months that was significant in hypertensive patients [89]. A 
subsequent study on the same population in the FlexPAD trial moreover displayed 
a reduction in central SBP and DBP after flaxseed supplementation[90]. 
The possible stronger effect of dietary fish on BP, compared to EPA/DHA 
supplementation, raises some unanswered questions. First, it warrants 
consideration that the biological role of single nutrients probably cannot be 
separated from the wide range of other substances contained in a food. For 
example, fish is rich in vitamins [91], amino acids [92] and some trace elements 
[93] that may also exert favorable vascular effects. Second, the intake of certain 
foods should be assessed in the context of the whole diet, considering the balance 
between the different nutrients that may exert a variety of actions and interactions. 
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Vascular effects of omega-3 FA 
A clinically relevant action of omega-3 FA is the BP-lowering effect, which is 
believed to derive from reduced systemic vascular resistance and improved 
endothelial function, thus interfering with the atherosclerotic process [94]. The 
modulation of vascular functions remains, in our opinion, one of the key aspects 
of cardiovascular protection by omega-3 FA.  
Studies on animal models suggest that EPA, but probably not DHA and DPA, 
may induce Ca++-independent activation and translocation of endothelial nitric 
oxide synthase (eNOS) with consequent endothelium-dependent vasodilation [95]. 
In vivo, EPA induces an increase in eNOS phosphorylation via the up-regulation 
of uncoupling protein-2 (UCP-2) and activation of AMP-activated protein kinase 
[96]. In the past few decades, dozens of studies in humans were conducted with 
divergent results concerning the effect of omega-3 FA on endothelium-dependent 
vasodilation, whereas no effect was consistently observed regarding omega-3 FA 
supplements on endothelium-independent dilation. Two meta-analysis, including 
16 clinical trials, show improvement in endothelial function after omega-3 FA 
supplementation [97,98]. However, this result warrants a careful evaluation as 
follows: first, in the meta-analysis conducted by Wang and colleagues, in addition 
to trials with EPA + DHA, studies with ALA supplements were also included, 
whereas Xin and colleagues considered only EPA + DHA supplementation for the 
analysis. Moreover, the sample size in most of the primary studies was low, and 
the significance of the results appeared mainly dependent on the contribution of 
the low-quality studies[99,100]. Regardless, both meta-analyses included a high-
quality randomized double-blind trial in 312 healthy non-smoking subjects with 
increasing doses of EPA + DHA (0.45, 0.9 and 1.8 g/day)[101]. Compliance with 
the intervention was verified by a significant increase in the EPA and DHA 
content of red blood cell membranes; however, endothelial function, as measured 
by Flow Mediated Dilation (FMD), was not related to EPA+DHA intake[101]. 
Thus, further studies and large-scale RCT remain required to define the role of 
omega-3 FA on endothelial function. Moreover, the evidence concerning the 
effect of EPA and/or DHA on arterial stiffness suggests a possible protective 
effect, though the clinical significance remains to be clarified. The largest 
observational study was conducted in a subcohort of the Framingham study, 
including 3,055 subjects as follows: a moderate association between red blood cell 
omega-3 FA content and several measures of arterial stiffness was observed, in 
particular, the carotid-femoral pulse wave velocity, which is considered the gold 
standard index of aortic stiffness. However, after multivariable adjustment, only a 
modest correlation between higher omega-3 content in red blood cell membranes 
and lower aortic stiffness remained [102]. A recent small interventional study on 
29 subjects receiving EPA + DHA supplements (2 g/day) reported a significant 
improvement not only in flow-mediated dilation but also in pulse wave velocity, a 
measure of aortic stiffness [103]. Despite the scarce and mostly underpowered 
RCT in humans, a recent meta-analysis appears to confirm the association 
between omega-3 FA supplements and arterial stiffness and arterial compliance; 
interestingly, the results were not affected by BP changes, indicating a possible 
BP-independent effect of omega-3 FA on arterial function [104].  
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Moreover, epidemiological and experimental studies suggest that EPA and DHA 
are associated with less vascular calcification, probably due to their preventive 
effect on tissue remodeling [105–107]. 
A population-based observational study on 1,570 subjects in the Netherlands 
investigated the correlation between fish and EPA + DHA intake, assessed using a 
170-item semiquantitative food-frequency questionnaire and coronary 
calcification measures determined by CT scanning according to Agatston’s 
method. The investigators found that subjects with a higher fish intake had a 
significantly lower prevalence of mild to moderate coronary calcification 
compared to subjects who did not consume fish, whereas EPA + DHA intake 
showed no significant association [108]. No interventional trials on humans are 
available to date to determine the effect of EPA and DHA on vascular 
calcifications. 
Clinical effects of omega-3 in children 
 
The incidence of obesity and type 2 diabetes reported in children has increased in 
the last few decades and it has been shown that obesity plays a pivotal role in the 
development of insulin resistance, which is related to hyperinsulinemia, 
hypertension, hyperlipidemia, type 2 diabetes and increased risk of atherosclerotic 
disease. Moreover considerable evidence shows that overweight in childhood and 
adolescence is associated with insulin resistance, dyslipidemia and high blood 
pressure in young adults[109].  
In the last few years, there has been emerging interest also for the possible 
beneficial effect of Omega-3 in childhood with respect to cardiovascular risk 
factors.  
Some observational studies and a limited number of interventional studies indicate 
a positive effect of Omega-3 supplements on blood pressure control, even if the 
data currently available are small and not unequivocal (see Table 1). A recent 
cross-sectional study on seventy-three 8-11 year-old Danish children shows a 
positive association of mean arterial pressure with whole-blood DHA only in boys 
and this correlation remains also after adjustment for energy intake, body-fat 
percentage and physical activity. OMEGA-3 FA were measured in whole-blood 
and were found to be associated with fish intake, recorded for 7 days by a Web-
based dietary assessment specifically for children[110].These findings were in 
agreement with a previous randomized trial of the same group, showing a 
decrease in systolic blood pressure in healthy 12-mo children (n=83), after 3 
months of fish oil supplements (mean estimated EPA and DHA assumption: 924 
mg/day). Infants were randomly assigned to fish oil supplements or not and to two 
different milk types and the effect of fish oil supplementation was adjusted for the 
effects of milk intervention. The fish oil supplements were also inversely 
associated with plasma triglycerides and directly with total cholesterol and LDL 
cholesterol[111]. A positive effect on systolic and diastolic blood pressure was 
found also in adolescent boys aged 13-15 after a 16-week fish oil supplementation 
(1.5g EPA and DHA) compared with the control group receiving vegetable 
oil[112]. In contrast, a cross-sectional study in a hundred and nine 17 year-old 
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adolescents found a poorer metabolic profile, included higher systolic blood 
pressure levels, associated with a higher DHA content in red blood cell 
membranes, which remained also after adjustment for physical activity and 
dietary factors [113]. 
Data from the National Health and Nutrition Examination Survey indicate that a 
higher dietary intake of EPA and DHA, recorded by two 24-hours dietary recall, 
in 354 children, aged 8-15 years, born with reduced birth weight, are associated 
with lower systolic blood pressure and pulse pressure[114]. These findings were 
consistent with a previous exploratory analysis, which showed a significant 
inverse association of serum Omega-3 PUFA with systolic blood pressure in 
young adults, aged 24-39 years, born with impaired foetal growth[115]. These 
data suggest that Omega-3 PUFA could play a role in blood pressure control in 
subjects with low birth weight, which is a known factor independently associated 
with an increased risk of cardiovascular events in adulthood[116]. 
A cross-sectional study performed on 814 Australian adolescents (13-15 year-old) 
suggests a possible role of gender in modulating the relationship between Omega-
3 FA and blood pressure: systolic and diastolic blood pressure were inversely 
associated with EPA and DHA intake, assessed with a 3-day diet record, in boys 
but not in girls[117]. 
Furthermore, an association between blood pressure and the Omega-3 content was 
found in boys but not in girls also in the above mentioned cross-sectional study 
conducted by Damsgaard[110] and in a trial in breast-fed infants of mother 
receiving Omega-3  supplements, but the latter found an unfavourable relation of 
fish oil supplements with blood pressure control[118]. 
Some studies have investigated the long term effect of Omega-3 FA supplements 
administered in early infanthood through lactation or to the mothers during 
pregnancy but the results are not unequivocal. The interest stemmed from 
evidence that breast feeding, rich in EPA and DHA, in contrast to the first formula 
milk, is associated with lower blood pressure in childhood and 
adulthood[119,120]. 
In an interventional study, children who received human milk with an Omega-3 
FA content above the median had a nearly 5 mmHg lower systolic and 2.5 mmHg 
diastolic blood pressure at the age of 12 years compared with never breast-fed 
children, but Omega-3 FA content below the median in the milk was not 
associated with blood pressure levels at 12 years[121]. In contrast, in a previous 
trial boys of mother receiving fish oil supplements during the first 4 months of 
lactation showed a higher diastolic blood pressure at the age of 7 years compared 
with the olive oil control group[118].  
In another study investigating the long-term effects of Omega-3 supplements, the 
supplements of Omega-3 FA from infancy to 5 years (canola oil and tuna oil), 
with a contemporary reduction of omega-6 FA assumption in order to provide an 
Omega-3 to Omega-6 ratio of 1:5, do not affect blood pressure and vascular 
structure at the age of 8 years, even if the concentration of Omega-3 FA in the 
plasma were higher in the intervention group compared with controls[122]. 
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Omega-3 FA supplements are effective in lowering triglyceride levels in adults, 
therefore in international guidelines their consumption is suggested for patients 
who need to lower triglycerides. No effects on the other plasma lipid levels such 
as cholesterol are evident in adults. Little is known about the lipid lowering 
action of EPA and DHA in children and adolescents, only a small number of 
clinical trials are available and the results are not always encouraging. In two 
recent interventional studies in children and adolescents with hypertriglyceridemia 
(n= 111 and n=25 respectively), aged 8-18 and 9-19 years old respectively, 3-6 
months fish oil supplements, at the doses of 500-1000 and 3360 mg per day, did 
not lower plasma triglycerides compared with control group[123,124]. 
In contrast a positive effect in lowering plasma triglycerides was found in 103 
obese children and adolescents after 12 weeks of 1.8 g/day of Omega-3 
supplements, compared with the control group receiving metformin, and the other 
plasma lipids were not affected by the treatment[123,124]. 
The evidence of an action of Omega-3 FA on cholesterol is scanty and not 
conclusive: Damsgaard found a positive correlation between EPA levels and HDL 
levels in 8-11 years-old children[110]. However in a previous study fish oil 
supplements were associated to higher total and LDL cholesterol in 9-12 months 
infant[111]. In an observational study no association was found between fish 
consumption, assessed by a 7 day pre-coded food diary, and serum lipid profile in 
hundred-and-nine adolescents[113]. 
A large amount of data, from epidemiological studies, indicate a protective effect 
of Omega-3 FA on glucose metabolism and insulin sensibility in adults[125,126]. 
Accordingly, the results of many clinical trials support the positive effect of 
Omega-3 on glycemic control, however some showed negative results[127,128]. 
The evidence from observational studies and clinical trials in children is limited 
but supports a beneficial effect of Omega-3 also during childhood (see Table 2).  
A cross-sectional study on 5-12 years-old children showed a moderate but 
significant correlation between fasting insulin levels and HOMA-IR and the 
Omega-3 Index, which is the percentage of EPA and DHA contained in red blood 
cell membranes, as an index of chronic Omega-3 intake[129]. Interestingly, in this 
population, obese children had altered erythrocyte fatty acid composition 
unrelated to reported dietary intake and showed  lower levels of Omega-3 Index 
compared with non-obese children[129]. 
Moreover, lower plasma and erythrocyte membrane levels of AA and DHA were 
found in 40 diabetic children compared with non-diabetic controls[130]. However 
in a longitudinal study conducted on 167 children at increased genetic risk for 
type 1 diabetes for the development of persistent islet autoimmunity, Omega-3 
and Omega-6 FA levels in red blood cell membranes were not associated with the 
development of type I diabetes[131]. In a clinical trial on 76 overweight and 
insulin resistant children the supplementation with 900 mg per day of Omega-3 
FA for 1 month decreased fasting insulin and HOMA-IR, also after adjustment for 
pubertal status and weight loss[132]. Accordingly, a recent trial showed a 
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reduction of glucose and insulin levels while reducing HOMA-IR after 12 weeks 
of 1.8 g of Omega-3 supplementation in 201 obese and insulin resistant children, 
also after adjustment for sex, age and change in BMI[124].  
There is also increasing interest on the use of Omega-3 supplements in the 
treatment of non-alcoholic fatty liver disease (NAFLD), which is pathogenically 
linked to insulin resistance and metabolic syndrome. According to the evidence of 
a positive effect of EPA and DHA supplements on liver steatosis in adults, also 
the few clinical trials available in children support the hypothesis that DHA can 
decrease liver fat content in children with NAFLD[133,134]. 
Animal models show positive results encouraging the use of Omega-3 FA to 
prevent diet-induced obesity[135] and some trials in overweight adults and in 
obese diabetic women have also reported a beneficial effect in fat mass 
reduction[136,137]. Nowadays, there is no clear evidence in children and the 
attention is mainly focused on the possible programming effect of Omega-3 fatty 
acids in breast milk on later infant and young children body composition. The 
results from the available studies are divergent: some studies show an inverse 
correlation between maternal Omega-3 FA intake and Omega-3 FA content in 
formula milk and later body composition[138–140], others show a direct 
correlation[141–143], finally in some studies no significant correlation was 
found[118,144–146]. A recent study on 201 obese children and adolescents 
indicates a beneficial effect of Omega-3 supplements (1.8 g EPA and DHA for 12 
weeks), without other lifestyle interventions, on weight reduction[124]. In contrast 
Nobili reported no effect on BMI after 6 months DHA supplements in children 
compared with placebo, but the doses of DHA were low (250-500 mg/day)[134]. 
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Table 1. Studies about the effect of Omega-3 PUFA on blood pressure.  
Author, 
year 
Study design and aim No. subjects Source and dose Time period BP outcome 
Damsgaard CT, 
2013[110]  
Cross-sectional study on 8-11 y-o children. 
To investigate the relationship between 
whole-blood EPA and DHA and Metabolic 
Syndrome features 
73 
(F=44, M=29) 
Fish intake assessed by a specific 
pediatric dietary assessment; amount 
consumed estimated by portion size 
among 4 different images 
--- Positive association of mean arterial 
pressure with DHA only in boys 
after adjustment for energy intake, 
body-fat percentage and physical 
activity 
Damsgaard CT, 
2006[111]  
RCT: 9-12 mo infants randomly  assigned to 
fish oil or no supplements and to cow’s milk 
or infant formula. To investigate the effect of 
fish oil on BP and lipid profile in infants 
83  
(F=42; M=41) 
Fish oil (mean estimated EPA and 
DHA assumption: 924 mg/day) 
3 months Lower SBP (-6.3 mmHg) in infants 
administred fish oil, also after 
adjustment for milk intervention 
Pedersen MH, 
2010[112]  
RCT on 13-15 y-o boys with a control group 
receiving vegetable oil. To investigate the 
effects of fish oil on cardiovascular risk 
factors 
78  
(F=0; M=78) 
Fish oil (1.5 g/day long-chain 
Omega-3 FA) 
16 weeks Lower SBP and DBP (-3.8 and -2.6 
mmHg respectively) in fish oil 
group 
Lauritzen L, 
 2012[113]  
Cross-sectional study on 17 y-o adolescents. 
To investigate the association between fish 
intake and Metabolic Syndrome features 
109  
(M=44; F=109) 
Fish intake assessed by 7 days food 
record with pre-coded response 
categories; intake registered in 
household measures and portion size 
based on images 
--- Higher DHA status correlated with 
higher SBP, after adjustment for sex, 
body fat percentage, dietary factors 
and physical activity 
Skilton RM, 
2013[114]  
Cross-sectional study on  8-15 y-o children 
born with low birth weight. To investigate the 
relation between Omega-3 FA and BP in 
children with relative hypertension related to 
reduced birth weight 
354  
(F=174;M=180) 
Fish intake assessed by two 24-h 
dietary recall, the second after 3-10 
days 
--- Children in the highest tertile of 
dietary EPA and DHA intake had 
significantly lower SBP (−4.9 mm 
Hg and pulse pressure (−7.7 mm 
Hg) than children in the lowest 
tertile 
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Table 1 – continued 
 
F, female; M, male; y-o, years old; Omega-3 FA, omega-3 fatty acid; RCT, randomized controlled trial; DB-RCT, double blind- randomized controlled trial; 
BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; EPA, epoxyeicosatrienoic acid; DHA, docosahexaenoic acid. 
 
 
 
Author, 
year 
Study design and aim No. subjects Source and dose Time period BP outcome 
O’Sullivan TA, 
2012[117]  
Cross-sectional study on 13-15 y-o 
adolescents. To investigate the relation 
between Omega-3 FA and BP 
814 
(F=395;M=419) 
Three-day diet record measured in 
household units 
--- Inverse association between 
Omega-3 FA and SBP, DBP and 
mean arterial pressure in boys 
Ayer JG,  
2009[122]  
RCT on children in the first 5 years, 
randomly assigned to fish oil and reduction 
of Omega-6 FA or control (sunola oil). To 
investigate BP and arterial structure and 
function in 8 y-o children who received 
Omega-3 FA supplements in the first 5 years 
of life 
410 
(F=203;M=207) 
Canola oil and tuna oil, doses 
depending on age; every tuna oil 
capsule had 6% EPA and 27% 
DHA. 
Follow-up at the 
age of 8 years 
No significant differences in BP 
between intervention group and 
control group 
Van Rossem L, 
2012[121]  
Observational cohort-study in breast-fed 
children with a never-breast-fed children 
control group. To investigate the association 
between fatty acid composition of infant milk 
feeding and blood pressure at the age of 12 
yeasr. 
314 
(F=161;M=153) 
Assessment of fatty acid 
composition of human milk. Infant 
formula (control) did not contain 
Omega-3 FA 
Follow-up at the 
age of 12 years 
Children who received human milk 
with an n-3 long-chain 
polyunsaturated fatty acids content 
above the median had a 4.79-mm 
Hg lower systolic and a 2.47-mm 
Hg lower diastolic blood pressure at 
age 12 years than control 
Asserhøj M, 
2009[118] 
DB-RCT on mother receiving fish oil or 
olive oil (control). To investigate whether 
fish oil supplements during lactation affect 
BP and body composition of children 
175 
(F=175; M=0) 
Fish oil (0.6 g/d EPA and 0.8 g/d 
DHA)  
Fish oil 
supplements in the 
first 4 months of 
lactation. Children 
follow-up at 2.5 y 
and 7 y. 
FO boys had 6 mm Hg higher DBP 
and mean arterial BP than controls, 
but girls  
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Table 2. Studies about the effect of Omega-3 PUFA on insulin sensitivity. 
Author, year Study design and aim No. subjects Source and dose Time period Insulin resistence outcome 
Burrows T,  
2011[129] 
Cross-sectional study on 5-12 y-o children. 
To investigate the relationship between 
Omega-3  Index, weight and insulin 
resistance 
48 
(F=28; M=20) 
Fat intake assessed by a 135-item 
semi-quantitative food frequency 
questionnaire 
--- A moderate correlation found 
between Omega-3 Index and fasting 
insulin level and HOMA-IR. 
Decsi T,  
2002[130] 
Observational study on 8-16 y-o diabetic 
children. To compare plasma and red blood 
cell membranes fatty acids in diabetic 
children with non diabetic controls 
80  
(F=50; M=30) 
Plasma and red blood cell 
membranes determination of AA, 
EPA, DHA and ALA 
--- Lower levels of AA and DHA in 
diabetic children compared with 
controls 
Miller MR,  
2011[131]  
Longitudinal study on 0-8 y-o children with 
islet autoimmunity. To investigate the 
correlation between Omega-3 FA intake and 
erythrocyte membrane Omega-3  fatty acid 
levels and type 1 diabetes 
167  
(F=82; M=85) 
Dietary intake assessed by a 111-
item semi-quantitative food 
frequency questionnaire 
--- No significant association between 
Omega-3 FA and Omega-6 FA 
erythrocyte membranes levels and 
the onset of type 1 diabetes 
Lòpez-Alarcòn M, 
2011[132]  
RCT on 9-18 y-o overweight and insulin 
resistant children. To investigate the effect of  
Omega-3 FA supplements on body weight 
and insulin resistance, compared to placebo 
group 
76  
(M; F not 
specified) 
900 mg of Omega-3 FA (360 mg 
DHA + 540 mg EPA) 
1 month Supplementation with Omega-3 FA 
decreased HOMA-IR by 15% after 
adjusting for puberty, treatment 
adherence, changes in adipokines, 
and weight loss 
Juàrez-Lòpez C, 
2013[124] 
Open-label study on  10-12 y-o obese and 
insulin resistant children assigned to Omega-
3 FA or Metformin (control). To investigate 
the effect of Omega-3 FA on HOMA-IR and 
BMI 
201  
(F=106 ; M=95) 
600 mg of Omega-3 FA (360 mg of 
EPA and 240 mg of DHA) 
12 weeks Reduction of glucose and insulin 
levels while reducing HOMA-IR in 
Omega-3 FA group compared to 
controls, also after adjustment for 
weight reduction, sex and age. 
  
F, female; M, male; y-o, years old; Omega-3 FA, omega-3 fatty acid; RCT, randomized controlled trial; DB-RCT, double blind- randomized controlled trial; 
HOMA-IR, homeostasis model assessment-estimated insulin resistance index; EPA, epoxyeicosatrienoic acid; DHA, docosahexaenoic acid; AA, arachidonic 
acid; ALA, alpha-linolenic acid; BMI, Body Mass Index. 
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Adverse effects of omega-3 PUFA 
Omega-3 supplement are generally considered safe and, where reported, the 
tolerability of Omega-3 FA in clinical trials, in children as well in adults, was 
good with no major adverse reactions. An adverse effect of Omega-3 FA 
supplements is the increased risk of bleeding, due to the potential antithrombotic 
effect, however the evidence available does not support a clinical relevant 
increased bleeding, even when Omega-3 FA supplements were concomitant with 
antiplatelet or anticoagulant therapy[147]. Another potential safety concern is the 
presence of contaminants, especially mercury and dioxins, in fish and fish oil, 
which has direct implications for dietary recommendation, in particular for some 
population such as pregnant women and infants[148].  
Conclusion and perspectives 
In summary, the clinical effect of Omega-3 FA on cardiovascular risk factors in 
children is not unequivocal. Actual evidence supports a beneficial effect of 
Omega-3 FA supplements on insulin sensitivity and a possible positive effect on 
blood pressure control whereas they are not yet conclusive concerning the effect 
on plasma lipids and body composition. Anyhow, there were few clinical trials in 
children and most of the evidence comes from epidemiological studies, sometimes 
with limited sample size. Indeed, doses of supplements varies largely as well as 
the duration of the interventions, and it is not easy to detect a dose-response effect 
among different studies.  
In humans, different CYP isoforms are responsible for Omega-3 or Omega-6 
metabolism, whereas other enzymes, such as the soluble epoxide hydrolase 
(EPHX2), convert these metabolites to mostly inactive compounds. 
Polymorphisms in these genes have been tested to evaluate their effects especially 
in blood pressure homeostasis with some encouraging results[149–157] and it is 
possible that also preferential dietary intake of Omega-3 vs Omega-6 could 
influence their effect. Thus, a suggestive hypothesis is that the beneficial effect of 
Omega-3 FA is not only dependent on their intake and content but also on the 
complex interaction between different nutrients and polymorphisms in genes 
involved in Omega-3 FA metabolism[158–166]. These complex interaction has 
seldom been explored in children and adolescents [162]. Further studies are 
needed to investigate all these points in order to find a better collocation of 
Omega-3 FA on the available armamentarium for preventive, possibly 
individualized, medicine. 
Omega–6 PUFA: biochemical characteristics and mechanisms of action 
Omega–6 PUFA are a family of polyunsaturated fatty acids that include, as main 
compounds, linolenic acid (LA) and arachidonic acid (AA). LA is an essential 
FA, whose main dietary sources are corn and sunflowers oil, nuts and nut oils and 
poultry[167]. AA is not strictly essential, indeed it can be metabolized in human 
from LA through desaturation and elongation steps catalyzed by Delta-6 and 
Delta-5 desaturase[168]. 
Like omega–3 PUFA, omega-6 PUFA are incorporated into cell membranes, 
interact with membrane structure, influence intracellular signaling, like the 
activation of NADPH oxidase, protein kinase C and a two-pore domain K+ 
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channel[169,170]. Moreover, they are further metabolized by LOX, COX and 
CYP450. AA is normally found incorporated into cell membrane phospholipids 
and is released by phospholipase A2 and therefore becomes available for the 
convertion to active lipid mediators. In particular COX converts AA to the “β-
series” prostaglandins (PG) (PGD2, PGE2, PGFβα, PGI2 and TXA2) by specific 
synthase and they act as autocrine or paracrine mediators through a G-protein-
coupled receptor (GPCR)[49]. TXA2 has pro-aggregatory effect, whereas PGI2 is 
anti-aggregatory and vasodilating[171]. 
LOX are a group of enzymes, classified on the basis of site of AA oxidation; the 
prominent animal isoforms are 5-, 8-, 12-, and 15-LOX. Through this metabolic 
pathway AA is converted to the “4-series” of leukotriens (LTB4, LTC4, LTD4, 
LTE4, LTF4) mainly in inflammatory cells and their action is also mediated by 
(GPCRs). In addition to GPCRs, PG and LT exert their effects also through the 
activation of peroxisomal proliferator-activated receptors (PPARs)[172,173]. The 
“4-series” LT is recognized as a proinflammatory cascade, i.e. LTB4 induces 
neutrophils chemotaxis and adhesion to endothelium and LTD4 induces eosinophil 
chemotaxis[174–176]. PGI2 and PGE2 are also involved in the inflammatory 
process and evoke hyperalgesia at peripheral and central nervous sites[177,178]. 
(Figure 3) 
AA can be metabolized by the cytochrome P 450 (CYP450) enzymes leading to 
the formation of EETs via CYP-epoxygenase and to 20-HETE via CYP-
hydroxygenase in many tissues, like endothelium, kidney, lung and heart, with 
possible tissue-specific effects[179–181]. For a widely explanation of CYP450 
metabolites of AA see below. 
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Figure 3. Reproduced with permission from Funk CD, Science 2001[172] 
Prostaglandin synthesis and actions. A generic cell when activated by mechanical trauma, 
cytokines, growth factors, or various inflammatory stimuli triggers signaling, including type IV 
cytosolic phospholipase (cPLA 2) translocation to ER and nuclear membranes, arachidonic acid 
release from membrane lipids and metabolism by COX-1 or COX-2 to the intermedi-ate PGH 2. 
Other PLA 2 subtypes could be involved in arachidonic acid release for eicosanoid synthesis but 
are not shown here. De novo COX-2 enzyme synthesis can be induced by a host of factors (top) to 
reinforce prostaglandin (PG) formation.  In a cell-type restricted fashion, a heterogeneous family 
of PGH 2 metabolizing enzymes can form PGE 2, PGD 2, PGF 2a, PGI2 (prostacyclin) and TxA2 
(thromboxane). These prostaglandins may undergo facilitated transport from the cell through a 
known prostaglandin transporter (PGT) or other carrier to exert autocrine or paracrine actions on a 
family of prostaglandin receptors EP 1, EP 2, EP 3, EP 4, DP 1, DP 2 , FP, IP, TP A , and TP B on 
the cell types indicated. Only a few of the many diverse activities of prostaglandins are shown 
here. Prostaglandins could potentially enter the nucleus and activate nuclear hormone receptors 
such as PPAR-g. PGES, PGE synthase; PGDS, PGD synthase; PGFS, PGF synthase; PGIS, 
prostacyclin synthase; TxS, thromboxane synthase. VSMC is vascular smooth muscle cell. OVLT 
in POA is the organum vasculosa lamina terminalis at the midline of the preoptic area. CO cells 
are cells of the cumulus oophorus. X marks the site of inhibition by NSAIDs (aspirin, ibuprofen, 
indomethacin) and the coxibs celecoxib and rofecoxib 
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Clinical effects of omega-6 PUFA 
In the last few decades a high omega-6/omega-3 PUFA ratio has been associated 
to an increased CV risk[182], raising the warning to reduce the dietary assumption 
of omega-6 PUFA, which is recommended to be under 10% of total energy intake 
according to the current guidelines[183,184]. Anyhow the effects of omega-6 
PUFA on the CV system is not to date clearly understood. Principal concerns 
regard the possible increase in 2-series PG and 4-series LT with a higher intake of 
omega-6, thus determining an increase in proinflammatory and proaggregatory 
status, which may worsen the atherosclerotic process. Moreover, previous 
suggested that there is no correlation between omega-6 FA and the risk of 
hypertension[80] and that the re-placement of SFA with omega-6 FA is not 
correlated to vascular and endothelial function[185]. Even arachidonic acid (AA) 
content was higher in adipose tissue of metabolically unhealthy obese adults as 
compared to metabolically healthy control[186]. 
On the other hand, other studies have suggested that omega-6 PUFA might reduce 
coronary heart disease: i.e. a large study performed in 11 American and European 
cohorts showed that PUFA were inversely associated with the risk of coronary 
events, when replacing 5% total energy intake from saturated FA (SFA) with 
PUFA; whereas the replacement with carbohydrates showed a modest direct 
association[187]. A longitudinal study showed an inverse relation between an 
increase in serum omega-6 FA and the prevalence of MetS in a Finnish 
population[188] and two large cohort studies have seen that dietary intake of 
omega-6 was inversely associated with total mortality[189]. Some studies indicate 
that, within omega-6 PUFA, especially linoleic acid (LA) may exert protective 
actions with respect to body fat distribution, insulin resistance[190], total 
mortality[189] and blood pressure control[191]. AA, measured in red blood cell 
membranes, can contribute to glucose homeostasis[192,193], some studies 
suggesting a beneficial effect only  in subject with low-normal insulin sensitivity 
but not in highly insulin-sensitive individuals[194]. 
In the current decade three meta-analysis were conducted in order to summarize 
the role of omega-6 PUFA on cardiovascular disease. A systematic review and 
meta-analysis of RCTs on 13,614 subjects quantified the effect of replacement of 
SFA with PUFA on coronary heart disease, showing a 10% decreased risk of 
coronary heart disease for each 5% energy of increased PUFA in place of SFA, 
with a greater benefits from studies of longer duration at the meta-regression 
analysis[195]. Anyhow a meta-analysis of observational, prospective studies and 
RCTs did not show a significant impact of omega-6 PUFA on coronary 
disease[73]. 
Furthermore, a Cochrane review on 660 participants found scarse evidence of an 
effect of increased or decreased omega-6 PUFA intake on blood pressure  and 
plasma lipids. However this data should be carefully taken into account because 
of the low number of included studies (four trials)[196]. 
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Clinical effect of omega-6 PUFA in children 
Little is known about the role of omega-6 PUFA on cardiovascular system in 
childhood and only a limited number of studies were conducted in children and 
adolescents. 
In an observational study 67 obese children had lower plasma omega-6 PUFA 
than the normal weighted controls[197]. In another work also plasma AA was 
lower in diabetic children with respect to healthy controls, whereas in the same 
population LA was higher than in control[130]. On the other hand, a recent study 
on 3-6 months infant with islet immunity showed that higher serum AA/DHA 
ratio and omega-6/omega-3 ratio was associated with an increased risk of type 1 
diabetes[198]. Consistent with these results, a study in healthy children indicates 
that AA, measured in adipose tissue and in skeletal muscle cells, was directly 
correlated to fasting insulin and HOMA-IR[199]. Anyhow the scanty number of 
studies, the lack of RCTs, the differences in the examined populations and in the 
utilized methods suggest a cautious interpretation of these findings and the need 
for further investigations. 
 
Omega-6 and omega-3 fatty acids and Cytochrome p450-derived eicosanoids 
in cardiovascular diseases 
In the following paragraphs it will be discussed the so-called third branch of 
metabolism of PUFA and the interaction between omega-6 and omega-3 PUFA 
pathways. 
CYP450-derived metabolites of AA 
The metabolites of AA generated through the three pathways and their clinical 
and biological effects are better understood compared to those derived from EPA 
and DHA. In this paragraph, we briefly review the evidence concerning the AA-
derived metabolites via CYP450, which have well known hemodynamic effects 
and, notably, may interfere with the formation of the eicosanoids of EPA and 
DHA.  
COX and LOX metabolize AA leading to the production of prostaglandins, 
prostacyclin, thromboxane and leukotrienes, which are involved in the modulation 
of pulmonary and renal function, and in vascular tone and inflammation [200]. 
Less attention was directed to the third metabolic pathway, the cascade leading to 
the formation of CYP-derived AA metabolites. In fact, CYP epoxygenase 
catalyzes the formation of epoxyeicosatrienoic acids (EETs), whereas CYP 
hydroxygenase leads to the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-
HETE) [52]. EETs are generally involved in protective mechanisms and exert an 
antihypertensive effect as follows: in most vascular beds, they act mainly as 
endothelium-derived hyperpolarizing factor (EDHF) and may also activate eNOS, 
leading to a vasodilatory effect [201]. Moreover, they exert a Na+-excreting 
action[200]. At the renal level, 20-HETE shares the Na+-excreting effect with 
EETs; conversely, in the vascular system, 20-HETE constricts renal, cerebral, 
mesenteric and skeletal muscle arterioles [200]. Consequently, 20-HETE acts in 
opposite directions, eliciting both pro- and anti-hypertensive effects. 
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Furthermore, EETs mediate anti-inflammatory actions [202] and their less potent 
metabolites dihydroxyeicosatrienoic acids (DHETs), produced by the soluble 
Epoxide-Hydrolase (sEH), have antithrombotic effects and may be involved in the 
inflammatory process, with some reports suggesting them to be pro-inflammatory 
[203] (Figure 4). Whereas a number of studies in animal models recognized a role 
of 20-HETE and/or EETs in the development of hypertension [204,205], to date a 
small number of human studies are available . In renovascular hypertension in 
particular, some clues were unveiled regarding the involvement of CYP-derived 
metabolites of AA, notably 20-HETE. [206]. Two studies indicated the 
involvement of CYP-derived metabolites of AA in the regulation of the maternal 
circulation during pregnancy and a possible contribution to pre-eclampsia, 
although their pathophysiological role is not defined to date[207,208].  
 
Figure 4: Reproduced with permission from Spector AA et al. Am J Physiol Cell Physiol 2007 
Membrane receptor mechanism of EET action. The key element in this mechanism is EET binding 
to a putative plasma membrane EET receptor that activates various intracellular signaling 
pathways to elicit a functional response. The intracellular signaling pathways are shown in 
different colors to indicate that each is active in different tissues under unique conditions. There is 
evidence that EETs utilize cAMP and tyrosine kinase cascade signal transduction mechanisms. 
Activation of large-conductance Ca2+-activated K+ (BKCa) channels occurs through a G s protein 
coupled to the putative receptor. Whereas the cAMP-PKA, phosphatidylinositol 3-kinase (PI3K)-
Akt, MAPK, and Src kinase pathways produce responses by activating gene expression, the anti-
inflammatory effect produced by the IKK pathway is due to inhibition of cytokine-induced NF- B 
activation. HB-EGF, heparin-binding EGF-like growth factor; EGFR, EGF receptor; CREBP, 
cAMP response-element binding protein.  
 
Figure Introduction n.18
  
 31 
Previous studies in animal models showed the possible modulation of BP by EETs 
in pregnancy[209,210], some of them suggesting instead their protective role 
against pregnancy-induced hypertension[210]. In pregnant women, high levels of 
EETs were found in the fetoplacental circulation compared to that of the maternal 
circulation [208] and within intrauterine tissues[211,212][210] and some studies 
support the hypothesis that EETs play a role in BP regulation in pre-eclamptic 
pregnancies[207,209]. 
Additionally, genetic studies provided some clues concerning the possible role of 
these compounds in BP regulation and cardiovascular risk. In fact, human genes 
encoding for the major CYP isoforms codifying for the enzymes that form EETs 
along with EPHX2, the sEH gene, are highly polymorphic and a number of 
studies have shown that some variants are associated with a higher risk of 
hypertension, stroke or other major cardiovascular endpoints[214] with a possible 
gender-specific effect.[151,152] 
Thus, a suggestive hypothesis is that omega-3 FA may additionally exert their 
action through the complex interaction with polymorphisms in genes encoding for 
CYP enzymes as was similarly hypothesized in a recent study, in which a stronger 
overtime reduction in BP was significantly associated with a higher Omega-3 
PUFA intake, but only in subjects carrying the CYP4F2 433VV genotype [215]  In 
fact, the analyzed genotype did not show an association with BP by itself in the 
whole population; but a significant correlation was found only when considering 
the interaction with  Omega-3 PUFA intake, thus suggesting that Omega-3 PUFA 
can exert their protective effect on BP only in people carrying selected genotypes. 
CYP450-derived metabolites of EPA and DHA 
As previously stated, not only AA but also EPA and DHA are metabolized by 
COX and LOX, but particularly by CYP450 leading to the biosynthesis of a wide 
range of compounds that are currently attracting active research. The EPA-derived 
counterparts of EETs through the metabolism of CYP-epoxygenase are 
epoxyeicosatetraenoic acids (EEQs), whereas the DHA-derived counterparts are 
epoxydocosapentaenoic acids (EDPs). CYP-hydroxylase converts EPA to 19- and 
20-hydroxyeicosapentaenoic acid (19- and 20-HEPE) and DHA to 22-
hydroxydocosahexaenoic acid (22-HDoHe), which are the counterparts of 20-
HETE [216] (Figure 5). 
 
Epoxy metabolites of AA, EPA and DHA are further metabolized by the sEH, 
generating dihydroxy-fatty acids, or diols, which are the DHETs 
dihydroxyeicosatetraenoic acids (DiHETE) and dihydroxydocosapentaenoic acids 
(DHDP), respectively. This metabolic step is moreover the object of competition 
between AA and DHA/EPA for enzymatic binding [217].  
 
The biological properties of the epoxides and diols derived from EPA and DHA 
are not yet completely understood, although substantial interest has been raised 
recently. In fact, the EPA and DHA epoxides have at least similar but often 
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stronger effects than EETs, in particular concerning their vasodilator [56],anti-
inflammatory [58,217,218] and analgesic actions [217].  
Animal models using canine and porcine coronary microvessels [56,219] and in 
rat cerebral artery [55] support the hypothesis that EEQs and EDPs act as 
endothelium-derived hyperpolarizing factor (EDHF) by activating Ca++-activated 
K+ channels and that they have a greater vasodilatory action with respect to EETs, 
which might be the mechanism, or at least one of the mechanisms, responsible for 
the BP-lowering effect of omega-3 PUFA.  
Other studies in animal models stress the role of omega-3 epoxides in BP control 
as follows: in Angiotensin II-dependent hypertensive mice, an omega-3 rich diet 
in combination with the sEH inhibitor lowered BP, suggesting that omega-3 
epoxides contribute to BP lowering [220]. Moreover, the same group focused 
attention on DHA-derived epoxides and provided some particular clues regarding 
19,20-EDP as a mediator of the anti-hypertensive effect of DHA[57]. 
Additionally, in CYP1A1 knockout mice, the involvement of 17,18-EEQ and 
19,20-EDP in BP control has been shown, suggesting vasodilation via increases in 
nitric oxide as a pathophysiological mechanism [221]. 
Moreover, the CYP/sEH-derived metabolites of omega 3 PUFA are involved in 
angiogenesis regulation, at minimum in retinal and tumoral vascularization as 
follows: omega-3 epoxide have anti-angiogenic properties[222–224], whereas 
sEH-derived diols may exert pro-angiogenic action [225]. Contrarily, several 
studies on animal models revealed that EETs were linked to angiogenesis[226–
228].  
Finally, EPA and DHA epoxides, along with EETs, exert anti-inflammatory 
actions[58,217,229]. Thus, our hypothesis maintains that the cardioprotective 
effects of Omega-3 FA may be explained, at least partially, by the replacement of 
AA-derived EETs by the more effective EPA- and DHA-derived EEQs and EDPs. 
Because no reports are available concerning the biological role of 20-HEPE and 
22-HDoHE in hemodynamic modulation in humans, the question of whether they 
share or perhaps antagonize the vasoconstrictor action of 20-HETE remains 
unanswered.  
 
  
 33 
 
Figure 5: Reproduced with permission from Bonafini S et al. POLM  2017[230] 
Main AA, EPA and DHA metabolites via CYP450/sEH and their principal actions. 
The metabolites of AA, EPA and DHA are constituted by different isomers, which are listed in the 
figure; the illustrated structure refers to the underlined isomer. 
AA: Arachidonic acid; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; EETs: 
Epoxyeicosatrienoic acids; 20-HETE: hydroxyeicosatetraenoic acid; EEQs: epoxyeicosatetraenoic 
acids; 20-HEPE: 20-hydroxyeicosapentaenoic acids; EDPs: epoxydocosapentaenoic acids; DHET: 
dihydroxyeicosatrienoic acid; DiHETE: dihydroxyeicosatetraenoic acid; DHDP: 
dihydroxydocosapentaenoic acid; 22-HDoHE: 22-hydroxydocosahexaenoic acid  
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Metabolic interactions between omega-3 and omega-6 PUFA  
The wide range of the metabolic pathways and biological effects of omega-3 FA 
makes it difficult to completely understand the clinical role of omega-3 FA and 
their metabolites, which remain a matter of debate. The overall picture is 
complicated by the possible interactions with other nutrients and dietary 
compounds that are far from being completely elucidated. 
First, consideration should be given to the competition of omega-3 FA with 
omega-6 FA for the binding with several enzymes. ALA competes with LA for 
metabolism by delta-6 desaturase and the subsequent enzymes of the pathway, 
leading to the formation of EPA and AA, respectively [32]. The COX pathway 
catalyzes the production of prostanoids, such as the pro-thrombotic TXA2 and the 
anti-thrombotic PGI2, starting from AA. The counterparts derived from EPA exert 
more potent antiaggregatory (TXA3 and PGI3) and weaker pro-inflammatory 
actions (LTB5) [52].The anti-inflammatory effect of omega-3 is further explained 
by a novel family of compounds, the so-called protectins, resolvins and maresins 
[231]. 
Indeed, previous studies have demonstrated that many isoforms of CYP enzymes 
convert EPA and DHA with equal or even higher metabolic capacities compared 
to AA and notably, they show largely different regioselectivity [216]. In animal 
models, EPA and DHA have been demonstrated to replace AA in membrane 
phospholipids and concomitantly, clear modification exists in the balance of their 
metabolites with a tissue-specific effect. In rats fed with EPA + DHA 
supplements, the endogenous formation of EETs, EEQs and EDPs was shifted in 
favor of EPA and DHA metabolites with different rates in the various tissues, e.g., 
in the heart, the EET: EEQ: EDP ratio shifted from 87:0:13 to 27:18:55 , whereas 
the modification was in the same direction but with different rates in  other 
tissues, like kidney and liver; only in brain the changes were slight[59]. 
Additionally, 20-HETE decreased after EPA + DHA supplementation with a 
concomitant increase in 20-HEPE and 22-HDoHE [59]. An interventional study in 
humans tested the effect of EPA + DHA supplements on the Omega-3 Index and 
on the balance of metabolite production. The results were consistent with the 
previous study on rats as follows: after increasing doses of omega-3 FA 
supplements for 8 weeks in 20 healthy volunteers, the Omega-3 Index increased 
in a time- and dose-dependent manner and a large increase was also observed in 
the EPA-derived metabolites via CYP epoxygenase. In particular, the ratio 
between the metabolites and precursors of fatty acids indicated that CYP 
epoxygenase was 8.6 times more efficient in EPA metabolism and 2.2 times more 
efficient in DHA metabolism compared to AA. Regarding the CYP-
hydroxygenase pathway, no modification in 20-HETE and 22-HDoHE were 
observed, whereas the concentration of 20-HEPE increased 3-fold. Notably, the 
effect on COX and LOX remained rather weak with respect to that on the CYP 
epoxygenases, indicating that CYP-dependent metabolites of EPA and DHA are 
the putative mediators of the cardiovascular protective effects of omega-3 FA[54].  
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Possible confounders when evaluating the clinical effect of omega-3 FA 
Notwithstanding the understanding of the biological mechanisms of action of 
EPA, DHA and their metabolites, uncertainty remains about their clinical 
efficacy. In particular, as stated previously, a discrepancy between observational 
and interventional studies is often evident. A possible confounder is the use of 
vegetables oils as controls, and often olive oil, which may in turn exert protective 
actions[232–234], thus partially blurring the positive effect of omega-3 FA.  
Moreover, the protective effect was reported in trials using fish as the source of 
omega-3 FA compared to EPA+DHA supplements, although supplementation 
may easily provide higher doses of omega-3 FA than those supplied by fish in the 
diet. In our opinion, further investigation is warranted to elucidate this complex 
issue, that is, whether a favorable effect of omega-3 FA should be traced to these 
dietary fatty acids alone or to the overall sources of these compounds. Fish in 
particular is rich in many macro and micronutrients[235], such as vitamin D,  
branched chain amino acids, potassium and magnesium, that may act 
independently or even synergistically with omega-3 FA[236–238]. Furthermore, 
the intake of each individual nutrient should be considered in assessing the whole 
dietary pattern as follows: the intake of fish may be generally assumed to indicate 
healthier dietary habits and in particular, higher fish consumption is usually 
associated with higher vegetable and fruit intake and lower intake of meat, which 
are altogether often related to a higher socioeconomical status [239,240].Thus, the 
effects of Omega-3 FA may indeed derive from the interaction with other 
nutrients, such as fiber, olive oil or antioxidants, which are considered to play a 
role in cardiovascular risk reduction [241]. Indeed, some recent studies and meta-
analyses have called attention to the role of dietary models rather than single 
nutrients with respect to cardiovascular risk. A systematic review of prospective 
studies or RCT investigating the relationship between dietary exposure and 
coronary heart disease identified vegetables, nuts, fish and marine Omega-3 FA, 
fruit, fiber and the “Mediterranean diet” as protective factors, whereas trans fatty 
acids and foods with high glycemic indexes were recognized as harmful factors 
[242]. A recent RCT showed that a Mediterranean diet supplemented with olive 
oil or nuts, which are rich in omega-6, reduced the incidence of major 
cardiovascular events (myocardial infarction, stroke or death from cardiovascular 
causes) in primary prevention [243] [244].  
In our opinion, greater attention should be directed additionally to the balance 
between the different types of fatty acids. Undeniably, consideration should be 
given to the profound change in dietary patterns during the last century in Western 
countries whereby the omega-6: omega-3 FA balance shifted from a ratio of 1-2:1 
in the Paleolithic era to the current 15-20:1 ratio [29] . This unbalance and the 
changes in the dietary intake of vegetables, fiber, nuts and berries are considered 
key factors in the development of cardiovascular disease. 
Finally, the response to omega-3 FA supplements, in terms of modifications of 
their metabolite profile, appears to show a high grade of inter-individual 
variability[245], which may consequently obscure the clinical effect of omega-3 
supplementation in large clinical trials. 
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In conclusion, evidence from observational studies, in particular, support the 
recommendation to enhance the intake of omega-3 FA, primarily from seafood, to 
reduce cardiovascular risk. We believe that their protective effects are probably 
mediated by an improvement in vascular function with a consequent 
antihypertensive effect due to the shift of CYP-derived metabolites to more potent 
vasodilatory agents. Persistent debate remains concerning the best source of 
omega-3 FA and it is not yet clarified whether the beneficial effects may be 
explained only by their specific biological actions or rather by their complex 
balance and interactions with a variety of nutrients and polymorphisms of genes 
implicated in their metabolic pathways. 
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Study 1: Omega-6 fatty acids in erythrocyte membranes are inversely 
associated with several features of the metabolic syndrome in a sample of 
obese children 
 
Introduction Study 1 
In the last few decades the lifestyle changes in western countries led to an increase 
in the prevalence of overweight/obesity and cardiovascular (CV) risk factors, 
which often accompany the body weight excess, not only in adults but also in 
children[109]. In particular, a central distribution of obesity is associated with a 
higher CV risk profile through the clustering of CV risk factors that leads to the so 
called metabolic syndrome (MetS). Insulin resistance often accompanies obesity 
and plays a pivotal pathophysiological role in the development of MetS. Non-
alcoholic fatty liver disease (NAFLD) can be considered the hepatic manifestation 
of MetS because of the common risk factors, like central obesity, insulin 
resistance and dyslipidemia[246]. NAFLD by itself is associated with an 
increased morbidity and mortality for cardiovascular disease[247]. 
An unbalanced diet is a common factor that might promote several of the 
components of MetS and NAFLD. A hyperlipidemic diet may influence the onset 
and progression of obesity; however, increasing attention is paid not only to the 
quantity but also to the quality of fat. Indeed, epidemiological and intervention 
studies indicate that saturated fatty acids (SFA) might negatively affect insulin 
sensitivity[248] and plasma lipid profile[249]. However, randomized controlled 
trials (RCTs) and successive meta-analyses gave controversial results about the 
link between SFA and cardiovascular risk[195,250]. Anyhow, there is general 
agreement that dietary assumption of SFA should be lower than 10% but which is 
the best macronutrient to replace them remains matter of debate. 
On the other hand, omega-3 polyunsaturated fatty acids (PUFA) are generally 
recognized as healthy nutrients. They positively affect plasma lipid profile, insulin 
sensitivity[251], might exert beneficial effect on blood pressure (BP)[77,230,252] 
and on abdominal obesity[253] and moreover can play an important role in 
prevention and treatment of NAFLD, even in children[246]. The increasing 
interest in the potential beneficial effect of omega-3 PUFA and the concern that a 
high omega-6/omega-3 PUFA ratio is associated with an increased cardiovascular 
risk led to the advisement of reducing the dietary intake of omega-6 PUFA; 
anyhow the role of total and single omega-6 PUFA in cardiovascular disease is 
not clarified yet[254]. 
Notably, new insights indicate a protective role of omega-6 FA, and in particular 
linoleic acid (LA), with respect to body fat distribution and insulin resistance[190] 
and total mortality[189]. A longitudinal study showed an inverse relation between 
an increase in serum omega-6 PUFA and the prevalence of MetS in a Finnish 
population[188]. Thus, further investigations are needed in order to clarify these 
issues in adults and even more in children. Therefore, we aimed at investigating 
the associations of individual CV risk factors, characterizing the MetS, with 
erythrocyte membrane FA, markers of the preceding two-three months intake, in a 
group of overweight and obese children. 
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Methods Study 1 
Overweight and obese children were recruited consequently from October 2012 to 
September 2014, coming from the “Pediatric Obesity Outpatients Unit” of the 
University Hospital of Verona and of the “Local Health Unit n. β0” (ASL β0) of 
Verona. Inclusion criteria were: children and adolescents aged 5-18 years old; 
overweight or obesity (BMI≥90th and 95th percentile for sex and age, 
respectively)[255]. WHO reference for BMI was used for categorizing children 
into the overweight and obese groups[2] Exclusion criteria were: hepatic or renal 
chronic diseases, malignancies, diabetes mellitus, other therapies potentially 
affecting glucose and/or lipid metabolism; obesity secondary to genetic disorders 
and/or syndromes. 
A subgroup of 25 children accepted to undergo a clinical follow-up and repeated 
the evaluation at least 6 months after the enrolment. All the families received at 
baseline individualized advices about a correct lifestyle including regular physical 
activity and a dietician proposed modification of the diet settled with the family 
starting from the habitual diet of the children. Children did not take any 
pharmacological treatment during the follow-up period. At the follow-up visit the 
children underwent all the same investigations as at baseline. On the basis of the 
change in BMI at follow-up visit compared to the first evaluation, regardless to 
the change in BMI percentile, the children were classified as good (decreased 
BMI) or poor (increased BMI) compliers to the suggested lifestyle advices. 
 
STUDY DESIGN 
The study was conducted according to a cross-sectional observational design for 
the first part and according to a longitudinal observational study for the follow-up 
of the subgroup of 25 children. The study was approved by the Ethical Committee 
of Verona (CE n. 2218), and written informed consent was obtained from each 
participant’s parents. 
ASSESSMENTS 
Each child was evaluated in a single occasion, between 8 and 9 a.m. A 
questionnaire was administered to the patients and to the parents, dealing with 
medical history, family history, physiological and pathological information and 
use of drugs. Then, the participants underwent a physical examination. They were 
advised not to engage in strenuous exercise and to avoid consuming caffeine 
containing beverages within 12 hours preceding the vascular studies. 
During the visit, blood pressure was measured with a semiautomatic oscillometric 
device (TM-2551, A&D instruments Ltd, Abingdon Oxford, UK) for 3 times, 3 
minutes apart with the patient lying supine for at least 10 minutes before the first 
measurement in a room with controlled temperature (22-24°C). The mean value of 
the 3 clinostatic measurements were calculated and considered for z-score and 
percentile calculation. Afterward, BP levels were confirmed by a measurement in 
the sitting position by the oscillometric device and by auscultatory method. 
Ambulatory blood pressure measurement was recorded by an oscillometric device 
(Spacelabs 90217; Spacelabs Inc., Issaquah, Whashington, USA), which 
measured BP every 15 minutes during the day and every 30 minutes during the 
night. Children and parents recorded physical activities, resting and sleeping time 
and symptoms on a dedicated diary. After recording, the daytime and nighttime 
periods (set to default at 0700 and 2200 h, respectively) were adapted to “real” 
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awake and sleep times according to what was declared in the diary of activity, as 
previously indicated[256]. 
All of the values derived from BP measurements were transformed in z-score and 
percentile, according to normative values[257,258]. The 95th of office and 
ambulatory BP measurements was used as cut-off for hypertension, according to 
current European guidelines[26].   
Body weight, height, and waist and hip circumferences were measured with the 
patient wearing light clothes. Body weight was measured by a calibrated balance 
and height by a calibrated stadiometer[259].  
Waist circumference was transformed in z-score and percentile according to 
normative values[260]. 
Metabolic Syndrome definition 
In an exploratory analysis, we defined the MetS according to the diagnostic 
criteria suggested by the International Diabetes Federation[261]. Anyhow we 
decided to extend the diagnosis to all age categories and replace the suggested cut-
off point of BP with the 90th percentile for sex and age of SBP and DBP, 
according to the normative values[258] and to the definition of pre-
hypertension/hypertension indicated by the current guidelines[26]. 
Laboratory measurements 
Blood samples were collected after an overnight fast. Laboratory measurements, 
including fasting plasma glucose, insulin, total cholesterol, HDL-cholesterol, 
triglycerides, AST, ALT and GGT were measured using standardized methods. 
Insulin resistance has been estimated with HOMA Index (HOMA-IR), which was 
calculated by Matthews formula (fasting insulin (mU/mL)*fasting glucose 
(mmol/L)/22.5)[262]. 
Fatty liver index (FLI), derived from an algorithm based on BMI, waist 
circumference, triglycerides and GGT, were calculated as previously described 
[263] 
Red blood cell membrane fatty acids measurement 
EDTA-blood tubes were centrifuged, plasma and buffy coat taken off, and 
erythrocytes frozen at -80°C until analysis. Erythrocyte fatty acid composition 
was analyzed using the HS-Omega-3 Index® methodology as previously 
described[264]. Fatty acid methyl esters were generated from erythrocytes by acid 
transesterification and analyzed by gas chromatography using a GC2010 Gas 
Chromatograph (Shimadzu, Duisburg, Germany) equipped with a SP2560, 100-m 
column (Supelco, Bellefonte, PA) using hydrogen as carrier gas. Fatty acids were 
identified by comparison with a standard mixture of fatty acids characteristic of 
erythrocytes. A total of 26 fatty acids were identified and quantified. 
Results are given as percentage of total identified fatty acids after response factor 
correction. The coefficient of variation for EPA plus DHA and for most other 
fatty acids was 4%. Analyses were quality-controlled according to DIN ISO 
15189. 
Estimation of Δ9, Δ6  and Δ5 desaturase activity 
Δ9, Δ6  and Δ5 desaturase are enzymes responsible for the endogenous formation 
of monounsaturated and polyunsaturated FA and their activity has been associated 
with insulin-glucose homeostasis and with central obesity[265]. 
We estimated the desaturase activity as the ratio of product to precursor of 
individual red blood cell membrane FA as follows: Δ9-desaturase (SCD) = 
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C16:1n-7/C16:0 and C18:n-9/C18:0 (they will be referred to as  SCD-16 and  
SCD-18, respectively);  Δ6-desaturase (D6D) = C18:3n-6/C18:2n-6 and  Δ5-
desaturase (D5D) = C20:4n-6/C20:3n-6. 
Hepatic ultrasonography 
Children underwent abdomen ultrasonography (US) using a convex probe 
(ACUSON S2000TM system, Siemens, Erlanger, Germany). The presence of 
significant liver steatosis was defined by an experience sonographer. 
STATISTICS 
Data are presented as median and range unless otherwise stated. The normal 
distribution of each variable was evaluated by the Kolmogorov-Smirnov test. 
Differences in the measured parameters between groups (MetS presence, steatosis, 
gender, pubertal state) were analyzed by T-test or Mann Whitney U test, as 
appropriate, at univariate analysis, and by unconditional logistic regression 
models at multivariate analysis. Unless otherwise specified, covariates included in 
the multivariate models were age, sex, BMI percentile and the features associated, 
at univariate analysis, with MetS presence, steatosis, gender, and pubertal state, 
respectively.   
Since MetS-associated features were non-normally distributed, bivariate 
correlations were estimated by the non-parametric Spearman correlation 
coefficient (rS). After log-transformation of MetS-associated features, general 
linear models were applied to assess the association of FA with MetS-associated 
features, after adjustment for age, sex and BMI. 
In longitudinal study, significant variations in children features between baseline 
and follow-up were evaluated with the Wilcoxon signed rank test. 
Two-tailed tests with a p<0.05 were considered statistically significant in the main 
analysis. In order to take into account the multiple comparisons, along with 
original p-values, the false discovery rate (FDR) adjusted p-values were also 
calculated and reported in the tables, where appropriate. The analyses were 
performed with Statistical Analysis System (SAS) Software, version 9.2. 
 
Results Study 1 
General characteristics at baseline 
Seventy patients (40 males and 30 females) were included in the study and 25 
children completed the follow-up (11 males and 14 females). Mean age was 11.5 
± 2.5 years; mean BMI was 29.4 ± 4.4 Kg/m2, which in all cases was higher than 
the 90th percentile, as for inclusion criteria. Five children (7.1%) fulfilled the 
diagnostic criteria of MetS. Sixty-three children underwent abdomen 
ultrasonography (US) and in 34 (53%) children hepatic steatosis was detected. 
Blood samples for laboratory measurements and FA analysis were obtained from 
all children. 
Omega-3 Index was 4.7 ± 0.8 %; mean value of ALA was 0.08 ± 0.03 %, and LA 
was 12.0 ± 1.6 %. 
Anthropometric, clinical and biochemical characteristics of the children are listed 
in Table 1, and the FA contents of erythrocytes in Supplemental Table 1.  
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Correlations between red blood cell membrane FA and features of MetS 
Omega-3 PUFA, as well as EPA and DHA, correlated directly with waist 
circumference; moreover, EPA showed direct correlations with insulin, HOMA-
IR and with FLI (Table 2). 
To the contrary, total omega-6 PUFAs (LA+ gamma-linolenic acid (GLA) + 
dihomo-gamma-linolenic acid (DGLA) + AA + docosatetraenoic acid (DTA) + 
eicosadienoic acid + C22:5n6) was inversely correlated with several 
anthropometric and laboratory measurements related to MetS; within omega-6 
PUFA, AA in particular was associated with almost the same characteristics as the 
class of FA (Table 2 and Figure 1). Conversely, gamma-linolenic acid (GLA) 
showed a direct correlation with some features of Mets, especially with total 
cholesterol, triglycerides, fasting insulin, HOMA-IR and FLI. 
Total content of SFA was directly correlated with several features of the MetS, 
within SFA, palmitic acid (PA) in particular directly correlated with several 
individual characteristics (Table 2 and Figure 2). 
Omega-9 FAs and trans-FAs, when considered either the single FA or their sum, 
did not show significant correlations with anthropometric, clinical and laboratory 
parameters of MetS. 
 
Correlations between red blood cell membrane FA and features of NAFLD 
As for the correlation with individual components of the MetS, omega-6 PUFA 
and in particular AA showed an inverse correlation with FLI and transaminases, 
whereas SFA, and particularly PA, resulted directly correlated (see Table 2). 
 
Correlations between desaturase activity and features of MetS 
D6D activity showed direct correlations with waist circumference (rS = 0.249), 
triglycerides (rS = 0.370), fasting insulin (rS = 0.404), HOMA-IR (rS = 0.423) and 
with FLI (rS = 0.402). 
D5D activity was inversely correlated to triglycerides (rS = -0.401), and FLI (rS = 
-0.319). (Supplemental Figure S1) 
No significant differences were found in desaturase activity according to gender, 
pubertal status and presence of hepatic steatosis. 
 
Regressions 
After adjustment for sex and age all the correlations shown in Table 2 remained 
significant. When also BMI was included in the regression most associations 
remained significant, especially the ones with laboratory parameters (see Table 2). 
 
Analysis by subgroups 
When comparing children with and without MetS (n: 5 and 53, respectively), we 
observed a significantly higher SBP, triglycerides, PA and D6D and lower HDL-
cholestreol, AA and omega-6 in patients with MetS, after adjustment by age and 
BMI. Otherwise, no feature was associated with liver steatosis at multivariate 
analysis. The characteristics of the subgroups are detailed in Supplemental Table 
2 and Supplemental Table 3. 
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Follow-up  
Twenty-five children (11 males and 14 females) completed the follow up. The 
mean time of follow-up was 16.2 ± 9.2 months. The main characteristics at the 
follow-up visit are detailed in Table 3. 
We found a significant reduction of BMI percentile, 24-h SBP and DBP 
percentile, total cholesterol and tryglicerides in children at follow up compared to 
baseline and a significant increase in HDL levels (Table 3). 
We found that the basal values of AA were inversely correlated with the change 
over time of waist circumference (rS =-0.506) and office SBP (rS =-0.710). 
  
Discussion Study 1 
The main result of our study is the evidence that omega-6 FA, and in particular 
AA, are inversely associated, whereas SFA directly, with many components of 
MetS in obese children. Even if the observational design of the study does not 
allow to proof a causal link, our results could suggest, on one side, a protective 
role of omega-6 FA and, on the other side, a harmful effect of SFA with respect to 
cardiovascular risk factors and NAFLD.   
Anyhow, these associations of opposite sign could simply reflect a healthier 
dietary habit, with a preferential intake of omega-6 PUFA with respect to SFA. 
Therefore, the relative increase in omega-6 PUFA could not be, or not only, 
protective per se but instead be a marker of the reduction of other potentially 
harmful components of the diet, like saturated FA. Indeed, a diet rich in 
polyunsaturated FA is often associated to healthier dietary pattern, which may 
involve also other macronutrients[240]. 
Despite an increasing expectation from a beneficial effect on cardiovascular risk 
profile and NAFLD in children by omega-3 PUFA, and in particular EPA and 
DHA[246], we did not find any significant beneficial association between either 
EPA or DHA and clinical/laboratory characteristics of our population. To the 
contrary, we found a direct association of EPA with some characteristics of the 
MetS, in particular insulin and HOMA-IR. The effect of omega-3 PUFA on 
glucose metabolism is not clearly defined and trials in humans did not give 
unequivocal results[266,267]. In our sample, that at baseline was taking a free diet 
without any supplement, the level of omega-3 PUFA was very low, far below the 
8% threshold suggested for CV protection[268] and this could also be a 
confounding element.  
We choose red blood cell membrane FA as a biomarker of dietary intake of FA 
because of the stability of their values, especially of essential FA, which reflect 
the mean dietary intake in the preceding few months[269], and because it is more 
reliable compared to dietary self-report or questionnaire, especially in children. 
Our results confirm that total amount of SFA is associated with an unfavourable 
cardiovascular risk profile in obese children and, within this family of FA, 
palmitic acid show to be related to almost all the characteristics of the MetS. It has 
been already shown that palmitic acid is one of the most abundant circulating FA 
in obese children[270] and elevated palmitic acid levels can affect insulin 
homeostasis, which is the principal etiologic driver of the metabolic abnormalities 
clustering in the MetS. In particular, in vitro studies reported an impairment in 
insulin secretion in murine[271] and human[272] ȕ-cell lines due to palmitic acid, 
generally referred to as lipotoxicity. A few in vivo studies support this results: one 
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study in adults reported an altered postprandial insulin secretion and sensitivity in 
response to a high dietary intake of palmitic acid[273], another study in children 
and adolescents showed that obese subjects with higher circulating levels of 
palmitic acid have an increased and delayed insulin secretion[274]. Furthermore, 
it has been shown that palmitic acid in plasma triglycerides was higher in 
abdominally obese adults as compared to the controls without central obesity and 
this FA profile was directly correlated to HOMA-IR[275].  
As already stated above, our results might indicate also a protective role of 
omega-6 PUFA, and in particular of AA, with respect to several cardiovascular 
risk factors. Previous studies investigating the effect of omega-6 in cardiovascular 
disease gave conflicting results, some suggesting no association between omega-6 
PUFA and the risk of hypertension[80] and other that the replacement of SFA 
with omega-6 PUFA is not associated with vascular and endothelial function but 
might improve BP[185]. Indeed, dietary intake of LA may contribute to 
prevention and control of elevated blood pressure[191]. Thus, although omega-6 
PUFA have been for a long time counter-posed to the beneficial omega-3 PUFA, 
recent insight supports their potential cardiovascular protective effect[189]. 
Also when considering specifically AA, the omega-6 which drive the observed 
association, available data show contrasting results. A higher amount of AA was 
found in adipose tissue in metabolically unhealthy obese adults compared to 
metabolically healthy control[186]. Then, in healthy children, AA, measured in 
adipose tissue and in skeletal muscle cells, was directly correlated to fasting 
insulin and HOMA-IR[199]. Nevertheless, some studies indicated a protective 
effect of AA, especially when measured in red blood cell membranes, on glucose-
insulin homeostasis[192,193], even if some observations suggest a beneficial 
effect in subject with low-normal insulin sensitivity but not in highly insulin-
sensitive individuals[194]. Interestingly, our exploratory analyses at follow up 
confirm a possible protective effect of AA on body weight and BP control also 
over time. It is not clear why GLA, in contrast to the other omega-6 FA, is 
directly correlated with a poorer metabolic profile. On one side, previous studies 
have indicated that GLA leads to the production of anti-inflammatory compounds, 
but GLA may also inhibit the metabolism of AA, at least in some types of 
cells[276]. Moreover GLA is yielded from LA by D6D and leads to the 
production of DGLA, which is the substrate of D5D. Therefore the association of 
GLA with the clinical parameters could also reflect the activity of the desaturase 
enzymes.  
In fact, also the role of fatty acid desaturase (SCD, D6D and D5D) has been 
linked to visceral obesity[265] and insulin resistance, suggesting an increased 
SCD and D6D and a decreased D5D activity in subjects with impaired insulin 
sensitivity and related disorders[277–279]. Our results support the findings of 
previous studies in adults, showing that the estimated D6D activity is directly 
related to a poorer metabolic profile, whereas D5D activity is inversely related, in 
our group of obese children. 
In addition, omega-6 PUFA, SFA and D6D showed to be correlated with waist 
circumference,  marker of central adiposity, supporting the association of dietary 
fat with the body fat distribution and the cardiometabolic profile, even if the 
association disappears after further adjustment for BMI.[280,281] 
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Furthermore, the associations of the different FA and FA families with a possible 
hepatic involvement, configuring the NAFLD, beside the correlation with the 
individual components of the Mets, supports the hypothesis that NAFLD 
represents a continuum with MetS subtended by insulin resistance as the common 
pathophysiological background[282]. 
Our study has limitations: the sample size is relatively low, which can primarily 
expose to a problem of statistical power. Nevertheless, we were able to detect 
some meaningful associations between lipid composition of erythrocyte 
membrane and many parameters of the MetS.  These results need to be confirmed 
in other studies analysing also samples of children of different ages and body size, 
including non-obese children. Moreover, data coming from other ethnic groups, 
which often have different dietary habits, could help a better understanding of 
these associations. Then, it remains to be clarified if the putative beneficial effect 
of omega-6 PUFA is specific for obese children and/or viewable only when 
omega-3 PUFA are under a certain threshold.  
Moreover, as above mentioned, the observational design of the study do not allow 
any causative link and the small number of children included in the follow-up 
limits the interpretation of these data. Further studies are needed to confirm our 
results. 
Lastly, we lack data about the total food intake of fatty acids and the amount of 
fatty acids and the other macronutrients in the diet, even if dietary tools to collect 
these data are often inaccurate, especially in children. Anyhow, it is possible to 
speculate that data from dietary assessment, like food frequency questionnaire or 
food diary, together with the measurement of fatty acids in red blood cell 
membranes, could have led to discover weather, on one side, the balance between 
different fatty acids or with the other macronutrients, on the other side if the entire 
family or a single FA play a role in metabolic modulation. 
Strengths of our study regards the exploration of a topic in children, in which only 
a few studies are available, the in-depth characterization of the children’s clinical 
and laboratory characteristics of the MetS, finally the use of the gold standard 
technique for the assessment of fatty acids in red blood cell membrane. 
Unfortunately, the longitudinal part of the study has collected only 1/3 of the 
initial sample but still allowed to confirm at least some association finally 
strengthening our conclusions. 
Further studies, including intervention trials, are needed in order to better 
understand the actions of the different FA on the single components of the MetS 
even in children. 
In conclusion, the present study shows an association between FA, reflecting their 
dietary intake, and MetS, which supports the hypothesis that the quality of fat 
intake, beyond the quantity, can influence the metabolic profile in obese children. 
Our findings agree with the current dietary recommendation to reduce the intake 
of SFA and support a possible beneficial effect of polyunsaturated FA intake, 
especially omega-6 PUFA. The level of omega-3 PUFA in our sample of obese 
children, is extremely low so that its putative beneficial effect could have not been 
detectable. 
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Table 1. General characteristics of the obese children at baseline. 
FLI: fatty liver index; HDL: HDL cholesterol; O-SBP: Office systolic blood pressure; O-DBP: 
Office diastolic blood pressure; TC: total cholesterol; TG: Triglycerides; Waist: Waist 
Circumference. 
1
 Wilcoxon-Mann-Whitney U Test2 Multivariate model includes variables significantly associated 
with sex and pubertal status, respectively, at univariate analysis plus age, sex and percentile BMI, 
where appropriate. * p<0.05 after False-Discovery-Rate adjustment for multiple testing 
Variable 
Males 
(n=40) 
Median (range) 
Females 
(n=30) 
Median (range) 
p-
value1 
p-
value2 
Pre-pubertal 
(n=38) 
Median (range) 
Post-pubertal 
(n=32) 
Median (range) 
p-value1 p-
value2 
BMI (Kg/m2) 28.5 (23.1-42.7) 29.3 (24.5-40.6) 0.55 - 28.2 (23.9-38.4) 29.9 (23.1-42.7) 0.06 - 
Percentile BMI 98.3 (93.5-99.8) 98.7 (90.2-99.9) 0.50 0.36 98.9 (94.9-99.9) 98.0 (90.2-99.8) 0.03 0.56 
Waist (cm) 96.0 (79.0-122.0) 95.5 (82.0-119.0) 0.92 - 91.0 (79.0-122.0) 
97.0 (83.0-
119.0) 0.02 - 
Percentile Waist 97.1 (91.9-99.2) 98.2 (90.7-100.0) 0.04 0.11 97.9 (92.1-100.0) 97.0 (90.7-99.1) 0.01 0.09 
O-SBP (mmHg) 119.0 (102.0-163.0) 115 (105-143) 0.31 - 116.0 (102.0-163.0) 
122.0 (107.7-
152.3) 0.04 0.009 
Percentile O-SBP 85.1 (44.7-100.00) 78.2 (45.4-99.9) 0.92 - 80.8 (44.7-100.0) 
82.8 (45.4-
100.0) 1.00 - 
O-DBP (mmHg) 68.3 (52.0-88.3) 66.5 (56.7-83.7) 0.42 - 66.7 (56.7-88.3) 67.5 (52.0-83.7) 0.46 - 
Percentile O-DBP 65.7 (6.6-98.0) 65.4 (23.1-96.3) 0.93 - 66.1 (19.1-98.0) 63.2 (6.6-96.3) 0.29 - 
24h-SBP (mmHg) 118.0 (107.0-136.0) 
112.0 (100.0-
130.0) 0.001* 0.51 115.0 (102.0-136.0) 
117.0 (100.0-
130.0) 0.64 - 
Percentile 24h-SBP 74.0 (26.3-99.7) 51.7 (4.6-99.6) 0.10  - 75.6 (21.4-99.7) 51.1 (4.6-99.6) 0.01 0.08 
24h-DBP (mmHg) 68.0 (58.0-79.0) 64.0 (55.0-74.0) 0.001* 0.02 67.0 (55.0-79.0) 65.0 (58.0-78.0) 0.16 - 
Percentile 24h-DBP 56.6 (3.7-99.0) 34.5 (2.1-94.8) 0.005 * - 52.8 (2.1-99.0) 35.1 (3.7-98.4) 0.09 - 
TC (mg/dL) 160.0 (106.0-242.0) 
162.0 (93.0-
216.0) 0.96 - 163.0 (105.0-213.0) 
153.0 (93.0-
242.0) 0.75 - 
HDL (mg/dL) 49.0 (30.0-77.0) 52.0 (37.0-81.0) 0.07 - 50.0 (33.0-77.0) 49.0 (30.0-81.0) 0.91 - 
TG (mg/dL) 79.0 (28.0-285.0) 73.0 (34.0-143.0) 0.43 - 85.0 (28.0-285.0) 
69.0 (34.0-
208.0) 0.10 - 
AST (U/L) 27.5 (15.0-74.0) 21.5 (15.0-36.0) 0.004* 0.08 27.0 (15.0-74.0) 24.0 (15.0-59.0) 0.14 - 
ALT (U/L) 28.5 (13.0-189.0) 19.0 (13.0-61.0) 0.01 0.61 23.0 (13.0-189.0) 24.5 (13.0-157.0) 0.61 - 
GGT (U/L) 16.0 (4.0-79.0) 13.0 (6.0-28.0) 0.03 0.90 14.0 (4.0-79.0) 14.0 (4.0-47.0) 0.97 - 
Fast. GLU (mg/dl) 88.0 (81.0-117.0) 85.0 (70.0-99.0) 0.01 0.02 88.0 (75.0-117.0) 86.0 (70.0-108.0) 0.35 - 
Fast. INS (uU/ml) 19.2 (3.0-62.5) 17.8 (5.3-43.4) 0.79 - 17.8 (3.0-62.5) 20.7 (6.8-49.8) 0.28 - 
HOMA-IR 3.9 (0.6-18.0) 4.1 (0.0-8.0) 0.55 - 4.0 (0.6-18.0) 4.0 (0.0-12.4) 0.74 - 
FLI 31.9 (6.3-98.7) 31.5 (7.3-91.7) 0.46 - 25.3 (6.3-95.6) 33.4 (7.3-98.7) 0.30 - 
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Table 2. Correlations between different erythrocytes membrane FA and clinical and laboratory features of MetS and NAFLD. 
 Waist Z-score 
waist  
24h-
SBP 
Z-score 
24h-SBP 
24h-DBP Z-score 
24h-DBP 
Total chol. HDL chol. Triglycerides Insulin Glucose HOMA-IR ALT GGT FLI 
Omega-6 -0.393° -0.055 -0.218 0.054 -0.023 0.034 -0.005 0.365^ -0.322^ -0.377^ -0.037 -0.338* -0.287* -0.256* -0.435° 
LA -0.167 -0.125 0.097 0.224 0.171 0.199 0.061 0.327^ -0.087 -0.050 -0.033 -0.103 ns-0.154 -0.228 -0.194 
AA -0.352^ -0.058 -0.313* -0.105 -0.212 -0.163 -0.176 0.129 -0.379^ -0.337^ -0.056 -0.265 -0.331^ -0.221 -0.472° 
GLA 0.211 0.158 0.137 0.102 0.191 0.168 0.286* -0.069 0.368^ 0.408° 0.164 0.375^ 0.141 0.200 0.351^ 
DGLA 0.057 0.072 0.150 0.090 0.131 0.134 0.226 -0.092 0.384^ 0.196 0.233 0.240 0.151 0.158 0.218 
SFA 0.237* 0.060 0.196 0.057 0.153 0.106 0.017 -0.265* 0.262* 0.203 -0.084 0.258 0.284* 0.400^ 0.479° 
PA 0.354^ 0.119 0.132 -0.046 0.054 0.000 0.180 -0.222 0.400° 0.287* -0.049 0.335* 0.239 0.339^ 0.515° 
Omega-3 0.299* 0.039 0.048 -0.158 -0.114 -0.150 -0.012 -0.025 -0.156 0.105 -0.036 0.027 -0.001 0.007 0.109 
ALA 0.008 0.117 -0.073 0.037 0.048 0.057 0.124 -0.065 0.300* 0.241 0.256* 0.230 0.025 0.125 0.126 
EPA 0.390° 0.295* 0.151 0.010 -0.072 -0.097 0.010 -0.133 0.155 0.292* 0.152 0.346* 0.094 0.001 0.312* 
DHA 0.279* -0.042 0.022 -0.193 -0.138 -0.172 -0.026 -0.049 -0.169 0.074 -0.079 -0.019 -0.017 -0.012 0.089 
D6D 0.249* 0.201 0.147 0.091 0.176 0.150 0.240 -0.161 0.370^ 0.404^ 0.165 0.423^ 0.162 0.238 0.402^ 
D5D -0.155 -0.077 -0.202 -0.102 -0.171 -0.158 -0.239 0.109 -0.401° -0.229 -0.217 -0.239 -0.182 -0.164 -0.319* 
*: p<0.05;   ^: p<0.01, still significant after False-Discovery-Rate adjustment for multiple testing;   °: p<0.001, still significant after False-Discovery-Rate 
adjustment for multiple testing 
In the table are reported the rS values of the correlations. The underlined correlations are significant after adjustment for sex, age and BMI. AA: arachidonic 
acid; ALA: alpha-Linolenic; ALT: alanine aminotransferase; DGLA: dihomo-gamma-linolenic acid; DHA: Docosahexaenoic acid; D5D: delta-5 desaturase; 
D6D: delta-6 destaurase; EPA: Eicosapentaenoic acid ; FLI: fatty liver index; GGT: gamma-glutamyltransferase; GLA: gamma-Linolenic acid; HOMA-IR: 
Homeostatic model assessment – insulin resistance; LA: Linoleic acid; omega-3 PUFA are calculated as the sum of  ALA, EPA, Docosapentaenoic acid (DPA) 
and (DHA) ; omega-6 PUFA are calculated as the sum of LA, GLA, DGLA, AA, Docosatetraenoic acid (DTA),Eicosadienoic acid and C22:5 ω6, saturated FA 
(SFA) are calcuated as the sum of C14:0, Palmitic acid, Stearinic acid and Lignocerinic acid; PA: palmitic acid; Waist: waist circumference 
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Figure 1. Correlations of  total omega-6 FA and AA with some features of MetS 
and NAFLD 
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Omega-6 FA are calculated as the sum of LA, GLA, DGLA, AA, Docosatetraenoic acid (DTA), 
Eicosadienoic acid and C22:5 ω6; AA: Arachidonic acid; FLI: fatty liver index; Delta waist 
circumference was calculated as (Waist circumference at follow-up – basal waist circumference) / 
follow-up period (months). 
Figure 2. Correlations of SFA and PA with some features of MetS and NAFLD 
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Saturated FA (SFA) are calcuated as the sum of C14:0, Palmitic acid, Stearinic acid and 
Lignocerinic acid; PA: palmitic acid; NAFLD: non alcoholic fatty liver disease; FLI: fatty liver 
index. 
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Table 3. Median difference between follow-up and baseline of general 
characteristics in the whole sample of obese children and according to decrease 
(good complier) or increase (poor complier) of BMI with respect to baseline. 
Variable 
All children 
(N=25) 
Median difference 
FU-BL 
All 
children  
p-value1 
Good compliers (N=15) 
Median difference       
FU-BL 
Good 
compliers 
p-value1 
Poor compliers (N=10) 
Median difference       
FU-BL 
Poor 
compliers  
p-value1 
BMI (Kg/m2) 
-0.4 0.11 -2.2 <0.0001 0.9 0.004 
Percentile BMI 
-1.2 <0.0001* -2.7 <0.0001 -0.5 0.19 
Waist (cm) 
-3.0 0.15 -4.0 0.04 2.5 0.82 
Percentile Waist. 
-0.5 0.18 -1.0 0.03 0.5 0.56 
O-SBP (mmHg) 
2.3 0.46 -2.3 0.55 9.0 0.13 
Percentile O-SBP 
-2.4 0.23 -8.7 0.04 4.9 0.56 
O-DBP (mmHg) 
2.0 0.38 -1.7 0.77 4.3 0.14 
Percentile O-DBP 
2.8 0.65 -5.1 0.56 10.5 0.19 
24h-SBP (mmHg) 
-0.5 0.39 -1.0 0.55 -0.5 0.57 
Percentile 24h-SBP 
-13.4 0.006 -16.3 0.02 -1.9 0.38 
24h-DBP (mmHg) 
0.0 0.26 0.0 0.66 -1.0 0.20 
Percentile 24h-DBP 
-4.4 0.009 -2.7 0.15 -7.0 0.02 
Tot. CHOL (mg/dL) 
-9.0 0.03 -9.0 0.06 -9.0 0.26 
HDL (mg/dL) 
3.0 0.03 3.5 0.06 1.0 0.44 
TRI (mg/dL) 
-13.5 0.02 -13.0 0.04 -14.0 0.25 
ALT (U/L) 
-3.0 0.11 -3.0 0.12 -2.0 0.67 
GGT (U/L) 
-2.0 0.24 -3.0 0.04 -1.0 0.75 
Glucose (mg/dl) 
-2.0 0.18 -2.0 0.09 0.0 1.00 
Insulin (uU/ml) 
-3.8 0.07 -4.7 0.19 -3.8 0.30 
HOMA-IR 
-0.8 0.25 -0.9 0.21 0.7 0.81 
 
ALT: alanine aminotransferase; BL: Baseline; BMI: Body Mass Index; FU: Follow-Up; GGT: 
gamma-glutamyltransferase; HDL: HDL cholesterol; HOMA-IR: Homeostatic model assessment – 
insulin resistance; O-SBP: Office systolic blood pressure; O-DBP: Office diastolic blood pressure;  
Tot. CHOL: total cholesterol; TRI: Triglicerides; Waist:Waist Circumference. 
Median difference FU-BL was calculated as the difference between the median value of the 
variable at follow-up (FU) and that at baseline (BL). 
1
 Wilcoxon Signed Rank Test for paired data 
* p<0.05 after False-Discovery-Rate adjustment for multiple testing 
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Supplemental Material Study 1 
 
Supplemental Table S1. Fatty Acids Composition of erythrocytes plasma 
membrane in the obese children at baseline. 
Variable 
Males 
(n=40) 
Median 
(range) 
Females 
(n=30) 
Median (range) 
Univ. 
 p-value1 
Multiv. 
 p-value2 
Pre-pubertal 
(n=38) 
Median (range) 
Post-pubertal 
(n=32) 
Median (range) 
Univ. 
 p-value1 
Multiv. 
 p-value2 
PA (%) 22.2 (20.4-24.7) 21.8 (20.3-23.7) 0.29 - 21.9 (20.4-24.4) 22.4 (20.3-24.7) 0.36 - 
LA (%) 11.7 (7.6-16.2) 11.9 (8.8-17.1) 0.38 - 12.2 (10.0-17.1) 11.5 (7.6-15.9) 0.10 - 
GLA (%) 0.1 (0.0-0.3) 0.1 (0.1-0.3) 0.33 - 0.1 (0.0-0.3) 0.1 (0.0-0.3) 0.19 - 
DGLA (%) 2.0 (1.6-3.2) 2.0 (1.3-2.7) 0.84 - 2.0 (1.6-3.2) 2.0 (1.3-2.8) 0.93 - 
AA (%) 16.0 (13.1-18.7) 16.4 (13.1-18.9) 0.12 - 16.2 (13.1-18.9) 16.2 (13.1-18.8) 0.51 - 
ALA (%) 0.1 (0.0-0.2) 0.1 (0.0-0.2) 0.56 - 0.1 (0.0-0.2) 0.1 (0.0-0.2) 0.04 0.10 
EPA (%) 0.4 (0.2-0.7) 0.4 (0.2-0.8) 0.40 - 0.4 (0.2-0.7) 0.4 (0.2-0.8) 0.09 - 
DHA (%) 4.3 (2.6-6.1) 4.4 (2.8-6.0) 0.38 - 3.9 (2.6-5.9) 4.7 (2.9-6.1) <0.0001* 0.001 
Omega3-Index (%) 4.6 (2.9-6.6) 4.6 (3.0-6.6) 0.36 - 4.3 (2.9-6.3) 5.1 (3.5-6.6) <0.0001* 0.001 
Omega-3 FA (%) 6.3 (4.3-9.0) 6.3 (4.5-8.7) 0.61 - 6.1 (4.3-8.5) 6.9 (5.2-9) 0.0004* 0.002 
Omega-6 FA (%) 35.4 (31.0-38.7) 35.6 (33.0-39.3) 0.08 - 36.1 (32.2-39.3) 35.0 (31.0-38.1) 0.02 0.002 
Omega-9 (%) 
16.4 (14.9-
19.8) 16.4 (14.0-19.4) 0.55 - 16.3 (14.4-19.4) 16.7 (14.0-19.8) 0.13 - 
SFA (%) 40.5 (38.0-42.2) 39.7 (37.7-41.6) 0.04 0.21 40.2 (38.0-42.2) 40.1 (37.7-42.1) 0.43 - 
D6D 0.009 (0.004-0.02) 0.008(0.004-0.02) 0.31 - 0.009 (0.004-0.02) 0.008 (0.005-0.02) 0.41 - 
D5D 7.6 (4.6-11.4) 8.1(5.7-13.6) 0.53 - 7.9 (4.6-11.1) 7.5 (5.1-13.6) 0.90 - 
AA: Arachidonic acid; ALA: alpha-Linolenic.PA: palmitic acid; DGLA: dihomo-gamma-linolenic acid; 
DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; D5D:  Δ5-desaturase = C20:4n-6/C20:3n-6; D6D: 
Δ6-desaturase = C18:3n-6/C18:2n-6; GLA: gamma-Linolenic acid;  Omega-3 Index: sum of Omega 3 fatty 
acids (EPA and DHA); LA: Linoleic acid; saturated FA (SFA) are calcuated as the sum of C14:0, Palmitic 
acid, Stearinic acid and Lignocerinic acid; Omega-3 FA are calculated as the sum of  ALA, EPA, 
Docosapentaenoic acid (DPA) and (DHA);  Omega-6 FA are calculated as the sum of LA, GLA, DGLA, AA, 
Docosatetraenoic acid (DTA),Eicosadienoic acid and C22:5 ω6 
1
 T-test or Wilcoxon-Mann-Whitney U Test, as appropriate 
2
 Multivariate p-values were calculated for fatty acids significantly associated with sex and puberal status, 
respectively, at univariate analysis. Covariates included general characteristics significantly associated with 
sex and pubertal status, respectively, at multivariate analysis (see Table 1a) plus age, sex and percentile BMI, 
where appropriate 
* p<0.05 after False-Discovery-Rate adjustment for multiple testing 
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Supplemental Table S2. General characteristic of the obese children divided 
according to the presence of liver steatosis and metabolic syndrome at baseline. 
FLI: fatty liver index; HDL: HDL cholesterol; O-SBP: Office systolic blood pressure; O-DBP: Office 
diastolic blood pressure;  TC: total cholesterol; TG: Triglycerides; Waist: Waist Circumference. 
1Wilcoxon-Mann-Whitney U Test; 2 For steatosis, multivariate model includes variables significantly 
associated with steatosis at univariate analysis plus age, sex and percentile BMI. Due to the low number of 
patients with MetS (N=5, all males), multivariate models were performed for each characteristic associated 
with MetS at univariate analysis with age and percentile BMI as covariates  * p<0.05 after False-Discovery-
Rate adjustment for multiple testing  
Variable Steatosis (n=34) 
Median (range) 
Not Steatosis (n=29) 
Median (range) 
p-value1 p-value2 MetS  (n= 5) 
Median (range) 
Not MetS (n=53) 
Median (range) 
p-value1 p-value2 
BMI (Kg/m2) 29.5 (23.9-42.7) 28.2 (23.1-37.2) 0.25 - 25.5 (23.1-42.7) 28.7 (23.9-40.6) 0.49 - 
Percentile BMI 98.8 (93.5-99.8) 98.2 (94.3-99.9) 0.33 0.16 97.5 (96.9-99.8) 98.6 (90.2-99.9) 0.38 0.99 
Waist(cm) 96.0 (79.0-119.0) 95.0 (82.0-121.0) 0.39 - 90.0 (83.0-118.0) 95.0 (79.0-122.0) 0.68 - 
Percentile Waist 97.7 (91.9-99.1) 97.1 (91.9-100.0) 0.53 - 97.3 (95.3-98.1) 97.3 (90.7-100.0) 0.48 - 
O-SBP (mmHg) 117.5 (102.0-152.3) 121.7 (105.0-163.0) 0.23 - 122.7 (112.7-152.3) 
119.0 (102.0-
163.0) 0.28 
- 
Percentile O-SBP 77.7 (47.5-100.0) 92.1 (48.3-100.0) 0.16 - 94.0 (68.8-100.0) 84.5 (45.4-100.0) 0.35 - 
O-DBP (mmHg) 67.3 (56.7-82.7) 67.0 (52.0-88.3) 0.89 - 70.7 (62.0-82.3) 68.0 (56.7-88.3) 0.92 - 
Percentile O-DBP 66.1 (19.1-93.5) 64.8 (6.6-98.0) 0.67 - 75.1 (40.7-87.1) 66.6 (19.1-98.0) 0.91 - 
24h-SBP (mmHg) 116.0 (107.0-130.0) 116.0 (100.0-136.0) 0.73 - 121.0 (118.0-128.0) 
115.0 (102.0-
136.0) 0.02 
0.04 
Percentile 24h-SBP 71.0 (24.5-99.6) 62.4 (4.6-99.7) 0.98 - 92.9 (27.0-99.1) 65.1 (13.3-99.7) 0.30 - 
24h-DBP (mmHg) 67.0 (58.0-79.0) 64.0 (55.0-78.0) 0.31 - 68.0 (58.0-78.0) 66.0 (55.0-79.0) 0.54 - 
Percentile 24h-DBP 48.6 (4.4-99.0) 34.5 (2.1-98.4) 0.40 - 60.5 (3.7-98.4) 42.5 (2.1-99.0) 0.70 - 
TC (mg/dL) 153.0 (105.0-242.0) 169.5 (125.0-216.0) 0.05 0.31 165.0 (124.0-242.0) 155.0 (93.0-216.0) 0.66 
- 
HDL (mg/dL) 49.0 (30.0-81.0) 50.4 (32.0-73.0) 0.29 - 33.0 (30.0-39.0) 50.0 (34.0-81.0) 0.002* 0.02 
TG (mg/dL) 75.0 (28.0-285.0) 81.5 (33.0-201.0) 0.94 - 196.0 (126.0-208.0) 72.0 (28.0-168.0) 0.001* 
0.04 
AST (U/L) 28.0 (15.0-74.0) 23.0 (16.0-33.0) 0.04 0.41 31.0 (22.0-59.0) 24.0 (15.0-58.0) 0.25 - 
ALT (U/L) 28.0 (13.0-189.0) 20.0 (13.0-37.0) 0.001* 0.63 34.0 (20.0-157.0) 22.0 (13.0-62.0) 0.21 - 
GGT (U/L) 16.0 (9.0-79.0) 13.0 (4.0-23.0) 0.01 0.41 16.0 (13.0-47.0) 14.0 (4.0-32.0) 0.26 - 
Fast. GLU (mg/dl) 86.0 (73.0-117.0) 88.0 (70.0-101.0) 0.82 - 93.0 (82.0-101.0) 86.0 (70.0-117.0) 0.26 - 
Fast. INS (uU/ml) 19.1 (3.0-62.5) 18.5 (5.3-49.8) 0.33 - 27.9 (19.6-49.8) 17.6 (3.0-62.5) 0.04 0.07 
HOMA-IR 3.7 (0.0-18.0) 4.1 (1.2-12.4) 0.73 - 6.9 (4.0-12.4) 3.7 (0.0-18.0) 0.10 - 
FLI 36.0 (6.30-98.70) 26.7 (8.9-80.6) 0.11 - 39.0 (23.4-98.7) 29.9 (6.3-91.7) 0.25 - 
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Supplemental Table S3. Fatty Acids Composition of erythrocytes plasma 
membrane of the obese children divided according to the presence of liver 
steatosis and metabolic syndrome at baseline 
Variable Steatosis (n=34) 
Median (range) 
Not Steatosis (n=29) 
Median (range) 
p-value1 MetS  (n= 5) 
Median (range) 
Not MetS (n=53) 
Median (range) 
p-value1 Multiv. 
 p-value2 
PA (%) 22.0 (20.4-24.7) 22.4 (20.7-23.9) 0.50 23.8 (21.3-24.7) 21.7 (20.3-23.7) 0.0003* 0.008 
LA (%) 11.7 (7.6-16.2) 11.9 (8.8-17.1) 0.65 11.5 (8.9-12.5) 11.9 (7.6-17.1) 0.21 - 
GLA (%) 0.1 (0.0-0.2) 0.1 (0.1-0.3) 0.32 0.1 (0.1-0.2) 0.1 (0.0-0.3) 0.02 0.18 
DGLA (%) 2.1 (1.6-2.8) 1.8 (1.3-3.2) 0.15 2.1 (1.9-2.8) 1.9 (1.5-3.2) 0.15 - 
AA (%) 16.1 (13.1-18.8) 16.5 (13.4-18.9) 0.38 14.4 (13.9-15.2) 16.4 (13.1-18.9) 0.003* 0.01 
ALA (%) 0.1 (0.0-0.2) 0.1 (0.0-0.2) 0.95 0.1 (0.1-0.2) 0.1 (0.0-0.2) 0.23 - 
EPA (%) 0.4 (0.2-0.7) 0.4 (0.2-0.8) 0.80 0.4 (0.3-0.6) 0.4 (0.2-0.7) 0.21 - 
DHA (%) 4.4 (3.2-5.9) 4.3 (2.6-6.1) 0.69 4.5 (3.8-5.8) 4.3 (2.6-5.9) 0.20 - 
Omega-3 Index (%) 4.6 (3.5-6.5) 4.6 (2.9-6.6) 0.68 4.9 (4.3-6.5) 4.6 (2.9-6.3) 0.17 - 
Omega-3 PUFA (%) 6.3 (5.4-9.0) 6.6 (4.3-8.7) 0.46 6.8 (5.6-9) 6.3 (4.3-8.5) 0.22 - 
Omega-6 PUFA (%) 35.2 (31.0-38.7) 35.6 (32.1-39.3) 0.53 33.8 (31.0-35.1) 35.6 (32.6-39.3) 0.0002* 0.006 
SFA (%) 40.0 (37.7-42.2) 40.1 (38.6-41.8) 0.74 41.4 (40.9-42.2) 39.8 (37.7-41.6) 0.004* 0.08 
D6D 0.008 (0.004-0.02) 0.009 (0.004-0.02) 0.22 0.01 (0.01-0.02) 0.008 (0.004-0.02) 0.01 0.04 
D5D 7.3 (5.3-12.1) 8.6 (4.6-13.6) 0.13 7.3 (5.1-7.5) 8.2 (4.6-12.8) 0.08 - 
 
AA: Arachidonic acid; ALA: alpha-Linolenic.PA: palmitic acid; DGLA: dihomo-gamma-linolenic acid; 
DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; D5D:  Δ5-desaturase = C20:4n-6/C20:3n-6; D6D: 
Δ6-desaturase = C18:3n-6/C18:2n-6; GLA: gamma-Linolenic acid;  Omega-3 Index: sum of Omega 3 fatty 
acids ( EPA and DHA); LA: Linoleic acid; saturated FA (SFA) are calcuated as the sum of C14:0, Palmitic 
acid, Stearinic acid and Lignocerinic acid; Omega-3 FA are calculated as the sum of  ALA, EPA, 
Docosapentaenoic acid (DPA) and (DHA);  Omega-6 FA are calculated as the sum of LA, GLA, DGLA, AA, 
Docosatetraenoic acid (DTA),Eicosadienoic acid and C22:5 ω6 
1
 T-test or Wilcoxon-Mann-Whitney U Test, as appropriate 
2
 Multivariate models were performed for each characteristic associated with MetS at univariate analysis with 
age and percentile BMI as covariates   
* p<0.05 after False-Discovery-Rate adjustment for multiple testing 
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Supplemental Figure S1. Correlations between desaturase activity and features 
of MetS 
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 D6D: Δ6-desaturase = C18:3n-6/C18:2n-6; D5D:  Δ5-desaturase = C20:4n-6/C20:3n-6; FLI: Fatty 
Liver Index. 
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Study 2: Possible role of omega-3 and omega-6 PUFA and their metabolites 
via CYP450 in the modulation of blood pressure and arterial stiffness in 
a sample of obese children 
 
Introduction Study 2 
The prevalence of overweight and obesity in children and adolescents has been 
increasing in the last few decades worldwide. Childhood obesity can affect nearly 
every organ system and have serious brief term and long term consequences, 
including metabolic and hemodynamic complications, such as hypertension, 
insulin resistance and dyslipidemia[283].  
Beside the impact of body mass index (BMI) per se on blood pressure (BP), 
several mechanisms are implicated in hemodynamic controls. Dietary habits and 
in particular lipid intake can influence not only the weight but also 
haemodynamics[230]. Indeed, in the last years many studies tried to assess the 
role of several polyunsaturated fatty acids (PUFA), such as arachidonic acid 
(AA), an omega-6 PUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), which belong to omega-3 PUFA family, suggesting a beneficial 
cardiovascular effect of omega-3 (n-3) PUFA[68,77], whereas it is not clear 
whether omega-6 PUFA are cardioprotective or not[188,189].  
Omega-6 and omega-3 PUFA can be metabolized via cytochrome P-450 
(CYP450) in lipid mediators, which can have profound effects on blood pressure 
control[230]. 
AA can be metabolized by different CYP450 enzymes leading to the formation of 
several compounds: 5-6, 8-9, 11-12, 14-15-epoxyeicosatrienoic acids (EETs) via  
epoxygenase and 20-hydroxyeicosatetraenoic acid (20-HETE) via hydroxylases. 
In general, EETs have been shown to play a protective role in cardiovascular 
diseases through their anti-inflammatory, vasodilating and sodium excreting 
effects[201,202]. They are further metabolized by soluble epoxide hydrolase 
(sEH) to dihydroxyeicosatrienoic acids (DHETs), which are less potent or even 
inactive compounds. Instead, 20-HETE exerts a natriuretic action at kidney level, 
but, in the systemic vasculature, it induces vasoconstriction[284,285]. Linoleic 
acid (LA) is also metabolized by CYP450 epoxygenase to 9,10- and 12,13-
epoxyoctadecenoic acids (EpOMEs), which are converted by sEH to 9,10- and 
12,13-dihydroxyoctadecenoic acids (DiHOMEs). They have a potential toxic 
cardiovascular effects, probably mediated by mitochondrial dysfunction, and may 
affect the cardiac inotropic response, but the evidences are rare and 
diverging[286,287].  
Epoxyeicosatetraenoic acids (EEQs), yielded from EPA, have vasodilating and 
anti-inflammatory properties and are further metabolized by sEH to 
diydroxxyeicosatetraenoic acids (DiHETEs)[218,221,288].  
Epoxydocosapentaenoic acids (EDPs), derived from DHA via CYP-epoxygense, 
are potent vasodilators[221]; they are hydroxylaletd by sEH to 
dihydroxydocosapentaenoic acids (DiHDPAs). EPA and DHA can bind also 
CYP-hydroxylase producing 20-hydroxyeicosapentaenoic acid (20-HEPE) and 
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22-Hydroxydocosahexaenoic acid (22-HDoHE) respectively, whose biological 
activity is still largely unknown. 
Thus, the aim of the present study was to explore the effect of the contents of 
different PUFA in erythrocytes plasma membranes, an index of their dietary 
intake, and of their metabolites via CYP450/sEH in the modulation of 
haemodynamic parameters and especially BP in a sample of obese children.  
 
 
Methods Study 2 
Obese children were recruited consequently from October 2012 to September 
2014, coming from the “Pediatric Obesity Outpatients Unit” of the University 
Hospital of Verona and of the “Local Health Unit n. β0” of Verona. Inclusion 
criteria were: children and adolescents aged 5-18 years old; overweight or obesity 
(BMI≥85th and 95th percentile for sex and age, respectively). We excluded 
children with hepatic or renal chronic diseases, malignancies, diabetes mellitus, 
lipid-lowering therapy, secondary causes of obesity. 
STUDY DESIGN 
The study was conducted according to a cross-sectional observational design. The 
study was approved by the Ethical Committee of the University Hospital of 
Verona (CE n. 2218), and written informed consent was obtained from each 
participant’s parents. 
ASSESSMENTS 
Each child was evaluated in a single occasion, between 8 and 9 a.m. A 
questionnaire was administered to the patients and to the parents, dealing with 
medical history, family history, physiological and pathological information and 
use of drugs. Then, the participants underwent a physical examination. They were 
advised not to engage in strenuous exercise and to avoid consuming caffeine 
containing beverages within 12 hours preceding the vascular studies. 
During the visit, blood pressure was measured with a semiautomatic oscillometric 
device (TM-2551, A&D instruments Ltd, Abingdon Oxford, UK) 3 times, 3 
minutes apart with the patient lying supine for at least 10 minutes before the first 
measurement in a room with controlled temperature (22-24°C). The mean value of 
the 3 clinostatic measurements were calculated and considered for z-score and 
percentile calculation. Afterward, BP levels were confirmed by a measurement in 
the sitting position by the oscillometric device and by auscultatory method. 
Ambulatory blood pressure measurement was recorded with an oscillometric 
device (Specelabs 90217; Spacelabs Inc., Issaquah, Whashington, USA), which 
measured BP every 15 minutes during the day and ever 30 minutes during the 
night. Children and parents recorded physical activities, resting and sleeping time 
and symptoms on a dedicated diary. After recording, the daytime and nighttime 
periods (set to default at 0700 and ββ00 h, respectively) were adapted to “real” 
awake and sleep times according to what was declared in the diary of activity. 
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All of the values derived from BP measurements were transformed in z-score and 
percentile, according to normative values[257,258]. The 95th of office and 
ambulatory BP measurements was used as cut-off for hypertension, according to 
current European guidelines[26]. 
Body weight, height, and waist and hip circumferences were measured with the 
patient wearing light clothes. Body weight was measured by a calibrated balance 
and height by a calibrated stadiometer. 
Body mass index (BMI) calculated as weight in Kg divided by the square of 
height in m; waist/hip ratio was calculated as waist circumference in cm divided 
by hip circumference in cm and waist/height ratio (WHtR) was calculated as waist 
circumference in cm divided by height in cm. 
Waist circumference was transformed in z-score and percentile according to 
normative values[260]. Overweight or obesity  were defined for BMI≥90th and 
95th percentile for sex and age, respectively[255]. WHO reference for BMI was 
used for categorizing children into the overweight and obese groups[2]. 
Carotid Intima-media Thickness (cIMT) was assessed by ultrasound of carotid 
arteries (LogiQ P5 Pro) and the cIMT was estimated tracking the artery wall in the 
last centimeter of the common carotid artery and calculated by a dedicated 
software (Multimedia Video Engine II (MVE2) DSP Lab., Pisa CNR, Italy). The 
relative z-score and percentile were calculated according to reference values[289]. 
Endothelial function was assessed by ultrasound of the brachial artery using the 
Flow Mediated Dilatation (FMD) technique according to international guidelines 
and with the aid of a dedicated hardware (Multimedia Video Engine II (MVE2) 
DSP Lab., Pisa CNR, Italy)[290]. Common carotid artery distensibility (DC) was 
calculated as: DC = ΔA /(A* ΔP) where A is the diastolic lumen area, ΔA is the 
stroke change in lumen area, and ΔP is pulse pressure (PP). Changes in diameters 
were detected using ultrasound B-mode image sequences of the right and left 
common carotid arteries acquired at different steps and analyzed by the above 
mentioned automatic system[291]. The relative z-score and percentile were 
calculated according to reference values[289]. 
 Stiffness Index (SI) and Reflection Index (RI) were estimated by the Digital 
Volume Pulse (DVP) method and were obtained with the digital 
photoplethysmography PulseTracePT1000 (MicroMedical Ltd, Gillingham, Kent, 
UK)[292]. 
CYP-derived eicosanoids measurement 
Plasma samples (500 microliters) were subjected to alkaline hydrolysis and 
subsequent solid phase extraction was performed as described previously[293]. 
500 µL Methanol, 300 µL 10 molar sodium hydroxide and deuterated internal 
standards were added to 500 µL Plasma. The samples were hydrolyzed for 30 
minutes at 60 °C. The solution containing free fatty acids and metabolites were 
neutralized with acetic acid and adjusted to pH = 6.2. 
A solid phase extraction procedure using Agilent Bond-Elut-Certify II was 
performed as formerly described by Rivera[293].  
The LC-ESI-MS/MS method for determination of metabolites was described in 
detail in previous papers[294].  
  
 56 
Red blood cell membrane fatty acids measurement 
EDTA-blood tubes were centrifuged, plasma and buffy coat taken off, and 
erythrocytes frozen at -80C until analysis. Erythrocyte fatty acid composition was 
analyzed using the HS-Omega-3 Index® methodology as previously 
described[264,295]. Fatty acid methyl esters were generated from erythrocytes by 
acid transesterification and analyzed by gas chromatography using a GC2010 Gas 
Chromatograph (Shimadzu,Duisburg, Germany) equipped with a SP2560, 100-m 
column (Supelco,Bellefonte, PA) using hydrogen as carrier gas. Fatty acids were 
identified by comparison with a standard mixture of fatty acids characteristic of 
erythrocytes. A total of 26 fatty acids were identified and quantified. 
Results are given as percentage of total identified fatty acids after response factor 
correction. The coefficient of variation for EPA plus DHA and for most other 
fatty acids was 4%. Analyzes were quality-controlled according to DIN ISO 
15189. 
 
STATISTICS 
Data are presented as the median and range unless otherwise stated. The statistical 
analysis was performed using the software Statistical Package for Social Sciences 
software (SPSS / PC for Windows version 21.0). Bivariate nonparametric 
correlations were estimated by Spearman coefficient (rS).  
Differences in the measured parameters between normotensive and hypertensive 
children were analyzed by nonparametric (Wilcoxon-Mann-Withney U) tests. A 
two-tailed test with a p<0.05 was considered statistically significant. 
Results Study 2 
General characteristics 
We enrolled 70 children from October 2012 to October 2014, aged 5 to 17 years 
old. Four children had a BMI>90th and 66 children had a BMI >95th percentile for 
sex and age. All children had a central distribution of adiposity (percentile of 
waist circumference > 90th percentile). ABPM was available for 68 subjects. 
Plasma eicosanoids were measured in 69 children. Girls showed higher BP at the 
ABPM compared to boys. The mean Omega-3 Index was 4.7%. General 
characteristics of the obese children split in males and females and normotensive 
and hypertenive, diagnosed on the basis of ABPM (daytime, nighttime or 24-
hours SBP or DBP >95th percentile), are detailed in Table 1, plasma eicosanoids 
in Table 2. The characteristics of the children divided according to pubertal status 
are listed in Supplemental Table S1. 
When dividing the population in two groups, hypertensive (n: 18) and 
normotensive (n: 50), no differences in FA or their derived-eicosanoids via 
CYP450/sEH were found between the two groups, except higher concentration of 
EEQs and DiHETEs in hypertensive compared to normotensive (see Table 2). 
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Table 1. General characteristics of the obese children divided according to gender 
and hypertensive status 
 Males 
(n: 40) 
Females 
(n: 30) 
 Normotensive 
(n: 50) 
Hypertensive 
(n: 18) 
 
Variable median (range) median (range) p-value* median (range) median (range) p-value* 
BMI, Kg/m2 28.53 (23.06-42.75) 29.31(24.48-40.65) 0.469 28.33 (23.93;42.75) 30.33 (23.06;38.43) 0.104 
z-score BMI 2.13 (1.51-2.83) 2.22 (1.29-3.29) 0.809 2.05 (1.29;2.83) 2.41 (1.75;3.29) 0.005 
waist circ, cm 96 (79-122) 95.5 (82-119) 0.917 95.5 (80;121) 97.50 (79;122) 0.303 
z-score waist circ 1.89 (0-2.4) 2.09 (1.32-3.5) 0.473 1.88 (1.32;2.49) 2.12 (1.65;3.50) 0.006 
cIMT, mm 0.47 (0.33-0.61) 0.42 (0.32-0.55) 0.030 0.44 (0.32;0.61) 0.46 (0.32;0.56) 0.330 
z-score cIMT 2.15 (-1.86-3.81) 1 (-2.22-4.95) 0.091 1.20 (-2.22;3.67) 1.78 (-1.86;4.95) 0.334 
DC, 10-3/KPa 39.68 (19.46-54.01) 43.81 (27.42-63.1) 0.032 42.67 (19.46;63.10) 37.59 (19.71;58.61) 0.104 
z score DC media -1.52 (-4.17-0.01) -1.12 (-2.85-0.47) 0.102 -1.15 (-4.17;0.47) -1.65 (-4.12;-0.11) 0.080 
CC, mm2/KPa 1.16 (0.59-1.51) 1.16 (0.65-1.79) 0.907 1.20 (0.77;1.68) 1.04 (0.59;1.79) 0.072 
FMD, % 7.6 (-1.1-16) 6.2 (-0.3-14.2) 1.00 7 (-1.10;14.20) 6.90 (-0.30;16) 0.670 
RI, % 60.33 (33-83.33) 57.83 (20.33-81.67) 0.520 59.33 (31;81.67) 57.67 (20.33;83.33) 0.693 
SI, m/s 6.19 (5.03-9.07) 6.1 (4.73-8.44) 0.887 6.21 (5.03;8.44) 6.05 (4.73;9.07) 0.822 
O-SBP, mmHg 119 (102-163) 115 (105-143) 0.469 117 (102;163) 122.50 (109;160.33) 0.026 
z-score O-SBP 1.04 (-0.13-5.21) 0.78 (-0.12-3.21) 0.469 0.75 (-0.13;5.21) 1.65 (-0.04;4.95) 0.007 
O-DBP, mmHg 68.33 (52-88.33) 66.5 (56.67-83.67) 0.227 66.50 (52;88.33) 74.83 (58;83.33) 0.162 
z-score O-DBP 0.4 (-1.51-2.06) 0.4 (-0.74-1.78) 0.809 0.36 (-1.51;2.06) 0.89 (-0.62;1.72) 0.023 
24h-SBP, mmHg 118 (107-136) 112 (100-130) 0.004 114 (100;125) 121 (110;136) ≤0.001 
z-score 24h-SBP 0.64 (-0.63-2.77) 0.04 (-1.69-2.66) 0.141 0.04 (-1.69;1.70) 1.30 (0.05;2.77) ≤0.001 
24h-DBP, mmHg 68 (58-79) 64 (55-74) 0.006 65 (57;79) 69 (55;79) 0.001 
z -score 24h-DBP 0.17 (-1.79-2.32) -0.4 (-2.02-1.63) 0.050 -0.39 (-1.79;2.32) 0.41 (-2.02;2.14) 0.001 
Day-SBP, mmHg 123 (109-142) 115 (102-137) 0.014 117.50 (102;132) 126 (113;142) ≤0.001 
z-score day-SBP 0.58 (-1.1-2.93) 0.19 (-1.84-2.65) 0.327 0.20 (-1.84;1.35) 1.26 (0.01;2.93) ≤0.001 
Day-DBP, mmHg 71 (63-85) 67 (58-80) 0.055 68.50 (59;79) 73.50 (58;85) 0.013 
z-score day-DBP -0.2 (-1.57-2.23) -0.85 (-2.07-1.24) 0.025 -0.54 (-1.90;1.15) 0.21 (-2.07;2.23) ≤0.001 
Night-SBP, mmHg 108.5 (100-124) 104.5 (92-128) 0.592 105.50 (92;117) 116 (106;128) ≤0.001 
z-score night-SBP 0.8 (-0.28-2.63) 0.68 (-0.71-3.09) 0.801 0.51 (-0.71;1.59) 1.86 (-0.15;3.09) ≤0.001 
Night-DBP, mmHg 60.5 (49-73) 57 (48-69) 0.011 57 (48;66) 64 (52;73) ≤0.001 
z-score night-DBP 0.73 (-1.35-2.56) 0.36 (-1.18-1.7) 0.078 0.30 (-1.35;1.58) 1.25 (-0.48;2.56) ≤0.001 
BMI: body mass index; waist circ: waist circumference; cIMT: carotid intima-media thickness; 
DC: carotid distensibility; CC: carotid compliance; FMD: flow-mediated dilation; O-SBP/DBP: 
office systolic/diastolic blood pressure; 24h-SBP/DBP: 24-hours systolic/diastolic blood pressure; 
day-SBP/DBP: daytime systolic/diastolic blood pressure; night-SBP/DBP: nighttime 
systolic/diastolic blood pressure.  
*Wilcoxon-Mann-Whitney U test. 
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Table 2. Plasma eicosanoids and erythrocyte membrane FA profiles in obese 
children, divided according to gender and hypertensive status 
 Male (n: 40) Female (n: 30)  Normotensive (n: 50) Hypertensive (n: 18)  
Variable Median (Range) Median (Range) p-
value* 
Median (Range) Median (Range) p-
value* 
EpOMEs, ng/mL 11.56 (3.98;24.94) 10.41 (5.82;19.12) 0.561 10.49 (3.98;23.40) 10.75 (4.91;24.94) 0.687 
DiHOMEs, ng/mL 7.19 (2.28;44.93) 6.33 (2.72;13.55) 0.280 6.33 (2.28;24.73) 7.46 (3.11;44.93) 0.310 
EETs, ng/mL 7.5 (4.55;13.51) 7.64 (4.57;13.62) 0.835 7.33 (4.55;13.62) 8.37 (4,59;10.46) 0.108 
DHETs, ng/mL 4.14 (2.18;6.84) 4.03 (2.79;5.59) 0.840 3.99 (2.29;5.59) 4.03 (2.18;6.52) 0.334 
EEQs, ng/mL 0.34 (0.18;1.22) 0.37 (0.15;1.64) 0.593 0.33 (0.15;1.64) 0.41 (0.18;0.99) 0.038 
DiHETEs, ng/mL 0.92 (0.57;3.55) 0.91 (0.45;2.04) 0.393 0.85 (0.45;3.55) 1.16 (0.56;2.97) 0.017 
EDPs, ng/mL 2.86 (1.79;7.01) 3.12 (1.99;6.86) 0.208 2.85 (1.84;7.01) 3.31 (1.79;5.35) 0.190 
DiHDPAs, ng/mL 0.9 (0.58;1.83) 0.92 (0.62;1.46) 0.581 0.88 (0.58;1.83) 0.91 (0.64;1.46) 0.604 
LA, % 11.7 (7.64;16.17) 11.93 (8.81;17.14) 0.627 11.68 (7.64;16.17) 12.35 (10.07;17.14) 0.116 
GLA, % 0.11 (0.04;0.29) 0.09 (0.05;0.33) 0.326 0.10 (0.04;0.15) 0.11 (0.06;0.33) 0.422 
DGLA, % 1.99 (1.57;3.2) 2 (1.27;2.73) 0.836 1.89 (1.27;2.78) 1.99 (1.57;3.20) 0.511 
AA, % 15.96 (13.06;18.73) 16.38 (13.14;18.91) 0.093 16.38 (13.06;18.91) 15.58 (13.36;18.73) 0.087 
ALA, % 0.08 (0.02;0.19) 0.08 (0.02;0.23) 0.533 0.07 (0.02;0.23) 0.08 (0.03;0.19) 0.966 
EPA, % 0.37 (0.22;0.74) 0.4 (0.19;0.81) 0.391 0.37 (0.19;0.74) 0.41 (0.25;0.81) 0.149 
DHA, % 4.3 (2.58;6.13) 4.35 (2.81;5.96) 0.437 4.36 (2.81;6.13 4.27 (2.58;5.96) 0.497 
Omega-3 Index, % 4.63 (2.87;6.61) 4.62 (3.00;6.57) 0.440 4.62 (3.00;6.61) 4.60 (2.87;6.57) 0.761 
Omega-3 PUFA, % 6.33 (4.32;9.02) 6.3 (4.46;8.7) 0.444 6.43 (4.51;9.02) 6.26 (4.32;8.70) 0.616 
Omega-6 PUFA, % 35.36 (31.02;38.68) 35.55 (33.04;39.29) 0.211 35.6 (31.02;39.29) 35.25 (32.07;38.68) 0.611 
SFA, % 40.45 (38;42.15) 39.65 (37.65;41.61) 0.044 40.18 (37.65;42.07) 39.60 (38.00;42.15) 0.404 
D5 7.62 (4.56;11.38) 8.06 (5.70;13.63) 0.527 8.06 (5.08;13.63) 7.35 (4.56;10.64) 0.373 
D6 0.008 (0.001;0.002) 0.008 (0.001;0.002) 0.301 0.01 (0.004;0.002) 0.01 (0.004;0.002) 0.552 
DHETE: dihydroxyeicosatrienoic acid; DiHDPA: dihydroxydocosapentaenoic acid; DiHETE: 
dihydroxyeicosatetraenoic acid; DiHOME: dihydroxyoctadecenoic acid; EDP: 
epoxydocosapentaenoic acid; EEQ: epoxyeicosatetraenoic acid; EET: epoxyeicosatrienoic acid; 
EpHOME: epoxyoctadecenoic acid; HDHA: hydroxydocosahexaenoic acid; AA: Arachidonic 
acid; ALA: alpha-Linolenic.PA: palmitic acid; DGLA: dihomo-gamma-linolenic acid; DHA: 
Docosahexaenoic acid; EPA: Eicosapentaenoic acid;  Omega-3 Index: ( EPA +  DHA)/total 
FA*100; LA: Linoleic acid; saturated FA (SFA) are calcuated as the sum of C14:0, Palmitic acid, 
Stearinic acid and Lignocerinic acid; Ω-3 FA are calculated as the sum of  ALA, EPA, 
Docosapentaenoic acid (DPA) and DHA;  Ω-6 FA are calculated as the sum of LA, GLA, DGLA, 
AA, Docosatetraenoic acid (DTA),Eicosadienoic acid and C22:5 ω6.  
* Wilcoxon-Mann-Whitney U test. 
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Correlations between fatty acids and the relative CYP450/sEH metabolites 
LA was directly correlated with DiHOMEs in the whole population, with 12,13-
EpOME and DiHOMEs in hypertensive and with the single isomer 9,19-
DiHOME in normotensive children.  
EPA directly correlated with EEQs and DiHETEs in the whole population and in 
the subgroups, with stronger correlations in hypertensive subjects. DHA was 
directly correlated with EDPs and DiHDPAs in the whole population and in 
normotensive and with EDPs in hypertensives. No correlations where found 
between AA and the relative metabolites via CYP450/sEH. (Table 3a, 3b, 3c, 3d) 
Table 3a. Correlations between LA and the relative  eicosanoids via CYP450/sEH  
LA 
 Whole population Normotensive Hypertensive 
9,10-EpOME -0.102 0.06 0.289 
12,13-EpOME 0.094 0.06 0.315* 
9,10-DiHOME 0.438^ 0.311* 0.679^ 
12,13-DiHOME 0.399^ 0.265 0.618^ 
In the table are reported the rS values of the correlations. * : significance below 0.05; ^: 
significance below 0.01. Underlined correlations are significant after adjustment for sex, age and 
BMI.  DiHOME: dihydroxyoctadecenoic acid; EpHOME: epoxyoctadecenoic acid; LA: Linoleic 
Acid.  
 
Table 3b. Correlations between AA and the relative eicosanoids via CYP450/sEH  
AA 
 Whole population Normotensive Hypertensive 
5,6-EET 0.029 0.152 -0.049 
8,9-EET 0.061 0.162 -0.064 
11,12-EET 0.049 0.096 0.177 
14,15-EET 0.040 0.114 0.074 
5,6-DHET 0.032 0.196 -0.251 
8,9-DHET 0.105 0.201 -0.051 
11,12-DHET 0.014 0.166 -0.418 
14,15-DHET 0.210 0.218 0.220 
20-HETE -0.057 -0.076 -0.076 
In the table are reported the rS values of the correlations. * : significance below 0.05; ^: 
significance below 0.01. Underlined correlations are significant after adjustment for sex, age and 
BMI.  AA: Arachidonic Acid; EET: epoxyeicosatrienoic acid; DHET: Dihydroxyeicosatrienoic 
acids. 
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Table 3c. Correlations between EPA and the relative eicosanoids via 
CYP450/sEH  
EPA 
 Whole population Normotensive Hypertensive 
8,9-EEQ 0.434^ 0.267 0.784^ 
11,12-EEQ 0.575^ 0.482^ 0.794^ 
14,15-EEQ 0.641^ 0.590^ 0.808^ 
17,18-EEQ 0.552^ 0.509^ 0.643^ 
5,6-DiHETE 0.512^ 0.441* 0.652^ 
8,9-DiHETE 0.398^ 0.337* 0.446 
11,12-DiHETE 0.217 0.244 -0.023 
14,15-DiHETE 0.464^ 0.393^ 0.532* 
17,18-DiHETE 0.484^ 0.431^ 0.440* 
In the table are reported the rS values of the correlations. * : significance below 0.05; ^: 
significance below 0.01. Underlined correlations are significant after adjustment for sex, age and 
BMI. EEQ: epoxyeicosatetraenoic acid; DiHETE: Dihydroxyeicosatetraenoic acids; EPA: 
Eicosapentaenoic acid. 
 
Table 3d. Correlations between DHA and the relative eicosanoids via 
CYP450/sEH  
DHA 
 Whole population Normotensive Hypertensive 
7,8-EDP 0.482^ 0.553^ 0.666^ 
10,11-EDP 0.375^ 0.360* 0.569^ 
13,14-EDP 0.467^ 0.515^ 0.563^ 
16,17-EDP 0.502^ 0.591^ 0.546^ 
19,20-EDP 0.456^ 0.581^ 0.473 
7,8-DiHDPA 0.453^ 0.521^ 0.324 
10,11-DiHDPA 0.220 0.310* 0.205 
13,14-DiHDPA 0.256* 0.325* 0.290 
16,17-DiHDPA 0.386^ 0.531^ 0.086 
19,20-DiHDPA 0.383^ 0.565^ 0.010 
22-HDHA 0.039 0.067 -0.015 
In the table are reported the rS values of the correlations. * : significance below 0.05; ^: 
significance below 0.01. Underlined correlations are significant after adjustment for sex, age and 
BMI. EDP: epoxydocosapentaenoic acid; DiHDPA: dihydroxydocosapentaenoic acid; DHA: 
Docosahexaenoic acid. 
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Correlations of CYP450/sEH – derived eicosanoids with blood pressure and 
vascular tests 
In the whole population, total DiHOME and 9,10- DiHOME correlated with 
office and nighttime DBP and the relative z-score. Both isomer and total 
DiHOME were also directly correlated to RI. 20-HETE was directly correlated 
with office DBP and its z-score. (The correlations of eicosanoids with blood 
pressure, z-score of blood pressure and vascular tests are detailed in Table 4 and 
Supplemental Tables S2 and S3, respectively) 
 
Correlations of erythrocyte membrane FA with BP and vascular tests 
RI was directly correlated with LA and inversely with DHA and total omega-3 
PUFA. The z-score of IMT was inversely correlated with EPA. (The correlations 
of fatty acids with blood pressure, z-score of blood pressure and vascular tests are 
detailed in Table 5, Supplemental Table S4 and Table 6 respectively) 
 
Correlations of blood pressure with vascular tests 
DC and the relative z-score were inversely correlated with almost all office and 
ambulatory BP measurements. IMT directly correlated with 24-hours SBP and 
nighttime SBP. RI showed an inverse correlation with office SBP. (The 
correlations of blood pressure with vascular tests are detailed in Table 7 and 
correlations of z-score of blood pressure with vascular tests are detailed in 
Supplemental Table S5) 
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Table 4. Correlation between eicosanoids and blood pressure in the total population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the correlations. The correlations refer to the total amount of 
each ecosanoid acid. Singular isomers that are significant are reported below each correlation value. Underlined correlations are significant after adjustment for 
sex, age and BMI. DHETE: dihydroxyeicosatrienoic acid; DiHDPA: dihydroxydocosapentaenoic acid; DiHETE: dihydroxyeicosatetraenoic acid; DiHOME: 
dihydroxyoctadecenoic acid; EDP: epoxydocosapentaenoic acid; EEQ: epoxyeicosatetraenoic acid; EET: epoxyeicosatrienoic acid; EpHOME: 
epoxyoctadecenoic acid; HDHA: hydroxydocosahexaenoic acid; O-SBP/DBP: office systolic/diastolic blood pressure; 24h-SBP/DBP: 24-hours 
systolic/diastolic blood pressure; day-SBP/DBP: daytime systolic/diastolic blood pressure; night-SBP/DBP: nighttime systolic/diastolic blood pressure. 
Whole Population 
 Office SBP Office DBP 24h-SBP 24h-DBP Day-SBP Day-DBP Night-SBP Night-DBP 
EpOMEs -0.044 0.121 0.009 0.097 -0.010 0.098 -0.050 0.021 
DiHOMEs 
 
-0.076 0.288* 
 
9.10-DiHOME    0.323^ 
0.067 
 
 
0.179 -0.015 0.082 0.141 0.286* 
 
9.10-DiHOME    0.290* 
EETs 0.082 0.046 0.056 0.070 0.042 0.069 0.053 0.003 
DHETs 0.140 0.084 0.059 0.029 0.099 0.072 0.035 0.009 
EEQs 
 
-0.084 -0.147 
 
8.9-EEQ    -0.264* 
0.083 0.066 0.074 0.052 0.090 -0.025 
DiHETEs 
 
-0.057 -0.119 0.153 0.149 0.164 0.088 0.119 0.154 
EDPs -0.078 -0.110 0.021 -0.043 0.033 -0.038 -0.040 -0.093 
DiHDPAs -0.022 -0.043 -0.010 -0.067 0.045 -0.042 -0.136 -0.106 
22-HDHA -0.055 -0.048 -0.087 -0.181 -0.101 -0.173 -0.065 -0.201 
20-HETE 0.121 0.265* -0.006 0.059 -0.102 -0.037 0.104 0.178 
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Table 5. Correlation between erythrocyte membrane fatty acids and blood 
pressure measurements in the whole population, and after division in hypertensive 
and normotensive children. 
Whole population 
 Office SBP Office DBP 24h-SBP 24h-DBP Day-SBP Day-DBP Night SBP Night DBP 
Omega-6 PUFA -0.04 0.12 -0.22 -0.02 -0.247* 0.01 -0.15 -0.09 
LA -0.11 0.14 0.1 0.17 0.07 0.14 0.06 0.14 
AA -0.06 -0.14 -0.313* -0.21 -0.267* -0.11 -0.295* -0.344^ 
DGLA 0.08 0.13 0.15 0.13 0.1 0.07 0.14 0.12 
Omega-3 PUFA 0.1 -0.13 0.05 -0.11 0.08 -0.09 0.06 -0.03 
ALA -0.11 0.08 -0.07 0.05 -0.07 0.06 -0.01 0.01 
EPA 0.04 -0.15 0.15 -0.07 0.17 -0.08 0.15 0.01 
DHA 0.1 -0.11 0.02 -0.14 0.04 -0.13 0.01 -0.04 
Hypertensive 
 Office SBP Office DBP 24h-SBP 24h-DBP Day-SBP Day-DBP Night-SBP Night-DBP 
Omega-6 PUFA 0.319 0.270 -0.101 -0.244 -0.280 -0.255 0.064 -0.162 
LA -0.006 0.221 -0.359 -0.244 -0.384 -0.263 -0.383 -0.246 
AA 0.046 -0.145 0.101 -0.238 -0.031 -0.136 0.253 -0.245 
DGLA 0.096 0.184 0.351 0.030 0.239 -0.117 0.137 0.144 
Omega-3 PUFA -0.097 -0.448 0.229 -0.081 0.234 -0.018 0.242 -0.102 
ALA -0.194 -0.037 -0.158 0.137 -0.102 -0.082 0.07 0.179 
EPA -0.608* -0.563^ -0.067 -0.244 0.049 -0.172 -0.178 -0.383 
DHA -0.070 -0.395 0.152 -0.051 0.184 -0.002 0.128 -0.063 
Normotensive 
 Office SBP Office DBP 24h-SBP 24h-DBP Day-SBP Day-DBP Night SBP Night DBP 
Omega-6 PUFA -0.58 0.042 -0.245 0.066 -0.229 0.113 -0.188 0.009 
LA -0.180 0.089 0.056 0.233 0.062 0.208 0.052 0.229 
AA -0.034 -0.144 -0.325* -0.221 -0.268 -0.124 -0.335* -0.340* 
DGLA 0.040 0.071 0.078 0.103 0.035 -0.084 0.117 0.044 
Omega-3 PUFA 0.183 0.006 0.052 -0.126 0.085 -0.134 0.062 -0.013 
ALA -0.151 0.180 -0.123 0.102 -0.093 0.101 -0.084 -0.030 
EPA 0.169 -0.049 0.060 -0.131 0.092 -0.136 0.090 -0.044 
DHA 0.188 0.025 0.057 -0.151 0.067 -0.176 0.025 -0.025 
 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the 
correlations. AA: Arachidonic acid; ALA: alpha-Linolenic; DGLA: dihomo-gamma-linolenic acid; 
DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; LA: Linoleic acid; Omega-3 PUFA are 
calculated as the sum of  ALA, EPA, Docosapentaenoic acid (DPA) and (DHA);  Omega-6 PUFA 
are calculated as the sum of LA, GLA, DGLA, AA, Docosatetraenoic acid (DTA),Eicosadienoic 
acid and Cββ:5 ω6 
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Table 6. Correlations between erythrocyte membrane fatty acids and vascular 
tests in the whole population, and after division in hypertensive and normotensive 
children. 
 cIMT Z-score  
IMT 
DC Z-score  
DC 
RI SI FMD % 
Whole population 
Omega-6 PUFA -0.058 0.004 0.050 -0.027 0.142 -0.011 -0.209 
LA 0.086 0.105 0.131 0.106 0.354^ 0.147 -0.130 
AA -0.176 -0.144 0.097 0.051 -0.227 -0.222 -0.011 
DGLA -0.046 -0.030 -0.191 -0.207 0.023 0.123 0.211 
Omega-3 PUFA -0.129 -0.236 -0.162 -0.105 -0.291* -0.222 0.198 
ALA 0.064 0.059 0.022 0.016 0.008 -0.009 -0.031 
EPA -0.192 -0.272* -0.067 -0.012 -0.145 -0.175 0.164 
DHA -0.102 -0.200 -0.106 -0.054 -0.284* -0.197 0.133 
Hypertensive  
Omega-6 PUFA -0.070 -0.040 -0.191 -0.188 0.243 -0.017 -0.347 
LA -0.080 -0.003 0.197 0.197 0.468 0.412 -0.382 
AA -0.267 -0.269 0.038 0.030 -0.199 -0.571* -0.132 
DGLA 0.130 0.110 -0.235 -0.259 0.113 0.284 0.421 
Omega-3PU FA -0.063 -0.131 -0.165 -0.156 -0.439 -0.527* 0.001 
ALA 0.375 0.304 -0.121 -0.062 -0.027 0.155 0.084 
EPA -0.246 -0.308 0.403 0.393 -0.290 -0.189 0.271 
DHA -0.028 -0.057 -0.085 -0.088 -0.419 -0.519* -0.144 
Normotensive 
Omega-6 PUFA -0.001 0.111 0.113 0.017 0.073 -0.041 -0.122 
LA 0.142 0.181 0.132 0.108 0.289 -0.002 -0.185 
AA -0.067 -0.016 0.088 0.043 -0.287 -0.141 0.166 
DGLA -0.144 -0.132 -0.179 -0.202 -0.005 0.075 0.084 
Omega-3 PUFA -0.130 -0.250 -0.163 -0.087 -0.224 -0.053 0.277 
ALA -0.085 -0.091 0.081 0.043 0.061 -0.092 -0.106 
EPA -0.243 -0.359* -0.174 -0.099 -0.126 -0.130 0.142 
DHA -0.097 -0.217 -0.137 -0.061 -0.202 0.005 0.258 
 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values 
of the correlations. The underlined values represent the correlations that remain 
significant after adjustment for sex, age and BMI. AA: Arachidonic acid; ALA: alpha-
Linolenic; DGLA: dihomo-gamma-linolenic acid; DHA: Docosahexaenoic acid; EPA: 
Eicosapentaenoic acid; LA: Linoleic acid; Omega-3 PUFA are calculated as the sum of  
ALA, EPA, Docosapentaenoic acid (DPA) and (DHA);  Omega-6 PUFA are calculated as 
the sum of LA, GLA, DGLA, AA, Docosatetraenoic acid (DTA),Eicosadienoic acid and 
Cββ:5 ω6; cIMT: carotid intima-media thickness; DC: carotid distensibility; FMD: flow-
mediated dilation; RI: reflextion index; SI: stiffness index. 
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Table 7. Correlations between blood pressure and vascular test in the whole 
population, and after division in hypertensive and normotensive children. 
  O-SBP O-DBP 24h-SBP 24h-DBP Day-SBP Day-DBP Night-SBP Night-DBP 
Whole Population 
cIMT 0.23 0.001 0.27 0.12 0.19 -0.03 0.33 0.21 
z-Score cIMT 0.15 -0.01 0.22 0.16 0.14 0.02 0.293* 00.22.00 
DC medio -0.627^ -0.332^ -0.449^ -0.272* -0.397^ -0.17 -0.490^ -0.336^ 
z-Score DC -0.572^ -0.332^ -0.395^ -0.285* -0.329^ -0.19 -0.464^ -0.330* 
FMD  -0.02 -0.03 0.06 0.11 0.08 0.12 0.01 0.11 
RI -0.255* -0.02 -0.1 0.01 -0.12 -0.04 -0.07 0.07 
SI -0.05 0.22 -0.15 0.12 -0.14 0.1 -0.24 0.03 
Hypertensive 
cIMT 0.058 -0.104 -0.038 -0.115 -0.193 -0.264 0.303 0.091 
z-Score cIMT -0.053 -0.130 -0.126 -0.093 -0.272 -0.241 0.197 0.122 
DC medio -0.744^ -0.200 -0.457 0.01 -0.602* -0.161 -0.517* -0.178 
z-Score DC -0.740^ -0.169 -0.487 -0.040 -0.630* -0.206 -0.479 -0.214 
FMD 0.054 0.203 0.635^ 0.575* 0.582* 0.548* 0.053 0.388 
RI 0.021 -0.080 -0.180 0.073 -0.093 0.156 -0.180 0.016 
SI -0.059 0.333 0.137 0.300 0.122 0.419 -0.265 0.245 
Normotensive 
cIMT 0.276 -0.004 0.321* 0.199 0.257 0.051 0.301* 0.230 
z-Score cIMT 0.175 -0.006 0.291* 0.252 0.232 0.107 0.273 0.258 
DC medio -0.582^ -0.343* -0.432^ -0.254 -0.374* -0.149 -0.471^ -0.330* 
z-Score DC -0.504^ -0.356* -0.354* -0.259 -0.282 -0.151 -0.417^ -0.303* 
FMD  0.04 -0.092 0.146 0.139 -0.146 -0.113 -0.109 -0.059 
RI -0.390* -0.027 -0.155 -0.04 -0.152 -0.098 -0.075 0.103 
SI -0.061 0.145 -0.253 -0.018 -0.257 -0.004 -0.231 -0.082 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the 
correlations. The underlined  values represent the correlations that remain significant after 
adjustment for sex, age and BMI. cIMT: carotid intima-media thickness; DC: carotid distensibility; 
CC: carotid compliance; FMD: flow-mediated dilation; O-SBP/DBP: office systolic/diastolic 
blood pressure; 24h-SBP/DBP: 24-hours systolic/diastolic blood pressure; day-SBP/DBP: daytime 
systolic/diastolic blood pressure; night-SBP/DBP: nighttime systolic/diastolic blood pressure. 
  
 66 
In an exploratory analysis, we tested whether the correlations of PUFA and the 
eicosanoids with BP and vascular tests were different in the two groups, as 
detailed in the following paragraphs and in supplemental material. 
 
Hypertensive children:  
Correlations of CYP450/sEH – derived eicosanoids with blood pressure and 
vascular tests 
EEQs, an in particular two isomers 11,12- and 17,18-EEQ, and DiHETEs, 
inversely correlated with office SBP. EDPs as well showed inverse correlations in 
particular with office DBP. 
EEQs were also inversely correlated with IMT and directly with DC. 
(Correlations of eicosanoids with BP values are detailed in Table 8 and those of 
the z-score of BP in Supplemental Table S6, Correlations of eicosanoids with 
vascular tests are presented in Table 9) 
 
Correlations of erythrocyte membranes FA with blood pressure and vascular tests 
In hypertensive children, we found inverse correlations between total omega-6 
PUFA with different ABPM, and in particular, LA inversely correlated with BP. 
AA inversely correlated with SI. Total omega-3 PUFA directly correlated with 
some BP measurements. (Correlations of FA with BP values are detailed in Table 
5 and those of the z-score of BP in Supplemental Table S4. Correlations of 
vascular tests are presented in Table 6) 
 
Correlations of blood pressure with vascular tests 
Office SBP and its z-score, 24-hours SBP were inversely correlated with DC and 
its z-score. Daytime SBP, daytime DBP and its percentile directly correlated with 
FMD. SI was inversely correlated with z-score of nighttime SBP. (The 
correlations of blood pressure with vascular tests are detailed in Table 7 and 
correlations of z-score of blood pressure with vascular tests are detailed in 
Supplemental Table S5) 
Regressions 
Most of the correlations remained significant after adjustment for sex, age and 
BMI, as detailed in the tables depicting the correlations. 
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Table 8 Correlations between eicosanoids and blood pressure measurements in hypertensive children 
Hypertensive 
 Office SBP Office DBP 24h-SBP 24h-DBP Day-SBP Day-DBP Night-DBP Night-DBP 
EpOMEs -0.256 -0.094 -0.315 -0.291 -0.428 -0.380 -0.271 0.068 
DiHOMEs -0.104 0.232 -0.252 -0.098 -0.363 -0.123 -0.266 0.037 
EETs -0.108 -0.287 -0.211 0.071 -0.087 0.183 -0.311 0.106 
DHETs 0.016 -0.109 -0.034 -0.050 0.112 0.046 -0.102 -0.047 
EEQs 
 
-0.539* 
11.12-EQQ    -0.694* 
17.18-EEQ    -0.584* 
-0.299 -0.2761 
11.12-EQQ    -0.492* 
-0.117 -0.080 -0.038 -0.439 
11.12-EQQ   -0.559* 
17.18-EEQ    -0.615^ 
-0.216 
DiHETEs 
 
-0.437 
17.18-DiHETE   -0.578* 
-0.120 -0.233 
17.18-DiHETE   -0.512* 
0.142 -0.076 
 
 
0.205 -0.348 
17.18-DiHETE   -0.596* 
0.089 
EDPs 
 
-0.176 
 
 
-0.519* 
7.8-EDP    -0.523* 
10.11-EDP    -0.540* 
16.17-EDP   -0.509* 
-0.093 -0.296 -0.038 -0.229 -0.361 
19.20-EDP    -0.598* 
-0.240 
DiHDPAs -0.090
 
-0.382
 
0.093 -0.183 0.277 -0.070 -0.195 -0.350 
22-HDHA  -0.135
 
-0.191
 
-0.252 -0.369 -0.107 -0.326 -0.109 -0.503* 
20-HETE -0.074
 
-0.147
 
-0.275
 
-0.213
 
-0.297
 
-0.254
 
0.033
 
-0.085
 
 * : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the correlations. The correlations refer to the total amount of each 
ecosanoid acid. Singular isomers that are significant are reported below each correlation value. Underlined correlations are significant after adjustment for sex, age and 
BMI. DHETE: dihydroxyeicosatrienoic acid; DiHDPA: dihydroxydocosapentaenoic acid; DiHETE: dihydroxyeicosatetraenoic acid; DiHOME: dihydroxyoctadecenoic 
acid; EDP: epoxydocosapentaenoic acid; EEQ: epoxyeicosatetraenoic acid; EET: epoxyeicosatrienoic acid; EpHOME: epoxyoctadecenoic acid; HDHA: 
hydroxydocosahexaenoic acid; O-SBP/DBP: office systolic/diastolic blood pressure; 24h-SBP/DBP: 24-hours systolic/diastolic blood pressure; day-SBP/DBP: 
daytime systolic/diastolic blood pressure; night-SBP/DBP: nighttime systolic/diastolic blood pressure. 
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Table 9. Correlations between eicosanoids and vascular tests in hypertensive children. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the correlations. The correlations refer to the total amount of each 
ecosanoid acid. Singular isomers that are significant are reported below each correlation value. Underlined correlations are significant after adjustment for sex, age and 
BMI. DHETE: dihydroxyeicosatrienoic acid; DiHDPA: dihydroxydocosapentaenoic acid; DiHETE: dihydroxyeicosatetraenoic acid; DiHOME: dihydroxyoctadecenoic 
acid; EDP: epoxydocosapentaenoic acid; EEQ: epoxyeicosatetraenoic acid; EET: epoxyeicosatrienoic acid; EpHOME: epoxyoctadecenoic acid; HDHA: 
hydroxydocosahexaenoic acid; cIMT: carotid intima-media thickness; DC: carotid distensibility; FMD: flow-mediated dilation; RI: reflextion index; SI: stiffness index. 
Hypertensive  
 cIMT  Z-Score  
cIMT  
DC  Z-Score  
DC  
RI  SI  FMD  
EpOMEs 
-0.063 0.034 0.050 0.093 0.206 0.275 -0.050 
DiHOMEs 
 
0.067 0.071 -0.132 -0.120 0.500* 
12.13-DiHOME    0.544* 
0.518* 
9.10-DiHOME    0.518* 
-0.004 
EETs -0.231 -0.061 0.314 0.214 0.294 -0.037 0.118 
DHETs -0.301 -0.273 0.155 0.071 0.032 0.066 0.296 
EEQs 
 
-0.605^ 
8.9-EEQ     -0.439* 
14.15-EEQ    -0.609^ 
17.18-EEQ    -0.615^ 
-0.620* 
8.9-EEQ     -0.539* 
14.15-EEQ    -0.657^ 
17.18-EEQ    -0.637* 
0.344 
11.12-EEQ    0.575* 
0.388 
11.12-EEQ    0.582* 
-0.278 -0.090 0.288 
DiHETEs 
 
-0.354 
5.6-DiHETE    -0.559* 
17.18-DiHETE    -0.550* 
-0.323 
5.6-DiHETE    -0.577* 
0.290 
 
 
0.209 0.134 0.153 
11.12-DiHETE    0.558* 
0.375 
5.6-DiHETE    -0.576* 
EDPs -0.098 0.002 0.312 0.237 -0.242 -0.527* 
13.14-EDP    -0.596* 
-0.220 
DiHDPAs -0.114 -0.104 0.148 0.086 -0.071 -0.131 -0.091 
22-HDHA -0.367 -0.461 0.011 0.050 -0.306 0.128 0.054 
20-HETE -0.058 0.034 0.073 0.005 0.346 0.022 0.023 
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Discussion Study 2 
Our main hypothesis was that dietary PUFA could affect hemodynamics, and in 
particular blood pressure, through the formation of the specific PUFA-derived 
metabolites via CYP450/sEH. Scarce are the evidence linking together the amount 
of fatty acids introduced by the diet and their metabolites via CYP450/sEH with 
hemodynamics in humans and, to our knowledge, this is the first study that 
investigated this link in children. Apart from the AA-EETs-DHETs cascade of 
metabolites, we found an interesting correlation between the metabolites via 
CYP450, supporting the idea that from a dietary assumption of specific omega-3 
PUFA (or at least a higher storage in plasma membrane) derives a higher 
production of their metabolites.   
Anyhow, our primary results do not support a major role of EETs/EEQs/EDPs on 
blood pressure maintenance in obese children, since they neither directly correlate 
with BP or other vascular exams in the whole sample nor are significantly 
different in normotensive as compared to hypertensive subjects, except EEQs that 
resulted higher in hypertensive children. Anyhow only a weak inverse correlation 
of 8,9-EEQ with office-DBP was detectable in the whole sample.  Moreover, we 
found also a weak inverse association between 20-HETE, a well-known 
vasoconstrictor compound, and office DBP but not with other BP measurements. 
The exploratory analyses in the subgroup of hypertensive children, instead seems 
to reveal a potential role of some metabolites (especially EEQs and EDPs) on BP. 
Especially EEQs, and in particular 11,12- and 17,18- isomers, showed inverse 
associations with several BP measurements and with the markers of vascular 
structure and function (namely, carotid IMT and distensibility) in hypertensive 
obese children. Even if this is only an exploratory analysis and should be 
examined with caution, it is compatible with the hypothesis that endothelium have 
other dominant vasodilatory substances such a nitric oxide and prostacyclin, so 
that the effect of endothelial derived hyperpolarizing factors (such as 
EETs/EEQs/EDPs) is viewable only in circumstances when these main 
mechanisms have been impaired. Interestingly, we found also a stronger 
association of FMD, an index of endothelial function, and daytime BP. 
A complex link between PUFA and BP is supported also by the literature where 
the putative beneficial effect of omega-3 PUFA on BP and subsequent 
cardiovascular events is often blurred, being evident in some trials but not in other 
or meta-analyses[76,77], with some studies available also in 
children[111,296][252]. We could hypothesize that also in these studies 
differences in the examined population could have led to different results. 
Despite plenty of studies in animal models[297], especially rats, the evidence that 
EETs could affect BP in humans is scanty. In particular, our group have found 
lower plasma EETs in patients affected by renovascular hypertension as compared 
to essential hypertension and controls[206] and an augmented production of EETs 
in plasma and placentas obtained by preeclamptic women[207,208].  
Little is known about the specific actions of the EPA/DHA-derived metabolites 
via CYP450/sEH on hemodynamic modulation both in animal models and 
humans but a few studies support a protective effect of blood pressure, at least for 
  
 70 
some single isomers[57,221] suggesting that their effect could be even more 
potent with respect to EETs.  
In our sample, the levels of the EPA-derived metabolites via CYP450/sEH were 
higher in hypertensive children, compared to normotensive. In the exploratory 
analysis, we also found that epoxymetabolites of EPA, and the relative diols, are 
inversely associated to SBP, whereas the epoxydes of DHA were inversely 
associated to DBP, especially in hypertensive subjects. Interestingly, EEQs and 
DiHETEs were also inversely associated with carotid IMT and distensibility in 
hypertensive but not in normotensive obese children. EPA itself showed a trend 
toward an inverse association with SBP in hypertensive subjects, even if it did not 
reach the statistically significance. 
Interestingly also some other study, according to our observation, suggests that 
EPA and DHA exert a stronger effect in hypertensive subjects as compared to 
normotensive [75–77].  
The observational design of the study and the exploratory analysis suggest to look 
at all these associations with caution. Anyhow, we hypothesize that EPA could 
exert a somehow protective action on blood pressure through their metabolites via 
CYP450/sEH, probably mediated by a beneficial influence on vascular structure 
and function, and this effect could be stronger in hypertensive obese children than 
in normotensive. The stronger correlations of EPA with its metabolites in 
hypertensive rather than in normotensive subjects support the hypothesis that their 
effect becomes more important when BP is higher.  
Indeed, DiHOME, the diols derived from LA via CYP450 and sEH metabolism, 
showed a direct correlation with diastolic BP in normotensive but not in 
hypertensive, as well as a direct association with RI suggesting that they 
negatively affect vascular stiffness and BP but only in normotensive obese 
children. Very little is known about the actions of EpOMEs and DiHOMEs; first 
data indicated a toxic effect of EpOME and probably of DiHOME that could be 
dose-dependent; they also could affect cardiac contractility, but the results are not 
always consistent[286,287]. On the other hand, a recent study has proposed a 
possible protective effect of 12,13-DiHOME on metabolic profile, due to its 
action on brown adipose tissue uptake of fatty acids[298]. Furthermore, an epoxy-
keto derivative of LA has been identified as a possible stimulating factor for 
aldosetrone secretion, but it is not to date understood its precursor and its 
metabolic pathway[299]. Furthermore, we found that LA was inversely correlated 
to BP in hypertensive subjects, suggesting a possible beneficial effect of LA on 
BP. These data are not easy to explain, considering at the same time the results of 
the metabolite of LA. Anyhow it should be considered that from each fatty acid 
derive a range of lipid mediators, which can have different actions. Moreover, also 
in a previous study in animal models it has been found a discrepancy in the effect 
of dietary intake of fatty acids, i.e. LA and ALA, on the composition of PUFA 
and their related metabolites[300].  
As above mentioned, the study has limitations: the sample size is relatively low, 
which can primarily expose to a problem of statistical power, thus, considering 
also the observational design of the study and the findings from the exploratory 
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analysis, the results should be carefully evaluated. Anyhow, some interesting 
correlations were found suggesting a link between the consumption of PUFA, 
their metabolic pathway via CYP450 and the haemodynamic homeostasis in obese 
children, opening this field to further investigations even in children. Furthermore, 
because of the major accuracy, we decided to define hypertension on the basis of 
ABPM, which is however not considered as the standard method for BP 
assessment in the clinical setting. Anyhow, we obtained also several office BP 
measurements, both in the supine position and in the recommended sitting 
position, that strengthened the results derived from ABPM. 
Globally, our data could suggest that single lipid mediators may exert specific 
actions in hemodynamic control in obese children, that may be different in 
hypertensive rather than in normotensive children. What remains to understand 
are the regulatory mechanisms that can modulate the metabolic pathways of the 
fatty acids, leading to the production of specific lipid mediators. Moreover, also 
the relations, or the competition, between different metabolic ways might affect 
the productions of active metabolites, thus influencing the final effect. 
In conclusion, this study sets out the steps to further investigate, in children as 
well in adults, the metabolism of dietary fatty acids, especially via CYP450, and 
the possible influence on hemodynamics and blood pressure control.  
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Supplemental Material Study 2 
Supplemental Table S1: general characteristics and eicosanoid profile in obese 
children devided according to pubertal status. 
  
  Post-Pubertal (n: 32) Pre-Pubertal (n: 38)   
Variable Mediana (Range) Mediana (Range) p values 
BMI, Kg/m2 29.85 (23.1;42.7) 28.21 (23.92;38.43) 0.23 
z-score BMI 2.06 (1.3;2.8) 2.29 (1.64;3.29) 0.23 
Waist, cm 97 (83;119) 91 (79;122) 0.26 
z-score Waist 1.87 (0;2.4) 2.04 (1.41;3.5) 0.01 
cIMT, mm 0.44 (0.3;0.6) 0.46 (0.33;0.56) 0.23 
z-score cIMT 1.19 (-2;3.7) 2.15 (-2.22;4.95) 0.09 
DC, 10-3/KPa 39.65 (19.5;56.2) 42.26 (19.71;63.1) 0.7 
z-score DC -1.23 (-4.2;0.5) -1.19 (-4.12;0.26) 0.9 
CC, mm2/KPa 1.14 (0.6;1.8) 1.16 (0.59;1.65) 0.9 
FMD % 7.9 (1.9;16) 6.6 (-1.1;13.6) 0.8 
RI, % 55 (20.3;76) 63.33 (37.33;83.33) 0.1 
SI, m/s 6.14 (4.7;9.1) 6.14 (4.73;8.44) 0.19 
O-SBP, mmHg 122 (107.7;152.3) 116 (102;163) 0.09 
z-score O-SBP 0.95 (-0.1;3.4) 0.87 (-0.13;5.21) 0.81 
O-DBP, mmHg 67.5 (52;83.7) 66.67 (56.67;88.33) 0.81 
z-score O-DBP 0.34 (-1.5;1.8) 0.42 (-0.88;2.06) 0.81 
24-h SBP, mmHg 117 (100;130) 115 (102;136) 0.81 
z-score 24h-SBP 0.03 (-1.7;2.7) 0.69 (-0.79;2.77) 0.26 
24h-DBP, mmHg 65 (58;78) 67 (55;79) 0.05 
z-score 24h-DBP -0.38 (-1.8;2.1) 0.07 (-2.02;2.32) 0.45 
day-SBP, mmHg 120 (102;138) 118 (104;142) 0.33 
z-score day-SBP 0.21 (-1.8;2.9) 0.58 (-1.07;2.93) 0.62 
day-DBP, mmHg 68 (61;85) 70 (58;84) 0.14 
z-score day-DBP -0.69 (-1.9;2.2) -0.33 (-2.07;1.98) 0.72 
night-SBP, mmHg 107 (95;128) 108 (92;124) 0.45 
z-score night-SBP 0.55 (-0.7;3.1) 1.11 (-0.7;2.63) 0.04 
night-DBP, mmHg 58 (48;67) 59 (51;73) 0.79 
z-score night-DBP 0.42 (-1.3;1.6) 0.57 (-0.88;2.56) 0.42 
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Supplemental Table S1 - continued 
 
 
 
 
 
 
 
 
BMI: body mass index; waist circ: waist circumference; cIMT: carotid intima-media thickness; 
DC: carotid distensibility; CC: carotid compliance; FMD: flow-mediated dilation; O-SBP/DBP: 
office systolic/diastolic blood pressure; 24h-SBP/DBP: 24-hours systolic/diastolic blood pressure; 
day-SBP/DBP: daytime systolic/diastolic blood pressure; night-SBP/DBP: nighttime 
systolic/diastolic blood pressure; DHETE: dihydroxyeicosatrienoic acid; DiHDPA: 
dihydroxydocosapentaenoic acid; DiHETE: dihydroxyeicosatetraenoic acid; DiHOME: 
dihydroxyoctadecenoic acid; EDP: epoxydocosapentaenoic acid; EEQ: epoxyeicosatetraenoic 
acid; EET: epoxyeicosatrienoic acid; EpHOME: epoxyoctadecenoic acid; HDHA: 
hydroxydocosahexaenoic acid. 
*Wilcoxon-Mann-Whitney U test. 
  
  Post-Pubertal (n: 32) Pre-Pubertal (n: 38)   
Variable Mediana (Range) Mediana (Range) p values 
EpOMEs, ng/mL 9.83 (4;22.3) 11.45 (4.91;24.94) 0.62 
DiHOMEs, ng/mL 6.01 (2.3;24.7) 7.84 (3.11;44.93) 0.63 
EETs, ng/mL 7.61 (4.6;13.6) 7.69 (4.55;13.51) 0.8 
DHETs, ng/mL 4.03 (2.3;6.5) 4.03 (2.18;6.84) 0.98 
EEQs, ng/mL 0.34 (0.2;1.6) 0.36 (0.17;1.22) 0.8 
DiHETEs, ng/mL 0.87 (0.5;3) 0.92 (0.52;3.55) 0.78 
EDPs, ng/mL 3.12 (1.8;6.9) 2.9 (1.79;7.01) 0.82 
DiHDPAs, ng/mL 0.98 (0.7;1.5) 0.82 (0.58;1.83) 0.02 
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Supplemental Table S2. Correlation between eicosanoids and z-score of blood pressure in the total population 
 
 
 
 
 
 
 
 
 
 
 
 
 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the correlations. The correlations refer to the total amount of each 
ecosanoid acid. Singular isomers that are significant are reported below each correlation value. Underlined correlations are significant after adjustment for sex, age and 
BMI.  
DHETE: dihydroxyeicosatrienoic acid; DiHDPA: dihydroxydocosapentaenoic acid; DiHETE: dihydroxyeicosatetraenoic acid; DiHOME: dihydroxyoctadecenoic acid; 
EDP: epoxydocosapentaenoic acid; EEQ: epoxyeicosatetraenoic acid; EET: epoxyeicosatrienoic acid; EpHOME: epoxyoctadecenoic acid; HDHA: 
hydroxydocosahexaenoic acid; O-SBP/DBP: office systolic/diastolic blood pressure; 24h-SBP/DBP: 24-hours systolic/diastolic blood pressure; day-SBP/DBP: 
daytime systolic/diastolic blood pressure; night-SBP/DBP: nighttime systolic/diastolic blood pressure.  
Total Population  
 Z-Score  
SBP 
Z-Score  
DBP 
Z-Score  
24h-SBP 
Z-Score  
24h-DBP 
Z-Score 
Day-SBP 
Z-Score  
Day-DBP 
Z-Score  
Night-SBP 
Z-Score  
Night-DBP 
EpOMEs -0.067 0.098 0.011 0.087 0.022 0.093 -0.044 0.038 
DiHOMEs 
 
0.032 0.359^ 
 
9.10-DiHOME   
 0.375^ 
0.133 0.179 0.043 0.077 0.193 0.309* 
 
9.10-DiHOME    0.312* 
EETs 0.091 0.036 0.036 0.061 0.029 0.059 0.001 0.006 
DHETs 0.152 0.077 0.056 0.036 0.090 0.081 -0.012 -0.020 
EEQs 
 
-0.115 -0.110 0.101 0.061 0.099 0.052 0.083 -0.019 
DiHETEs 
 
-0.065 -0.058 0.149 0.129 0.191 0.087 0.098 0.131 
EDPs -0.135 -0.114 -0.018 -0.040 -0.024 -0.031 -0.068 -0.067 
DiHDPAs -0.137 -0.091 -0.131 -0.065 -0.033 -0.021 -0.184 
 
16.17-DiHDPA 
   -0.261* 
-0.118 
22-HDHA -0.089 -0.092 -0.135 -0.183 -0.165 -0.163 -0.104 -0.236 
20-HETE 0.199 0.279* 0.003 0.059 -0.103 -0.51 0.132 0.153 
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Supplemental Table S3. Correlation between eicosanoids and vascular tests in the total population 
Total Population  
 cIMT  Z-Score  
cIMT  
DC medio Z-Score  
DC  
RI  SI  FMD % 
EpOMEs 0.056 0.067 0.057 0.076 -0.023 0.065 -0.159 
DiHOMEs 
 
-0.089 -0.060 0.055 0.044 0.402^ 
 
9.10-DiHOME    0.382* 
12.13-DiHOME    0.392^ 
0.231 -0.114 
EETs 0.082 0.107 0.019 -0.015 -0.045 0.022 -0.175 
DHETs -0.063 -0.015 -0.081 -0.081 -0.087 0.049 -0.037 
EEQs 
 
-0.183 -0.196 
 
14.15-EEQ    -0.241* 
-0.014 0.035 -0.138 -0.104 -0.008 
DiHETEs 
 
0.000238 0.005 -0.028 -0.020 -0.042 -0.110 0.191 
EDPs -0.079 -0.086 0.080 0.088 -0.150 -0.152 -0.159 
DiHDPAs -0.152 -0.167 0.065 0.093 -0.075 0.039 -0.093 
 
7.8-DiHDPA    0.250* 
22-HDHA -0.229 -0.246* -0.041 -0.036 -0.086 -0.132 -0.170 
20-HETE -0.009 0.046 -0.101 -0.125 0.123 0.142 -0.160 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the correlations. The correlations refer to the total amount of each 
ecosanoid acid. Singular isomers that are significant are reported below each correlation value. Underlined correlations are significant after adjustment for sex, age and 
BMI. DHETE: dihydroxyeicosatrienoic acid; DiHDPA: dihydroxydocosapentaenoic acid; DiHETE: dihydroxyeicosatetraenoic acid; DiHOME: dihydroxyoctadecenoic 
acid; EDP: epoxydocosapentaenoic acid; EEQ: epoxyeicosatetraenoic acid; EET: epoxyeicosatrienoic acid; EpHOME: epoxyoctadecenoic acid; HDHA: 
hydroxydocosahexaenoic acid; cIMT: carotid intima-media thickness; DC: carotid distensibility; FMD: flow-mediated dilation; RI: reflextion index; SI: stiffness index. 
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Supplemental Table S4. Correlation between fatty acids and z-Scores of blood 
pressure in hypertensive and normotensive population. 
Total population 
 z-Score 
SBP  
z-Score 
DBP  
z-Score 24-h 
SBP 
z-Score 24-h 
DBP 
z-Score Day-
SBP 
z-Score Day-
DBP 
z-Score 
Night-SBP 
z-Score Night-
DBP 
Omega-6 
FA 
0.14 0.21 0.05 0.03 -0.03 0.02 0.07 -0.08 
LA -0.03 0.18 0.22 0.20 0.19 0.13 0.21 0.16 
AA 0.01 -0.10 -0.11 -0.16 -0.10 -0.07 -0.15 -0.341^ 
DGLA 0.17 0.18 0.09 0.13 0.07 0.06 0.07 0.14 
Omega-3 
FA 
-0.08 -0.21 -0.16 -0.15 -0.06 -0.10 -0.06 -0.03 
ALA -0.04 0.12 0.04 0.06 0.04 0.08 0.05 0.03 
EPA -0.04 -0.16 0.01 -0.10 0.08 -0.09 0.05 0.04 
DHA -0.09 -0.21 -0.19 -0.17 -0.11 -0.13 -0.11 -0.04 
Hypertensive 
 z-Score 
SBP  
z-Score 
DBP  
z-Score 24-h 
SBP 
z-Score 24-h 
DBP 
z-Score Day-
SBP 
z-Score Day-
DBP 
z-Score 
Night-SBP 
z-Score Night-
DBP 
Omega-6 
FA 
0.346 0.323 -0.030 -0.220 -0.141 -0.249 0.113 -0.135 
LA 0.042 0.247 -0.265 -0.195 -0.257 -0.263 -0.168 -0.220 
AA 0.104 0.036 0.340 -0.214 0.263 -0.110 0.400 -0.253 
DGLA 0.100 -0.110 0.125 -0.009 0.071 -0.156 0.102 0.185 
Omega-3 
FA 
-0.174 -0.352 0.271 -0.119 0.267 -0.003 0.125 -0.125 
ALA -0.184 -0.187 -0.183 0.093 -0.146 0.077 -0.136 0.197 
EPA -0.576* -0.648^ 0.036 -0.271 0.079 -0.188 0.002 -0.382 
DHA -0.158 -0.224 0.218 -0.073 0.238 0.013 0.035 -0.088 
Normotensive 
 z-Score 
SBP  
z-Score 
DBP 
z-Score 24-h 
SBP 
z-Score 24-h 
DBP 
z-Score Day-
SBP 
z-Score Day-
DBP 
z-Score 
Night-SBP 
z-Score Night-
DBP 
Omega-6 
FA 
0.112 0.220 0.202 0.168 0.081 0.174 0.146 0.042 
LA -0.139 0.148 0.232 0.292* 0.166 0.247 0.249 0.251 
AA 0.081 -0.091 0.009 -0.153 -0.025 -0.059 -0.154 -0.333* 
DGLA 0.204 0.151 0.015 0.073 -0.002 0.007 0.097 0.083 
Omega-3 
FA 
-0.083 -0.097 -0.287 -0.160 -0.128 -0.115 -0.163 -0.029 
ALA -0.019 0.270 -0.008 -0.098 0.005 0.115 0.056 0.030 
EPA 0.005 -0.051 -0.143 -0.130 -0.069 -0.114 -0.042 -0.027 
DHA -0.096 -0.120 -0.315* -0.188 -0.173 -0.161 -0.212 -0.035 
 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the 
correlations. The underlined  values represent the correlations that remain significant after 
adjustment for sex, age and BMI. AA: Arachidonic acid; ALA: alpha-Linolenic; DGLA: dihomo-
gamma-linolenic acid; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; LA: Linoleic 
acid; Omega-3 FA are calculated as the sum of  ALA, EPA, Docosapentaenoic acid (DPA) and 
(DHA);  Omega-6 FA are calculated as the sum of LA, GLA, DGLA, AA, Docosatetraenoic acid 
(DTA),Eicosadienoic acid and Cββ:5 ω6; O-SBP/DBP: office systolic/diastolic blood pressure; 
24h-SBP/DBP: 24-hours systolic/diastolic blood pressure; day-SBP/DBP: daytime 
systolic/diastolic blood pressure; night-SBP/DBP: nighttime systolic/diastolic blood pressure. 
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Supplemental Table S5. Correlations between z-score of blood pressure with 
vascular tests in the general population, in hypertensive and in normotensive 
subjects 
 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the 
correlations. The underlined values represent the correlations that remain significant after 
adjustment for sex, age and BMI. cIMT: carotid intima-media thickness; DC: carotid distensibility; 
CC: carotid compliance; FMD: flow-mediated dilation; O-SBP/DBP: office systolic/diastolic 
blood pressure; 24h-SBP/DBP: 24-hours systolic/diastolic blood pressure; day-SBP/DBP: daytime 
systolic/diastolic blood pressure; night-SBP/DBP: nighttime systolic/diastolic blood pressure. 
  
  
Z-score    
O-SBP 
Z-score    
O-DBP 
Z-score  
24h-SBP 
Z-score  
24h-DBP 
Z-score 
Day-SBP 
Z-score 
Day-DBP 
Z-score 
Night-SBP 
Z-score 
Night-DBP 
Total Population 
cIMT 0.13 -0.05 0.2 0.08 0.14 -0.05 0.24 0.17 
z-Score cIMT 0.14 0.01 0.264* 0.14 0.18 0.001 0.289* 0.18 
DC -0.549^ -0.258* -0.312* -0.23 -0.293* -0.15 -0.376^ -0.293* 
z-Score DC -0.560^ -0.310* -0.334^ -0.252* -0.290* -0.16 -0.409^ -0.292* 
FMD -0.09 -0.06 -0.1 0.08 -0.05 0.11 -0.11 0.09 
RI -0.13 0.09 -0.01 0.03 -0.04 -0.04 -0.01 0.06 
SI -0.09 0.2 -0.18 0.14 -0.17 0.11 -0.23 0.06 
Hypertensive 
cIMT 0.318 0.079 -0.055 -0.039 -0.95 -0.134 0.136 0.174 
z-Score cIMT 0.171 -0.014 -0.132 -0.061 -0.161 -0.182 0.103 0.143 
DC medio -0.745^ 0.086 -0.354 0.086 -0.305* 0.042 -0.049 -0.022 
z-Score DC -0.701^ 0.103 -0.371 0.046 -0.358 -0.007 -0.005 -0.005 
FMD -0.055 -0.108 0.2 0.437 0.367^ 0.578* -0.258 0.247 
RI -0.046 -0.253 -0.358 -0.064 -0.345 -0.064 -0.33 -0.297 
SI -0.44 0.176 -0.46 0.42 -0.315 0.4 -0.765^ 0.118 
Normotensive 
cIMT 0.014 -0.187 0.163 0.133 0.112 -0.024 0.162 0.187 
z-Score cIMT 0.02 -0.109 0.265 0.204 0.187 0.046 0.224 0.211 
DC  -0.494^ -0.228 -0.252 -0.212 -0.239 -0.111 -0.365* -0.281 
z-Score DC -0.500^ -0.300* -0.265 -0.222 -0.213 -0.119 -0.397^ -0.268 
FMD -0.006 -0.034 -0.101 -0.007 -0.12 -0.041 0.002 0.055 
RI -0.259 0.078 -0.048 -0.025 -0.075 -0.083 -0.05 0.125 
SI -0.083 0.145 -0.249 0.029 -0.228 -0.009 -0.205 -0.005 
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Normotensive children: 
Correlations of blood pressure with vascular tests 
DC and the relative z-score were inversely correlated with office SBP and its z-
score, with office DBP and its z-score, with 24-hours SBP, daytime SBP, 
nighttime SBP and its z-score and with nighttime DBP. RI was inversely 
correlated with office SBP and SI with 24-h SBP. IMT and its z-score directly 
correlated with nighttime SBP and nighttime DBP. (The correlations of blood 
pressure with vascular tests are detailed in Table 3. and correlations of z-score of 
blood pressure with vascular tests are detailed in Supplemental Table S2 ) 
 
Correlations of erythrocyte membranes FA with blood pressure and vascular tests 
 In normotensive children AA showed an inverse correlation with BP, in 
particular nighttime BP, and an inverse correlation with RI. Also DHA was 
inversely correlated with RI. (Correlations of FA with BP values are detailed in 
Table 4 and those of the z-score of BP in Supplemental Table S3. Correlations of 
vascular tests are presented in Table 5) 
 
Correlations of CYP450/sEH – derived eoicosanoids with blood pressure and 
vascular tests 
In normotensive children 8,9-EEQs and 11,12-DiHETE showed several inverse 
correlations with DBP. EDPs inversely correlated with z-score of SBP, in 
particular office measurement. We found also a direct correlation of DiHOMEs 
with DBP. EDPs inversely correlated with the z-score of cIMT. RI was directly 
correlated with DiHOMEs and inversely with 5,6-EET and 5,6-DHET. 
(Correlations of eicosanoids with BP values are detailed in Supplemental Table 
S6 and those of the z-score of BP in Supplemental Table S7, Correlations of 
vascular tests are presented in Supplemental Table S8) 
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Supplemental Table S6. Correlations between eicosanoids and blood pressure measurements in normotensive children 
Normotensive 
 Office SBP Office DBP 24h-SBP 24h-DBP Day-SBP Day-DBP Night-SBP Night DBP 
EpOMEs -0.031 0.187 
 
0.107 0.184 0.112 0.235 -0.002 0.027 
DiHOMEs 
 
-0.080 0.313* 
 
9.10-DiHOME    0.349* 
0.072 0.197 -0.007 0.099 0.187 0.357^ 
 
9.10-DiHOME    0.355^ 
12.13-DiHOME    0.309* 
EETs 0.074 0.047 0.020 -0.028 -0.006 -0.023 -0.070 -0.188 
DHETs 0.200 
5,6-DHET 0.279* 
0.135 
 
0.019 0.045 0.054 0.065 -0.037 -0.005 
EEQs 
 
-0.057 -0.085 
 
8.9-EEQ    -0.331* 
-0.018 
 
 
0.026 -0.020 0.027 -0.049 -0.197 
DiHETEs 
 
-0.040 -0.150 
 
11.12-DiHETE    -0.293* 
0.049 0.032 0.069 -0.044 -0.034 -0.016 
EDPs -0.136 -0.042 -0.032 -0.037 -0.015 -0.035 -0.195 -0.187 
DiHDPAs -0.002 0.008 -0.076 -0.052 -0.037 -0.058 -0.252 -0.117 
22-HDHA 0.024 0.041 -0.031 -0.084 -0.072 -0.108 -0.027 -0.141 
20-HETE 0.134 0.285* 0.063 0.134 -0.050 0.001 0.157 0.258 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the correlations. The correlations refer to the total amount of each 
ecosanoid acid. Singular isomers that are significant are reported below each correlation value. Underlined correlations are significant after adjustment for sex, age and 
BMI. DHETE: dihydroxyeicosatrienoic acid; DiHDPA: dihydroxydocosapentaenoic acid; DiHETE: dihydroxyeicosatetraenoic acid; DiHOME: dihydroxyoctadecenoic 
acid; EDP: epoxydocosapentaenoic acid; EEQ: epoxyeicosatetraenoic acid; EET: epoxyeicosatrienoic acid; EpHOME: epoxyoctadecenoic acid; HDHA: 
hydroxydocosahexaenoic acid; O-SBP/DBP: office systolic/diastolic blood pressure; 24h-SBP/DBP: 24-hours systolic/diastolic blood pressure; day-SBP/DBP: 
daytime systolic/diastolic blood pressure; night-SBP/DBP: nighttime systolic/diastolic blood pressure. 
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Supplemental Table S7. Correlation between eicosanoids and z-scores of blood pressure in normotensive children 
Normotensive 
 Z-Score 
 SBP 
Z-Score  
DBP 
Z-Score  
24h-SBP 
Z-Score  
24h-DBP 
Z-Score 
Day-SBP 
Z-Score  
Day-DBP 
Z-Score  
Night-SBP 
Z-Score  
Night-DBP 
EpOMEs -0.037 0.180 0.055 0.178 0.110 0.229 -0.063 0.050 
DiHOMEs 
 
0.045 
 
 
0.405* 
 
9.10-DiHOME    0.423^ 
0.141 0.193 0.024 0.086 0.250 0.389^ 
 
9.10-DiHOME    0.387^ 
12.13-DiHOME    0.334^ 
EETs 0.016 -0.037 -0.110 -0.058 -0.086 -0.041 -0.213 -0.174 
DHETs 0.201 0.089 -0.017 0.046 0.015 0.068 -0.106 -0.059 
EEQs -0.091 -0.079 -0.055 0.013 -0.032 0.027 -0.098 -0.210 
DiHETEs 
 
-0.092 
 
11.12-DiHETE    -0.298* 
-0.119 -0.042 0.001 0.031 -0.053 -0.113 -0.053 
EDPs -0.283* 
 
13.14-EDP    -0.316^ 
19.20-EDP    -0.311* 
-0.129 -0.220 -0.057 -0.130 -0.026 -0.367* 
7.8-EDP    -0.367* 
10.11-EDP    -0.341* 
13.14-EDP    -0.361^ 
16.17-EDP    -0.313* 
19.20-EDP    -0.409* 
-0.159 
DiHDPAs -0.202 
 
 
-0.119 -0.289* -0.063 -0.156 -0.032 -0.379* 
7,8-DiHDPA      -0.381^ 
10,11-DiHDPA   -0.378^ 
 
16.17-DiHDPA    -0.401* 
-0.160 
22-HDHA -0.002 -0.014 -0.098 -0.096 -0.136 -0.101 -0.046 -0.201 
20-HETE 0.167 0.265 -0.008 0.113 -0.112 0.029 0.188 0.225 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the correlations. The correlations refer to the total amount of each 
ecosanoid acid. Singular isomers that are significant are reported below each correlation value. Underlined correlations are significant after adjustment for sex, age and 
BMI. DHETE: dihydroxyeicosatrienoic acid; DiHDPA: dihydroxydocosapentaenoic acid; DiHETE: dihydroxyeicosatetraenoic acid; DiHOME: dihydroxyoctadecenoic 
acid; EDP: epoxydocosapentaenoic acid; EEQ: epoxyeicosatetraenoic acid; EET: epoxyeicosatrienoic acid; EpHOME: epoxyoctadecenoic acid; HDHA: 
hydroxydocosahexaenoic acid; O-SBP/DBP: office systolic/diastolic blood pressure; 24h-SBP/DBP: 24-hours systolic/diastolic blood pressure; day-SBP/DBP: 
daytime systolic/diastolic blood pressure; night-SBP/DBP: nighttime systolic/diastolic blood pressure. 
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Supplemental Table S8. Correlations between eicosanoids and vascular tests in normotensive children  
Normotensive 
 cIMT  Z-Score  
cIMT  
DC  Z-Score 
 DC  
RI  SI FMD  
EpOMEs 0.056 0.058 0.041 0.071 -0.031 -0.048 -0.246 
DiHOMEs 
 
-0.194 -0.164 0.123 0.123 0.352* 
 
9,10-DiHOME    0.306* 
12,13-DiHOME    0.363* 
0.106 -0.247 
EETs 0.125 0.089 -0.017 -0.115 -0.204 0.021 -0.234 
DHETs -0.031 -0.016 -0.100 -0.258 -0.275 0.008 -0.173 
EEQs -0.199 -0.247 -0.047 -0.020 -0.122 -0.075 -0.058 
DiHETEs 0.001 -0.035 -0.082 -0.046 -0.164 -0.171 0.191 
EDPs -0.143 -0.213 
 
16,17-EDP    -0.290* 
19,20-EDP    -0.305* 
0.096 0.124 -0.182 -0.072 -0.096 
DiHDPAs -0.191 -0.262 
10,11-DiHDPA    -0.290* 
0.081 0.028 -0.195 0.034 -0.105 
22-HDHA -0.250 -0.268 -0.100 -0.117 -0.026 -0.058 -0.261 
20-HETE 0.0001 0.030 -0.151 -0.168 0.079 0.228 -0.044 
* : significance below 0.05; ^: significance below 0.01. In the table are reported the rS values of the correlations. The correlations refer to the total amount of each 
ecosanoid acid. Singular isomers that are significant are reported below each correlation value. Underlined correlations are significant after adjustment for sex, age and 
BMI.  
DHETE: dihydroxyeicosatrienoic acid; DiHDPA: dihydroxydocosapentaenoic acid; DiHETE: dihydroxyeicosatetraenoic acid; DiHOME: dihydroxyoctadecenoic acid; 
EDP: epoxydocosapentaenoic acid; EEQ: epoxyeicosatetraenoic acid; EET: epoxyeicosatrienoic acid; EpHOME: epoxyoctadecenoic acid; HDHA: 
hydroxydocosahexaenoic acid; cIMT: carotid intima-media thickness; DC: carotid distensibility; FMD: flow-mediated dilation; RI: reflextion index; SI: stiffness index. 
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Study 3: Blood pressure, fat distribution and vascular function in relation to 
polyunsaturated fatty acids in erythrocytes membranes, in children of 
primary schools: preliminary data 
 
Introduction Study 3 
A sedentary lifestyle and an unbalanced diet are the principal determinants of the 
onset of obesity in childhood as well as in adulthood. Longitudinal studies in 
children have documented that low levels of physical activity are unfavorably 
associated with the body composition[301–303].  
Anyhow the suggested targets, i.e. 60 minutes per day of physical activity 
(http://www.who.int/dietphysicalactivity/factsheet_young_people/en/), are 
reached by a minority of children, with various percentage according to the 
different ages[304]. On the other side, a diet rich in fat, in particular saturated 
fatty acids, is associated with a higher cardiovascular risk[305]. Moreover, a 
reduction in polyunsaturated fatty acids (PUFA) and an increased omega-6 to 
omega-3 PUFA ratio are correlated with a further increase in cardiometabolic risk, 
due to a worsening in insulin-sensitivity and a poorer plasma lipid profile[306]. 
The prevalence of obesity varies in the different Countries and in different age 
groups, because also to the different definitions and cut-off point available. In 
Italy it has been estimated that 12% children aged 8-9 year are overweight and 
22.2% obese, whereas the prevalence of severe obesity, based on WHO definition, 
is 4.5%[11]. A cross-sectional survey of childhood obesity was performed on 3923 
children aged 6-11 years from 19 Italian schools. About 27% of boys and 25% of 
girls were overweight and the prevalence of obesity was almost the same (21%) in 
boy and in girls. The prevalence of hypertension was 9.9% in boys and 13.9% in 
girls[15]. 
In this study we aimed to investigate the prevalence of body weight excess and 
elevated blood pressure in a sample of children of the 3rd and 4th classes of 
primary schools in Verona. We further investigated the influence of physical 
activity and dietary habits, in particular the intake of fatty acids, on weight excess, 
blood pressure and some indexes of vascular function. 
 
Material and methods Study 3 
Children were recruited from the 3rd and 4th classes of three primary schools of 
Verona South district. Inclusion criteria were the followings: children of the 
abovementioned classes who accepted to participate in the study and whose 
parents gave a written informed consent. Exclusion criteria were either the lack of 
written informed consent signed by the parents or refusal to participate by the 
child. 
 
Study design 
The study was conducted according to a cross-sectional observational design. The 
study was approved by the Ethical Committee of Verona (CESC n. 375). 
 
Assessment 
Children were evaluated in the morning from 8.00 a.m to 1 p.m. Fasting was not 
required. Two questionnaire were collected: a validated food frequency 
questionnaire (FFQ), integrated with specific questions about PUFA 
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intake[307,308] and a validated physical activity questionnaire (PAQ), integrated 
with semiquantitative data to calculate the weekly metabolic equivalent (METs) as 
presented in the international PAQ (iPAQ) [309–311]. 
The questionnaires were previously given and explained to the children and they 
were requested to fill it in with the aid of parents. All the questionnaires were then 
accurately checked by a dedicated dietician together with the child. 
Then, the participants underwent a physical examination with the collection of 
anthropometric measurements. Body weight, height, and waist and hip 
circumferences were measured with the patient wearing light clothes. Body 
weight was measured by a calibrated balance and height by a calibrated 
stadiometer. Body mass index (BMI) was calculated as weight in Kg divided by 
the square of height in m; overweight or obesity were defined for BMI≥90th and 
95th percentile for sex and age, respectively[255]. WHO reference for BMI was 
used for categorizing children into the overweight and obese groups[2]. Waist/hip 
ratio was calculated as waist circumference in cm divided by hip circumference in 
cm and waist/height ratio (WHtR) was calculated as waist circumference in cm 
divided by height in cm. Waist circumference was transformed in z-score and 
percentile according to normative values[260]. Through a bioelectrical impedance 
analysis (Tanita MC 780 MA ) was obtained an estimation of body composition 
and in particular an estimation of fat (%) and fat mass (FM, Kg), fat-free mass 
(FFM, Kg), total body water (TBW, Kg) and the basal metabolic rate (BMR, KJ 
and Kcal). During the visit blood pressure was measured by a semiautomatic 
oscillometric device with a specific validation for children (Omron 705 IT), [312], 
at least 3 times, 3 minutes apart with the patient lying supine for at least 10 
minutes before the first measurement in a room with controlled temperature (22-
24°C). The mean of the 3 BP measurements were transformed in z-score and 
percentile, according to normative values and current guidelines [258,313]. The 
95th of office BP measurements was used as cut-off for hypertension, according to 
current European guidelines[26]. 
 
Vascular tests 
Some indexes of systemic vascular stiffness, i.e. Stiffness Index (SI) and Reflexion 
Index (RI), were estimated by Digital Volume Pulse (DVP) method and were 
obtained with the digital photoplethysmography PulceTrace PT 1000 
(MicroMEdical Ltd, Gillingham, Kent, UK) as previously described[292]. 
Measures of the central arterial pressure waveform and pulse wave velocity as well 
as an assessment of arterial stiffness via waveform analysis (e.g., augmentation 
index, augmented pressure) were provided by SphygmoCor XCEL. 
To conduct a carotid-femoral PWV measurement, a cuff was placed around the 
femoral artery of the patient to capture the femoral waveform, and a tonometer 
was used to capture the carotid waveform. The distance between the carotid and 
femoral arteries was measured, and the velocity automatically determined by 
dividing the distance by the pulse transit time. The relative z-score and percentile 
were calculated according to reference values[314]. 
 
Laboratory measurements 
At 12 a.m., after at least 4 hours of fast, a few blood drops, in willing children, 
were collected by a fingerprick for plasma cholesterol, triglycerides and glucose 
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measurement, using an automatic point-of-care testing instruments (HPS 
MultiCare-in, Italy), as previously described [315]. 
 
For erythrocyte membrane fatty acid analysis, a single drop of scavenged whole 
blood was collected directly to a filter paper (Ahlstrom 226, PerkinElmer, 
Greenville, SC) that was pretreated with an antioxidant cocktail (Oxystop, 
OmegaQuant Analytics, LLC, Sioux Falls, SD) to protect unsaturated FAs from 
oxidation. After collection, cards were stored in a re-sealable plastic bag delivered 
immediately to Omegametrix GmbH (Martinsried, Germany) for analysis by 
capillary gas chromatography as described previously [316,317]. Fatty acid levels 
are expressed both as a weight percent of total blood fatty acids (composition). 
The stability of FAs collected and stored in this manner has been previously 
evaluated and no sample degradation was detected [318]. 
 
Estimation of Δ9 , Δ6  and Δ5 desaturase activity 
Δ9 , Δ6  and Δ5 desaturase are enzymes responsible for the endogenous formation 
of monounsaturated and polyunsaturated FA and their activity has been associated 
with insulin-glucose homeostasis and with central obesity. We estimated the 
desaturase activity as the ratio of product to precursor of individual red blood cell 
membrane FA as follows: Δ9-desaturase (SCD) = C16:1n-7/C16:0 and C18:n-
9/C18:0 (they will be referred to as  SCD-16 and  SCD-18, respectively);  Δ6-
desaturase (D6D) = C18:3n-6/C18:2n-6 and  Δ5-desaturase (D5D) = C20:4n-
6/C20:3n-6.[265,278] 
 
 
Follow-up of children with elevated BP 
The children who had elevated BP at the first evaluation were requested to 
undergo a medical examination that included a new height measurement, as above 
described, and BP measurement by the same semiautomatic oscillometric device 
(Omron 705 IT) as in the first visit. Blood pressure was measured in both arms, 
then in the arm with higher BP levels, BP measurements were repeated 5 times, 3 
minutes apart, with the children in the sitting position, in a quiet and tempered 
room, after at least 10 minutes resting. The mean of the last two measurements 
were then calculated and transformed in z-score and percentile according to 
current guidelines[313]. Than a BP measurement by a manual anaeroid device 
was obtained to confirm the oscillometric measurements. Children were advised 
to avoid strenuous physical activity before the medical examination.  
 
STATISTICS 
Data are presented as the mean ± standard deviation unless otherwise stated. The 
statistical analysis was performed using the software Statistical Package for Social 
Sciences software (SPSS / PC for Windows version 21.0). Bivariate parametric 
correlations were estimated by Pearson coefficient (r). 
Differences in the measured parameters between groups were analyzed by 
parametric (T-student test). A two-tailed test with a p<0.05 was considered 
statistically significant. 
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Preliminary results Study 3 
We enrolled 309 children, aged 8.64 ± 0.7 year, from March 2016 to May 2017 in 
3 primary schools of Verona. Hundred fifty-five were female (50%). General 
characteristics of the children are detailed in Table 1. 
All children underwent anthropometric measurements; vascular tests were 
performed in 303 children; 244 children accepted to undergo blood drop 
collection and FA analysis, as well glucose measurements, were obtained in 244 
children, whereas cholesterol was measured in 183 children and triglycerides in 
202 subjects. Results are missing in children who did not give the consent for 
blood drop or for technical reason (not enough blood to perform all the 
measurements). 
No significant differences of anthropometric parameters were found between 
males and females, except a higher body content of fat in girls (fat: 19 ± 8.3% vs 
22.3 ± 9.5%, p < 0.01 and fat mass: 7.2 ± 5.2 Kg vs 8.5 ± 5.7 Kg, p < 0.05, 
respectively). On the basis of the percentile of BMI, 19% (n: 60) of children were 
overweight and 13% (n: 42) were obese, without significant differences between 
boys and girls, even if the first showed a slightly higher prevalence of overweight 
and obesity in comparison to girls (overweight 20% vs 17% and obese 14% vs 
12%, p > 0.05, respectively) (Figure 1). 
Waist/height ratio, an index of central distribution of fat, was below 0.5 in 93% of 
normal-weight children, 48% in overweight children and 12% in obese children 
(Figure 2). 
When considering the subgroup of children with weight excess (obese + 
overweight) in comparison to the normal weight children, they showed higher 
SBP (including the z-score) and a higher percentile of PWV, which was anyhow 
within the normal range. The weight excess group had lower levels of total 
erythrocyte membrane omega-3 PUFA and of Omega-3 Index. The others FA did 
not differ between the groups. Omega-3 Index was lower than the suggested cut-
off point of 8% in 99.4% of the whole population and was lower than 4% in 
52.96%. In normal weight children the prevalence of Omega-3 Index below 4% 
was 47.3%, it increased to 55.3% in overweight and to 64% in obese subjects 
(Figure 3). On the basis of the percentile of basal BP measurements in the whole 
population, 22% (n: 65) children resulted to have BP values in the range of 
hypertension (>95th percentile) and 17% (n: 54) in the range of normal-high BP 
(>90th percentile but <95th percentile) and the prevalence of high blood pressure 
tended to be higher in obese children: 31% (n: 13/42) of obese children had BP in 
the range of hypertension and 12% (n: 5) in the range of normal-high BP, without 
statistically significant differences with the whole population. 
To date 25 willing children, who had BP in the range of hypertension at the basal 
visit, underwent the follow-up visit. At the re-evaluation of the children, after 
repeated BP measurements in standard conditions, only one child had BP levels in 
the range of hypertension and 2 children presented normal-high BP.  
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In the whole population, we found that SBP, DBP and central-DP were directly 
correlated with BMI, waist circumference, hip circumference and waist/height 
ratio, but the latter showed a weaker correlation with BP in comparison to the 
other anthropometric measurements. Even FM directly correlated with SBP, DBP 
and central-DP, whereas FFM was directly correlated with only SBP. When 
considering obese children, most correlations found in the whole population were 
significant and showed a higher strength. In particular, in obese subjects the direct 
correlation of waist/height ratio with BP was almost as strong as those of other 
anthropometric features and central-DP showed significant direct correlations 
with only waist circumference and waist/height ratio (The correlations of 
anthropometric features with BP and vascular tests are detailed in Table 2 for the 
whole population and in Table 3 for obese children, and showed in Figure 4). 
PWV showed direct correlations with SBP and DBP in the whole population, 
whereas in obese children it was more strongly correlated with DBP and central 
DP. 
In the whole population we found that Omega-3 PUFA and DHA showed a weak 
but significant inverse correlation with BMI (r= -0.134, p<0.05 and r=-0.143, 
p<0.05, respectively), waist/height ratio (r=-0.153, p<0.05) and the relative z-
scores, and also Omega-3 Index was inversely correlated to waist/height ratio (r=-
0.134, p<0.05), whereas GLA, an omega-6 FA, was directly correlated to z-score 
of BMI (r=0.149, p<0.05) and to waist/height ratio (r= 0.160, p<0.05). SFA and 
PA showed weak inverse correlation with BP (SFA - DBP: r= -0.130, p<0.05; PA 
- central-DP: r= -0.126, p<0.05) and with SI (r= -0.153, p<0.05 and r= -0.150, 
p<0.05, respectively). Omega-3 Index were also inversely correlated to plasma 
glucose and triglycerides (r= -0.169, p<0.01 and r= -0.142, p<0.05, respectively), 
as well as DHA. Total omega-6 PUFA were inversely correlated to triglycerides 
(r= -0.215, p<0.01) and also LA were inversely correlated, whereas omega-6 
PUFA showed a direct correlation with total cholesterol (r= 0.201, p<0.01). On 
the other hand, GLA showed a direct correlation with total cholesterol and 
glucose (r= 0.2169, p<0.01 and r= 0.158, p<0.05, respectively).  
The estimated activity of D5D showed an inverse correlation with waist 
circumference (r= -0.128, p<0.05), whereas D6D showed some weak correlations 
with waist/height ratio (r=0.165, p<0.05), plasma cholesterol and glucose (r= 
0.176, p<0.05 and r=0.172, p<0.01, respectively) (Figure 6). 
 In obese children we found that omega-3 PUFA were inversely correlated with z-
score of BMI (r= 0.350, p<0.05), whereas GLA and DGLA were directly 
correlated with some anthropometric measures (GLA-z-score BMI: r=0.350, 
p<0.05; DGLA-waist: r= 0.402, p<0.05; DGLA-waist/height: r= 0.347, p>0.05). 
In obese children total saturated FA (SFA) and palmitic acid (PA) were directly 
correlated with central-DP (r= 0.402, p<0.05 and r= 0.357, p<0.05, respectively); 
LA was directly correlated with SBP (r= 0.342, p<0.05). Omega-6 PUFA showed 
an inverse correlation with triglycerides (r= -0.610, p<0.019) and in particular LA 
was inversely correlated to triglycerides (r= -0.389, p< 0.05) and to plasma 
glucose (r=-0.370, p<0.05). The estimated activity of D5D showed inverse 
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correlations with waist circumference (r= -0.342, p<0.05) and with PWV (r= -
0.358, p<0.01) (Figure 6). 
Table 1. General characteristics of the children 
BMI: body mass index; FAT: FFM: free fat mass; TBW: total body water ; SBP: systolic blood 
pressure; DBP: diastolic blood pressure; Waist: waist circumference; RI: reflexion index; SI: 
stiffness index; Aix: augmentation index; PWV: pulse wave velocity; PA: palmitic acid; ALA: α-
linolenic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; LA: linoleic acid; GLA: 
gamma-linolenic acid; DGLA: dihomo-gamma-linolenic acid; AA: arachidonic acid; D5D: delta-5 
desaturase; D6D: delta-6 desatutrase.  
* Indipendent sample T-test
Variable Male            
(n: 154) 
Female           
(n: 155) 
p-value* Obese-Overweight 
(n:102) 
Normal-weight 
(n:204) 
p-value* 
BMI (Kg/m2) 18,1±3,2 18,3±3,7 0,662 21,8±3,1 16,3±1,6 0,0001 
Percentile BMI 63,8±30,1 61,8±32 0,575 93,7±4 46,4±26,2 0,0001 
Waist(cm) 63,5±9 62,4±10,4 0,339 71,7±8,3 58,1±6,5 0,0001 
Percentile Waist 56,8±31,2 55,6±31 0,740 85,1±15,8 40,5±25,4 0,0001 
Waist/Height ratio 0,5±0,1 0,5±0,1 0,845 0,5±0,1 0,4±0,1 0,0001 
Percentile W/H ratio 46,7±32 43,7±32 0,417 75,3±21,7 29,4±23,9 0,0001 
Waist/Hip ratio 0,9±0,1 0,8±0,1 0,309 0,9±0,1 0,8±0,1 0,002 
FAT 19±8,3 22,3±9,5 0,002 28,8±7,7 16,2±6,2 0,0001 
FAT_MASS (kg) 7,2±5,2 8,5±5,7 0,049 12,9±5,9 5,1±2,5 0,0001 
FFM (kg) 27±4,9 26,3±4,2 0,169 29,7±4,1 25±3,9 0,0001 
TBW (kg) 19,9±3,2 19,2±3,1 0,084 21,7±3 18,4±2,6 0,0001 
SBP (mmHg) 110,6±9,6 110,5±10,5 0,950 113±8,6 109,2±10,5 0,001 
Percentile -SBP 75,9±20,7 76,1±20,5 0,936 81±17,8 73,4±21,4 0,002 
DBP (mmHg) 66,4±7,6 67,1±8,1 0,428 67,5±7,7 66,3±7,9 0,199 
Percentile -DBP 70,1±19,8 72±19,7 0,386 71,9±19,2 70,6±20,1 0,572 
Central-DP (mmHg) 70,2±11,7 71,1±9,3 0,476 71,5±8,8 70,3±11,4 0,333 
RI (%) 77,7±11 73,5±13,3 0,003 71,6±12,9 77,9±11,5 0,0001 
SI (m/s) 6,2±1,3 6,6±1,9 0,073 6,3±1,3 6,5±1,8 0,407 
AIx (%) 6,9±13,6 9,5±12,9 0,097 7,9±13,1 8,4±13,4 0,787 
PWV (m/s) 4,7±1,5 4,6±0,9 0,778 4,8±1 4,6±1,4 0,213 
Glucose (mg/dl) 92,2±8,9 85,7±10,4 0,0001 89,3±9,4 87,8±10,5 0,270 
Cholesterol (mg/dl) 241,5±36,2 220,8±38,2 0,0001 228,15±40,4 231,9±37,7 0,534 
Triglyceride (mg/dl) 176,8±83,5 164,8±62,8 0,247 192,5±81,7 159,2±65,8 0,002 
PA, % 23,1±1,3 23±1,4 0,618 23,1±1,3 23±1,4 0,498 
ALA, % 0,2±0,1 0,1±0,1 0,345 0,1±0,1 0,2±0,1 0,133 
EPA, % 0,3±0,2 0,3±0,2 0,341 0,3±0,2 0,3±0,2 0,225 
DHA, % 2,8±0,7 2,9±0,7 0,584 2,7±0,7 2,9±0,8 0,013 
LA, % 19,9±2,3 19,8±2,8 0,924 19,7±2,2 19,9±2,8 0,523 
GLA, % 0,2±0,1 0,2±0,1 0,375 0,2±0,1 0,2±0,1 0,014 
DGLA, % 2±0,4 2±0,9 0,654 2±0,4 2±0,8 0,471 
AA, % 12,3±1,9 12,1±2 0,334 12,4±1,9 12,1±1,9 0,362 
Omega-3 Index, % 4±0,8 4±0,9 0,772 3,8±0,8 4,1±0,9 0,015 
Ω-3 PUFA, % 4,3±1,2 4,2±1 0,476 4,1±0,9 4,3±1,2 0,038 
Ω-6 PUFA, % 36,7±4,4 36,5±4,8 0,672 37±2,7 36,3±5,4 0,263 
Ω-9 FA, % 19,3±2,6 19,9±3,1 0,132 19,8±2 19,5±3,3 0,329 
Trans FA, % 0,7±0,3 1±3,8 0,349 0,6±0,3 0,9±3,4 0,420 
Saturated FA, % 24,9±2,8 24,8±2,8 0,782 25,1±1,5 24,7±3,3 0,303 
Total PUFA, % 60,3±6,2 60,5±7,1 0,806 60,9±2,4 60,2±8,2 0,396 
D5D 6.5±1.8 6.5±1.7 0.989 6.2±1.8 6.6±1.7 0.125 
D6D 0.010±0.007 0.009±0.004 0.272 0.011±0.007 0.009±0.004 0.007 
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Figure 1. Prevalence of overweight and obesity in the whole population and in 
males and females 
    
 
 
Figure 2. Distribution of waist/height ratio according to weight 
 
         
 
Figure 3. Omega-3 Index in the whole population and in the subgroups, divided 
according to gender and weight 
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Table 2. Correlations of anthropometric parameters with BP and vascular tests in 
the whole population 
 
In the table are presented the r values of the correlations. ^: p<0.01; *: p<0.05 SBP: systolic blood 
pressure; DBP: diastolic blood pressure; Central DP: central diastolic pressure; BMI: body mass 
index; FM: fat mass; FFM: fat free mass; hip: hip circumference; waist: waist circumference; 
PWV: pulse wave velocity. 
 
 
 
 
 
 
 
 
 
 
 
SBP 
z-score 
SBP DBP 
z-score 
DBP 
Central-
DP SI PWV 
z-score 
PWV 
BMI 0,291^ 0,236^ 0,158^ 0,089 0,138* -0,041 0,008 -0.024 
z-score BMI 0,257^ 0,214^ 0,133* 0,081 0,126* 0,021 -0,030 -0.050 
Waist 0,285^ 0,186^ 0,157^ 0,070 0,141* -0,004 0,069 0.038 
z-score Waist 0,261^ 0,176^ 0,161^ 0,103 0,140* 0,070 0,034 0.015 
Waist/Height 0,122* 0,092 0,099 0,070 0,065 0,010 -0,005 -0.003 
z-score Waist/Height 0,140* 0,128* 0,131* 0,129* 0,076 0,028 -0,02 0.023 
Hip 0,335^ 0,212^ 0,155^ 0,033 0,134* 0,018 0,061 0.012 
Waist/Hip 0,017 -0,08 0,023 0,008 0,030 0,003 0,019 0.048 
FM 0,327^ 0,237^ 0,204^ 0,111 0,191^ -0,062 0,050 0.008 
FFM 0,368^ 0,191^ 0,79 -0,084 0,110 0,003 0,101 0.032 
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Table 3. Correlations of anthropometric parameters with BP and vascular tests in 
obese children 
 
In the table are presented the r values of the correlations. ^: p<0.01; *: p<0.05 SBP: systolic blood 
pressure; DBP: diastolic blood pressure; Central DP: central diastolic pressure; BMI: body mass 
index; FM: fat mass; FFM: fat free mass; hip: hip circumference; waist: waist circumference; 
PWV: pulse wave velocity. 
 
SBP 
z-score 
SBP DBP 
z-score 
DBP 
Central-
DP SI PWV 
z-score 
PWV 
BMI 0,368* 0,321* 0,363* 0,313* 0,275 -0,228 -0,021 -0.158 
z-score BMI 0,067 0,087 0,043 0,055 0,051 -0,171 0,036 -0.055 
Waist 0,351* 0,291 0,380* 0,326* 0,356* -0,189 0,286 0.160 
z-score Waist 0,358* 0,314* 0,392* 0,364* 0,364* -0,086 0,314 0.226 
Waist/Height 0,312* 0,322* 0,383* 0,378* 0,360* -0,218 0,224 0.155 
z-score Waist/Height 0,289 0,304 0,360* 0,364* 0,374* -0,181 0,283 0.222 
Hip 0,326* 0,242 0,253 0,172 0,178 -0,106 0,061 -0.102 
Waist/Hip 0,127 0,140 0,243 0,263 0,296 -0,156 0,331* 0.352* 
FM 0,363* 0,292 0,352* 0,270 0,220 -0,255 -0,108 -0.270 
FFM 0,195 0,050 0,109 0,025 0,147 0,047 0,327* 0.202 
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Figure 4. Correlations of anthropometric parameters and blood pressure in the 
whole population and in obese subjects 
 
   
    
BMI: body mass index; SBP: systolic blood pressure. 
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Figure 5. Correlations of omega-3 and omega-6 PUFA in the whole population 
and in obese children. 
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Figure 6. Comparison of Delta-5 and Delta-6 desaturase activity in different 
weight classes and their correlation in the whole population and in obese children  
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Discussion Study 3 
 Even if the sample size is limited, our data confirm recent published prevalence 
of overweight and obesity  in a similar aged population by the national survey 
“Okkio alla salute” [319]. Furthermore, our data indicate that the increase in BMI 
is accompanied by an increase in central distribution of the fat, which is 
associated with a higher cardiovascular risk. Children with weight excess showed 
also higher BP levels, in particular SBP, and a higher percentile of PWV, although 
in the normal range [314], but significantly elevated in comparison to normal-
weight children. These data indicate an impact of weight excess on BP control and 
on arterial stiffness that are detectable also in the early childhood. When 
considering the different indexes of weight excess and fat distribution, stronger 
correlations of the markers of central obesity with BP and arterial stiffness were 
detectable in overweight and obese children rather than in normal weighted 
children. Moreover, also the bioelectrical impedance analysis confirms the results 
of the other anthropomentric measurements, indeed both fat mass and fat-free 
mass were correlated with BP in all children, whereas in obese children only fat 
mass was directly associated with BP.  
In the analysis of erythrocyte membrane fatty acids, which are an index of mid-
term dietary intake of fatty acids [320], we found a low level (nearly 4%) of 
omega-3 PUFA in the whole population and only 0.6% of children had an Omega-
3 Index over 8%, which is considered to be associated with a CV protection [183]. 
Moreover, omega-3 PUFA were inversely associated with BMI and high levels of 
omega-3 PUFA were found only in normal weight children. These data indicate a 
low intake of fish by the diet, in particular in overweight and even more in obese 
children. Beyond the putative protective CV effect of omega-3 PUFA, these 
results may be a marker of an unbalanced diet, in particular a low intake of fish is 
generally assumed to be associated with lower vegetable and fruit intake and 
higher intake of meat, depicting unhealthier dietary habits, that are, together with 
physical activity, the main determinant of weight excess [239,240].  
In our sample omega-6 PUFA, and LA in particular, showed an inverse 
correlation with triglycerides in the whole population, even stronger in obese 
subjects. This result can support the hypothesis of a protective role of omega-6 
PUFA on cardiometabolic risk factors, according to the findings of our first study 
(Bonafini et al., unpublished data, see above) and other previous observation 
[189,190]. Anyhow in the sample analyzed in the present work, the other 
cardiovascular parameters were not associated with omega-6 PUFA neither in the 
whole population nor in the obese group. 
Interestingly, within the omega-6 family, GLA seems to have an opposite 
association with the analyzed variables in comparison to the total amount of 
omega-6 PUFA, as we already found in the first presented study, and it was 
significantly higher in children with weight excess. Little is known about the 
action of GLA on metabolic profile, especially in children [276], and further 
investigation are needed in order to understand whether it might exert a role on 
metabolic homeostasis rather than being a marker of a poorer metabolic profile. 
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Indeed, GLA is the product of  D6D starting from LA, and a higher activity of this 
enzyme has been linked to insulin sensitivity[279] and to a unfavourable 
metabolic status[265,277]. In our population we found that the level of estimated 
D6D activity were higher in overweight and obese children as compared to 
normal-weight subjects, and it was correlated with indexes of central obesity. Our 
data confirm the current knowledge about D6D, as well as the results of our first 
study (see above).  
The enlargement of the sample size and the in-depth analysis of the food 
frequency questionnaires will give data also about different dietary patterns and 
their relationship with erythrocyte membrane fatty acids that will help to better 
understand the association of macronutrients with body composition and 
cardiovascular risk factors. 
In this study we found a high prevalence of elevated blood pressure in children at 
the first visit but the re-evaluation of the children with high BP, in standard 
condition, demonstrated a low prevalence of “real hypertension” in children. In 
fact, BP levels have been probably influenced by the contingent circumstances 
rather than by a real hypertensive status and thus we confirm the suggestions of 
current guidelines to accurately evaluate BP measurements in children and the 
need of repeated measurements before making a diagnosis of hypertension, or 
even of white-coat hypertension [26]. Indeed, our data contradict other recent 
surveys, in larger population with comparable percentage of obese subjects, which 
showed a prevalence of hypertension in the range of 8%. 
Anyhow, it is worthy of mention the finding of a positive association of weight 
excess with BP levels and arterial stiffness, which underlines the possible harmful 
effect of body weight and fat distribution on cardiovascular system, at least in a 
subclinical manner, in otherwise healthy children.  
Our study has limitations: the cross- sectional design of the study do not allow to 
conclude for a causative link of the associated variables. Anyhow, some 
meaningful associations were found, partially confirming our previous findings, 
thus suggesting a possible role of PUFA regarding the metabolic status of the 
children. It is worth underlining that the analysis of FA pattern on a blood drop is 
not completely comparable with the analysis obtained from RBC membranes 
extracted from a blood sample. Indeed, the results derived from blood drops 
reflect not only the FA in RBC membranes but also the plasma composition, and 
is therefore more influenced by the fasting status. Caution is therefore needed in 
the interpretation and comparison of the results of study 2 and 3, which were 
anyway obtained by analysis using the actual gold standard method, namely 
capillary gas chromatography. 
Moreover, as above mentioned, the number of children included in the BP follow-
up was low, so the results cannot be interpreted as the prevalence of hypertension 
among school-aged children. However, they underline the importance of a correct 
BP measurements, in standard conditions and with repeated measurements, in 
order to prevent an overestimation of the real prevalence of hypertension. 
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In conclusion, our data confirm a high prevalence of obesity/overweight in young 
children (8-10 years) attending the primary school in Verona South district, but, at 
a more careful evaluation denies a high prevalence of hypertension. Still, the 
correlations between anthropometric indexes, especially central distribution of fat 
with BP and arterial elasticity, call for an action to modify unhealthy behavior 
already in children to prevent a possible progression over time of target organ 
damages. 
The low intake of omega-3 PUFA seems to be one corrigible factor, but the lack 
of significant correlation with body fat, BP, elasticity and the very low correlation 
with triglycerides scales down their role as one of the major determinant of these 
risk factors. Also the putative role of omega-6 PUFA, which we previously found 
as inversely associated with several components of metabolic syndrome in a 
sample of obese children, is not completely confirmed in this collection, where 
only an inverse association with triglycerides were detectable. The specific role of 
GLA, which showed, at variance with other omega-6 but similarly to our previous 
study, a direct association with a worst metabolic profile, as well as the clinical 
effects of D5D and D6D activity, warrant further evaluations. 
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Final remarks 
 
Taken together our data indicate that weight excess, whose prevalence is elevated 
even in young children, is associated with a worst metabolic profile, vascular 
function and BP control even if in the range of normality, as compared to normal 
weight children. The putative beneficial effect of omega-3 PUFA appears rather 
weak, even if both the investigated samples presented low levels of omega-3 
PUFA, which might have blurred their biological effects. Then, the clinically 
relevant actions of their metabolites via CYP450/sEH on BP and vascular 
structure were detectable only in the subgroup of hypertensive obese children. 
Further investigations are needed to assess the stimuli and the conditions that can 
modulate these metabolic pathways, thus clarifying whether various lipid 
mediators can be involved in different clinical settings.  
Our results suggest a protective effect of omega-6 PUFA, and in particular of 
arachidonic acid, on metabolic profile and BP control, but do not support the 
hypothesis that CYPP450 metabolites mediate these effects. The role of linoleic 
acid and its CYP450/sEH-derived metabolites, which were associated to BP, 
remains unclear, also because of the scanty evidences in humans and especially in 
children. Interestingly, the enzymatic activity of delta-6 and delta-5 desaturase, 
two fundamental enzymes for the metabolism of PUFA, confirm their association 
with several features of the MetS, also in children. 
The enlargement of the sample size of the third study and the implementation of 
an intervention study with supplements of omega-6 and/or omega-3 PUFA in 
obese children will help to verify the current results and to better clarify the role 
of omega-6/omega-3 PUFA and their derived metabolites via CYP450/sEH in BP 
homeostasis and MetS in children. 
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a  b  s  t  r a  c t
Omega-3 polyunsatured fatty  acids  (-3 PUFA)  are  essential  nutrients  mainly  derived  from  fish  and
seafood but  present also  in  vegetables  such  as  nuts  and  seed-oils. Some epidemiological  and  clinical
studies indicate  a protection  of -3 FA  against cardiovascular  disease and  a  favourable  effect on car-
diovascular  risk  factors  control in adults. The  evidences of their  effects  in children  and  adolescents  are
scanty  but  a possible beneficial  role,  especially  for  insulin sensitivity and blood pressure control,  has  been
proposed. In  this  review  we  want to focus  especially  on the  evidences,  which  could justify  the  assump-
tion  of -3  in children  and  adolescents,  and to underline  the  aspects  which  need  further  investigation.
Mechanisms  through  which  -3  FA act  are  manifolds and  still a  matter  of investigation:  beside  their
interaction with  ion channel and  their  influence  on plasma membrane  fluidity,  probably  the  main effect
is acting  as  competitor  for  cytochrome  P-450  (CYP) with  respect  to -6  FA.  Thus, they can  modulate  the
biosynthesis  of eicosanoids  and  other lipid mediators,  which  likely exert  a protective action.  Another  sug-
gestive  hypothesis is that their  beneficial  effect  is  not dependent  only  on  the  intake  of -3 FA, but also  on
the  complex  interaction  between different nutrients  including -3 and  other  FAs  with  polymorphisms  in
genes  involved in -3 FA modulation. This  complex  interaction  has  seldom been  explored  in children and
adolescents. Further studies  are  needed  to  investigate  all these  points  in order to find  a  better  collocation
of -3  FA on the available armamentarium  for  preventive, possibly individualized,  medicine.
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1.  Biochemical characteristics and dietary sources of -3 FA
Fatty acids are a wide family of compounds with important and
manifold biological activities. The difference in chain length and
saturation status determines their biochemical characteristics and
their biological role. Omega-3 (-3) fatty acids are a family of long-
chain fatty acids containing more than one carbon–carbon double
bond (polyunsaturated fatty acids, PUFA). The main members of
this family are -linolenic acid (ALA, C 18:3), eicosapentaenoic acid
(EPA, C 20:5) and docosahexaenoic acid (DHA, C 22:6) [1].  ALA is an
essential nutrient for mammals because they lack enzymes where
to insert the double bond in  -3 position; the main dietary sources
are plants and plant oils, such as soybean oil, flaxseed oil, canola oil
and walnuts [2].
In mammals ALA can be converted to  EPA, but only in small
percentage, and the conversion of EPA to  DHA, if any, is  very limited
[3]. Accordingly EPA and DHA  are considered essential fatty acids,
deriving mainly from sea-food, especially high-fat cold-water fish,
such as salmon, mackerel, herring and trout [2].
Most of the clinical trials carried out to investigate the potential
benefits of -3 PUFA in  adults and in children have used fish oil
as supplements of -3 PUFA, however in  the last few years the
attention was focused also on alternative sources of -3 fatty acids,
like krill oil, vegetable oils, nuts and algae [4,5].
EPA and DHA enter the food chain trough marine phytoplankton,
proceeding through marine mammals and fish, which represent the
main dietary source for humans [2].
In natural fish  oil EPA and DHA are bond in triacylglycerides (TG).
Fish oil capsules are concentrates of marine oils, containing 30–90%
of EPA and DHA generally bond in  ethyl-ester (EE) or re-esterified
TG (rTG) [6,7].
Because of the reported health benefits of EPA and DHA, there
is  an increasing demand for products rich in marine -3 PUFA and
krill oil is an effective sources of these fats.
Krill are small red-coloured crustaceans (Euphausia superba)
representing the most dominant members of Antarctic zoo-
plankton [5]. They are rich in long-chain polyunsaturated fatty
acids, 40% of which are EPA and DHA, in form of phospholipids (PL).
In addition to -3 PUFA, krill oil contains carotenoid astaxanthin, a
potent antioxidant, vitamins A and E, and other fatty acids [8].
The American Food and Drug Administration has classified krill
oil as generally recognized as safe and previous clinical and pre-
clinical trials have  shown that  it is safe and well tolerated [8].  Only
a few studies have  tested the efficacy of krill oil compared with fish
oil and the results go in the direction of a possible stronger effect in
raising plasma and red blood cell membrane EPA and DHA [5,7,8].
ALA occurs in  vegetable food such as nuts, flaxseeds and veg-
etable oils like canola oil and soy-bean oil, which represent the main
sources of -3 in  vegetarian diets. However the bioavailability of
vegetable -3 FA remains a  matter of debate and seems to limit
their use as supplements [4]. Indeed, most studies using vegetable
sources of -3 (mainly flaxseed oil) report an increase in plasma
and red blood cell membranes content of ALA and partially of EPA
but not of DHA [9,10,11,12].  Moreover findings from short and long-
term trials with ALA supplements do not show clear evidence of a
protective action in  cardiovascular risk and therefore the question
whether ALA supplements could be important for cardiovascular
health remains unanswered [13].
Observational studies and clinical trials suggest a protective
effect of nuts consumption on coronary heart disease and some
intermediate biomarkers, such as blood cholesterol and blood pres-
sure [14–16].  The beneficial effect of nuts can be mediated through
several mechanisms: nuts are rich in  PUFA, with a  different content
of -6 and -3 in the various types, and in addition they con-
tain fibre, vitamin E, magnesium, potassium and arginine that  can
contribute to the blood pressure and lipid  lowering effect [17].
In  the last few years increasing interest was focused on algal
DHA-rich oil supplementation: clinical trials reported an increase in
plasma and red blood cell DHA content after algal oil supplements,
but not of EPA or  ALA [4] and, even if in  small number, indicate
comparable efficacy to fish oil in  potential beneficial changes in
some markers of cardiovascular risk, in particular on plasma lipid
profile [13].
2. Mechanism of action
-3  PUFA exert their biological activities through three main
classes of mechanisms: some biological effects depend on their
incorporation into cell membranes, other effects derive from a
direct interaction with ion channels and other cellular components
and, finally, EPA and DHA are  the parental compounds of bioactive
lipid mediators [2].  The exact mechanisms are not  yet completely
understood, especially it is  not clear whether EPA and DHA share
the same pathways or  not [18].
-3  PUFA can attenuate the response of T-cells and
macrophages through cell surfaces receptors, not  yet identified,
perhaps by changing the composition of membrane microdomains
[19].  A direct interaction with some cellular components can medi-
ate some short-term effects such as the antiarrhythmic effect,
which depends on a steric interference with ion channels [20],
for example the inhibition of the fast, voltage-dependent sodium
and L-type calcium currents [19]. Non-esterified -3 PUFA can also
directly interact with peroxisome proliferator-activated receptors
(PPARs) and others transcription factors, thus modulating gene
transcription [18].  Recently a  role of GPR120 has been discovered,
a  member of the family of fatty acid sensing G-protein-coupled
receptors (GPCR), mediating the anti-inflammatory and insulin-
sensitizing effects of -3 PUFA [21].
Other proteins that can be directly activated by AA and -3 FA,
and consequently probably influenced by their ratio, are protein
kinase C, NADPH-oxidase and a two-pore domain K+ channel [19].
Incorporation of EPA and DHA into cell membranes can mod-
ulate the properties of lipid rafts and thus alter the membrane
fluidity, affecting hormone receptor binding and the function of
membrane-associated proteins [2].
Moreover, EPA and DHA, mostly incorporated into the second
position of membranes phospholipids, can be  released by phos-
pholipase A2  (PLA2) and converted to a  variety of  eicosanoids
and other lipid mediators through three different metabolic path-
ways. The first two pathways involve cyclooxygenase (COX) and
liopoxygenase (LOX), leading to  the formation of prostaglandins,
thromboxanes, and leukotrienes; the third branch is  catalyzed by
cytochrome P 450 (CYP450) leading to the formation of eicosanoids.
Therefore EPA and DHA share the same metabolic pathways
of arachidonic acid (AA) and, moreover, it has been shown that
they compete with AA for binding with these enzymes, thus induc-
ing profound changes in metabolites biosynthesis that could in
part explain the beneficial actions of -3 compared to -6 FA
[18].  The competition of EPA and DHA with AA may  determine
the synthesis of TXA3, almost inactive, instead of TXA2, which has
pro-aggregatory properties. Furthermore, starting from -3 FA the
metabolism via  COX lead to  the formation of PGI3 that share the
antiaggregatory effect of the AA-derived PGI2. The metabolism of
EPA via LOX determine the biosynthesis of LTB5, less potent than
the pro-inflammatory AA-derived LTB4.
Moreover, -3 PUFA are also the precursors of novel families
of compounds, the so-called resolvins, protectins and maresins,
with anti-inflammatory and pro-resolving properties [22]. In par-
ticular EPA and DHA, through the complex metabolism involving
COX-2 and aspirin-dependent formation of intermediate metabo-
lite, followed by a conversion via LOX, are metabolized to  the
E-series of resolvins, starting from EPA, and to D-series of resolvins,
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protectins and maresins from DHA, which counteract the exces-
sive inflammatory while regulating the trafficking of leukocytes
and stimulating non-inflammatory phagocytosis of apoptotic neu-
trophils by macrophages [23].
CYP enzymes accept EPA and DHA as efficient substrates alter-
native to AA. CYP epoxygenases produce epoxyeicosatrienoic acids
(EETs) from AA, epoxyeicosatetraenoic acids (EEQs) from EPA and
epoxydocosapentaenoic acids (EDPs) from DHA. CYP hydroxy-
genases lead to  the biosynthesis of 20-hydroxyeicosatetraenoic
acid (20-HETE) from AA, 20-hydroxyeicosapentaenoic acid (20-
HEPE) from EPA and 22-hydroxydocosahexaenoic acid (22-HDoHe)
from DHA [18].  The role of epoxy- and hydroxy-metabolites of
AA in cardiovascular function is  well known: EETs are mainly
involved in antihypertensive and organ-protective mechanisms, in
particular they determine vasodilatation in  the systemic vascular
system, natriuresis in the kidney and act as endothelium-derived
hyperpolarizing factors. 20-HETE is involved in both anti- and pro-
hypertensive mechanisms, depending on the site of formation and
action. It shares with EETs the natriuretic effect but determines
vasoconstriction in  the vessels [22].
The evidence shows that LOX, COX and CYP enzymes have
the ability to metabolize EPA and DHA instead AA, but the rel-
ative efficiencies are not  well understood. EPA and DHA are
generally considered as poor substrates for LOX and COX, com-
pared with AA, whereas they are efficiently metabolized by CYP
enzymes with similar or  higher rates, compared with AA [18].  A
recent study on 20 healthy volunteers indicate that CYP epoxyge-
nases metabolize EPA with an 8.6-fold higher efficiency and DHA
with a 2.2-fold higher efficiency than AA, whereas the effects on
leukotriene, prostaglandin E, prostacyclin, and thromboxane for-
mation remained rather weak [24].  The evidence of the clinical
significance of EPA/DHA metabolism via CYP450 under in  vivo con-
ditions is still rare and further investigation is  needed.
In animal models, the biological activities of these compounds
are partially overlapped to the AA-derived counterparts and
partially specific: EEQs and EDPs  can be as strong as EETs in vasodi-
lation or even stronger in  some vascular beds like cerebral and
coronary vessels [25,26].  In an animal model of angiotensin II-
dependent hypertension it has been shown a  possible role of one
EDP isomer as a mediator of the antihypertensive effect of DHA [27].
Some EPA-epoxydes exert anti-inflammatory properties like some
EETs regioisomers [28].  Moreover some regioisomers of EEQs and
EDPs modify the contractility of neonatal cardiomiocytes, indicat-
ing a possible antiarrythmic effect [29].
The suggested hypothesis is that  CYP-dependent epoxy-
metabolites of EPA and DHA  may  contribute to the vasodilatory
and cardioprotective effects of -3 fatty acids and could also serve
as biomarkers of EPA/DHA supplementation.
Finally, the results of a  recent randomized controlled trial on
patients with peripheral vasculopathy suggest another possible
mechanism: after 6 months flaxseed oil supplementation, rich in
ALA, plasma eicosanoid profile changed with a decrease in  solu-
ble epoxide hydrolase products compared with controls and these
subjects exhibited a  significant decrease in  systolic BP. The authors’
conclusion is that flaxseed oil may  inhibit soluble epoxide hydro-
lase thus modifying the lipid mediator concentrations that can
contribute to the antihypertensive effect [30].
3. Clinical effects of -3
Since the late 1960s increasing attention was paid on -3 fatty
acid, in response to the reports of a  lower incidence of coronary
heart disease as well as immune and inflammatory disease in
Greenland Inuits, whose diet is rich in fish and other sea  food [2].
Data from epidemiological and clinical studies have shown that -
3 fatty acids reduce the incidence of cardiovascular disease, but
the mechanisms responsible for this protective effect are not com-
pletely elucidated [31,32].  The potential mechanisms proposed are
either through its hypotriglyceridemic effect [33,34],  a  reduced
susceptibility to  cardiac arrhythmias [35–37], a retardation of
atherosclerotic plaque growth [3],  an anti-inflammatory effect or
a mild hypotensive action [38].  The American Heart Association
(AHA) suggests an intake of fish, preferably oily fish, at least twice
per week for the general population; in  secondary prevention the
amount of EPA and DHA should rise to  1 g per day and the supple-
ments should be considered; high doses of -3 fatty acids (2–4 g)
are recommended in  patients needing the triglycerides lowering
effect [38].
4. Clinical effects of -3 in children
The incidence of obesity and type 2 diabetes reported in  chil-
dren has increased in  the last few decades and it has been
shown that obesity plays a pivotal role in the development of
insulin resistance, which is related to hyperinsulinemia, hyper-
tension, hyperlipidemia, type 2 diabetes and increased risk of
atherosclerotic disease. Moreover considerable evidence shows
that overweight in  childhood and adolescence is  associated with
insulin resistance, dyslipidemia and high blood pressure in  young
adults [39].
In the last few years, there has been emerging interest also for
the possible beneficial effect of -3 in childhood with respect to
cardiovascular risk factors.
Some observational studies and a limited number of interven-
tional studies indicate a  positive effect of -3 supplements on blood
pressure control, even if  the data currently available are small and
not  univocal (see Table 1). A recent cross-sectional study on seventy
three 8–11-year-old Danish children shows a  positive association
of mean arterial pressure with whole-blood DHA only in boys and
this correlation remains also after adjustment for energy intake,
body-fat percentage and physical activity. -3 FA were measured
in whole-blood and were found to be associated with fish intake,
recorded for 7 days by a  Web-based dietary assessment specifi-
cally for children [40]. These findings were in  agreement with a
previous randomized trial of the same group, showing a  decrease
in  systolic blood pressure in  healthy 12-months children (n =  83),
after 3 months of fish oil supplements (mean estimated EPA and
DHA assumption: 924 mg/day). Infants were randomly assigned to
fish oil supplements or not and to  two different milk types and
the effect of fish oil supplementation was  adjusted for the effects
of milk intervention. The fish oil supplements were also inversely
associated with plasma triglycerides and directly with total choles-
terol and LDL cholesterol [41].  A positive effect on systolic and
diastolic blood pressure was  found also in adolescent boys aged
13–15 after a  16-week fish oil supplementation (1.5 g EPA and DHA)
compared with the control group receiving vegetable oil [42].  In
contrast, a  cross-sectional study in a  hundred and nine 17-year-old
adolescents found a poorer metabolic profile, included higher sys-
tolic blood pressure levels, associated with a  higher DHA content in
red blood cell membranes, which remained also after adjustment
for physical activity and dietary factors [43].
Data from the National Health and Nutrition Examination Sur-
vey indicate that a higher dietary intake of EPA and DHA, recorded
by two 24-h dietary recall, in  354 children, aged 8–15 years, born
with reduced birth weight, are associated with lower systolic blood
pressure and pulse pressure [44].  These findings were consistent
with a  previous exploratory analysis, which showed a  significant
inverse association of serum -3 PUFA with systolic blood pres-
sure in young adults, aged 24–39 years, born  with impaired foetal
growth [45]. These data suggest that -3 PUFA could play a role in
blood pressure control in  subjects with low birth weight, which is
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Table 1
Studies about the effect of -3 FA  on  blood pressure.
Author, year Study design and aim No. subjects Source and dose Time period BP outcome
Damsgaard,
2013 [40]
Cross-sectional study on 8–11
y-o children.
To investigate the relationship
between whole-blood EPA and
DHA and Metabolic Syndrome
features
73
(F =  44, M = 29)
Fish intake assessed by a
specific paediatric dietary
assessment; amount
consumed estimated by
portion size  among 4
different images
– Positive association of mean
arterial pressure with DHA
only in boys after adjustment
for  energy intake, body-fat
percentage and physical
activity
Damsgaard,
2006  [41]
RCT: 9–12 months infants
randomly assigned to fish oil or
no supplements and to cow’s
milk or infant formula. To
investigate the effect of fish oil
on BP  and lipid profile in
infants
83
(F =  42; M = 41)
Fish oil (mean estimated
EPA and DHA assumption:
924 mg/day)
3 months Lower SBP (−6.3 mmHg) in
infants administered fish oil,
also  after adjustment for milk
intervention
Pedersen, 2010
[42]
RCT on  13–15 y-o  boys with a
control group receiving
vegetable oil. To investigate
the effects of fish oil on
cardiovascular risk factors
78
(F =  0; M = 78)
Fish oil (1.5 g/day
long-chain -3  FA)
16 weeks Lower SBP and DBP (−3.8 and
−2.6 mmHg, respectively) in
fish oil group
Lauritzen, 2012
[43]
Cross-sectional study on 17 y-o
adolescents. To investigate the
association between fish intake
and  Metabolic Syndrome
features
109
(M =  44;  F  = 109)
Fish intake assessed by 7
days food record with
pre-coded response
categories; intake
registered in household
measures and portion size
based on images
– Higher DHA status correlated
with higher SBP, after
adjustment for sex, body fat
percentage, dietary factors and
physical activity
Skilton, 2013
[44]
Cross-sectional study on 8–15
y-o children born with low
birth weight. To investigate the
relation between -3 FA and
BP in children with relative
hypertension related to
reduced birth weight
354
(F =  174;  M = 180)
Fish intake assessed by two
24-h dietary recall, the
second after 3–10 days
– Children in  the highest tertile
of dietary EPA and DHA intake
had significantly lower SBP
(−4.9 mm Hg and pulse
pressure −7.7 mm Hg) than
children in the lowest tertile
O’Sullivan,
2012  [47]
Cross-sectional study on 13–15
y-o adolescents. To investigate
the  relation between -3 FA
and BP
814
(F =  395;  M = 419)
Three-day diet record
measured in household
units
– Inverse association between
-3  FA  and SBP, DBP  and mean
arterial pressure in boys
Ayer,  2009 [52] RCT on  children in the  first 5
years, randomly assigned to
fish oil and reduction of -6  FA
or control (sunola oil). To
investigate BP  and arterial
structure and function in 8 y-o
children who received -3 FA
supplements in the first 5 years
of life
410
(F =  203; M =  207)
Canola oil and tuna oil,
doses depending on age;
every tuna oil capsule had
6% EPA and 27% DHA.
Follow-up at the
age of 8 years
No significant differences in  BP
between intervention group
and control group
Van  Rossem,
2012 [51]
Observational cohort-study in
breast-fed children with a
never-breast-fed children
control group. To investigate
the  association between fatty
acid composition of infant milk
feeding and blood pressure at
the  age of 12 years
314
(F =  161;  M = 153)
Assessment of fatty acid
composition of human
milk. Infant formula
(control) did not contain
-3 FA
Follow-up at the
age of 12  years
Children who received human
milk with an n-3 long-chain
polyunsaturated fatty acids
content above the median had
a 4.79-mm Hg lower systolic
and  a  2.47-mm Hg lower
diastolic blood pressure at age
12 years than control
Asserhøj, 2009
[48]
DB-RCT on  mother receiving
fish oil or olive oil (control). To
investigate whether fish  oil
supplements during lactation
affect  BP  and body composition
of children
175
(F =  175;  M = 0)
Fish oil (0.6 g/d EPA and
0.8 g/d DHA)
Fish oil
supplements in the
first 4 months of
lactation. Children
follow-up at  2.5
years and 7 years
FO boys had 6 mm Hg higher
DBP  and mean arterial BP than
controls, but girls
F, female; M,  male; y-o, years old; -3 FA, omega-3 fatty acid; RCT, randomized controlled trial; DB-RCT, double blind-randomized controlled trial; BP, blood pressure; SBP,
systolic  blood pressure; DBP, diastolic blood pressure; EPA, epoxyeicosatrienoic acid; DHA, docosahexaenoic acid.
a known factor independently associated with an increased risk of
cardiovascular events in  adulthood [46].
A cross-sectional study performed on 814 Australian ado-
lescents (13–15-year-old) suggests a  possible role of gender in
modulating the relationship between -3 FA and blood pressure:
systolic and diastolic blood pressure were inversely associated with
EPA and DHA intake, assessed with a  3-day diet record, in  boys but
not in girls [47].
Furthermore, an association between blood pressure and the
-3 content was found in  boys but not in girls also in the above
mentioned cross-sectional study conducted by Damsgaard [40] and
in a  trial in  breast-fed infants of mother receiving -3 supplements,
but the latter found an unfavourable relation of fish oil supplements
with blood pressure control [48].
Some studies have investigated the long term effect of -3 FA
supplements administered in  early infanthood through lactation or
to the mothers during pregnancy but the results are not  univocal.
The interest stemmed from evidence that breast feeding, rich in
EPA and DHA, in  contrast to the first formula milk, is associated
with lower blood pressure in childhood and adulthood [49,50].
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Table  2
Studies about the effect of -3  FA  on insulin sensitivity.
Author, year Study design and aim No.  subjects Source and dose Time
period
Insulin resistance outcome
Burrows, 2011
[60]
Cross-sectional study on  5–12
y-o children.
To investigate the relationship
between -3 Index, weight
and insulin resistance
48
(F  = 28; M =  20)
Fat intake assessed by  a
135-item
semi-quantitative food
frequency
questionnaire
– A moderate correlation found
between -3 Index and fasting
insulin level and HOMA-IR
Decsi,  2002
[61]
Observational study on 8–16
y-o diabetic children. To
compare plasma and red blood
cell membranes fatty acids in
diabetic children with
non-diabetic controls
80
(F = 50; M =  30)
Plasma and red blood
cell membranes
determination of AA,
EPA, DHA and ALA
–  Lower levels of AA and DHA in
diabetic children compared
with controls
Miller,  2011
[62]
Longitudinal study on  0–8 y-o
children with islet
autoimmunity. To investigate
the correlation between -3 FA
intake and erythrocyte
membrane -3 fatty acid levels
and type 1 diabetes
167
(F = 82; M =  85)
Dietary intake assessed
by a 111-item
semi-quantitative food
frequency
questionnaire
– No significant association
between -3 FA and -6 FA
erythrocyte membranes levels
and the onset of type 1 diabetes
Lòpez-Alarcòn,
2011  [63]
RCT on 9–18 y-o overweight
and insulin resistant children.
To  investigate the effect of -3
FA supplements on body
weight and insulin resistance,
compared to  placebo group
76
(M;  F  not specified)
900 mg of -3 FA
(360 mg DHA + 540 mg
EPA)
1 month Supplementation with -3 FA
decreased HOMA-IR by  15%
after adjusting for puberty,
treatment adherence, changes
in adipokines, and weight loss
Juàrez-Lòpez,
2013 [55]
Open-label study on 10–12 y-o
obese and insulin resistant
children assigned to -3  FA  or
Metformin (control). To
investigate the  effect of -3 FA
on HOMA-IR and BMI
201
(F = 106; M = 95)
600 mg of -3 FA
(360 mg of EPA and
240 mg of DHA)
12  weeks Reduction of glucose and
insulin levels while reducing
HOMA-IR in -3 FA group
compared to  controls, also
after adjustment for weight
reduction, sex and age
F, female; M,  male; y-o, years old; -3 FA, omega-3 fatty acid; RCT,  randomized controlled trial; DB-RCT, double blind-randomized controlled trial; HOMA-IR, homeostasis
model assessment-estimated insulin resistance index; EPA,  epoxyeicosatrienoic acid; DHA, docosahexaenoic acid; AA, arachidonic acid; ALA, alpha-linolenic acid; BMI,  body
mass  index.
In an interventional study, children who received human milk
with an -3 FA content above the median had a  nearly 5 mmHg
lower systolic and 2.5 mmHg  diastolic blood pressure at the age
of  12 years compared with never breast-fed children, but -3 FA
content below the median in the milk was not associated with blood
pressure levels at 12 years [51]. In contrast, in  a  previous trial boys
of mother receiving fish oil supplements during the first 4 months
of lactation showed a  higher diastolic blood pressure at the age of
7 years compared with the olive oil  control group [48].
In another study investigating the long-term effects of -3 sup-
plements, the supplements of -3 FA from infancy to 5 years
(canola oil and tuna oil), with a contemporary reduction of omega-6
FA assumption in order to  provide an -3 to -6 ratio of 1:5, do not
affect blood pressure and vascular structure at the age of 8 years,
even if the concentration of -3 FA in the plasma were higher in
the intervention group compared with controls [52].
-3 FA supplements are effective in  lowering triglyceride levels
in adults, therefore in international guidelines their assumption is
suggested for patients who need to  lower triglycerides. No effects
on the other plasma lipid levels such as cholesterol are evident in
adults. Little is known about the lipid lowering action of EPA and
DHA in children and adolescents, only a  small number of clinical
trials are available and the results are not always encouraging. In
two recent interventional studies in  children and adolescents with
hypertriglyceridemia (n =  111 and n =  25,  respectively), aged 8–18
and 9–19 years old respectively, 3–6 months fish oil supplements,
at the doses of 500–1000 and 3360 mg  per day, did not lower plasma
triglycerides compared with control group [53,54].
In contrast a positive effect in  lowering plasma triglycerides
was found in 103 obese children and adolescents after 12 weeks
of 1.8 g/day of -3 supplements, compared with the control group
receiving metformin, and the other plasma lipids were not  affected
by the treatment [55].
The evidence of an action of -3 FA on cholesterol is scanty and
not conclusive: Damsgaard found a positive correlation between
EPA levels and HDL levels in 8–11 years-old children [40].  However
in  a  previous study fish oil supplements were associated to higher
total and LDL cholesterol in  9–12 months infant [41].  In an observa-
tional study no association was found between fish  consumption,
assessed by a  7 day pre-coded food diary, and serum lipid profile
in hundred-and-nine adolescents [43].
A large amount of data, from epidemiological studies, indicate
a protective effect of -3 FA on glucose metabolism and insulin
sensibility in adults [56,57]. Accordingly, the results of many clin-
ical trials support the positive effect of -3 on glycemic control,
however some showed negative results [58,59]. The evidence from
observational studies and clinical trials in children is  limited but
supports a  beneficial effect of -3 also during childhood (see
Table 2).
A  cross-sectional study on 5–12 years-old children showed a
moderate but significant correlation between fasting insulin levels
and HOMA-IR and the -3 Index, which is the percentage of  EPA and
DHA contained in red blood cell membranes, as an index of chronic
-3 intake [60].  Interestingly, in  this population, obese children had
altered erythrocyte fatty acid composition unrelated to reported
dietary intake and showed lower levels of -3 Index compared with
non-obese children [60].
Moreover, lower plasma and erythrocyte membrane levels of
AA and DHA were found in  40 diabetic children compared with
non-diabetic controls [61].  However in  a longitudinal study con-
ducted on 167 children at increased genetic risk for type 1 diabetes
for the development of persistent islet autoimmunity, -3 and -
6 FA levels in red blood cell membranes were not associated with
the development of type I diabetes [62].  In a clinical trial on 76
overweight and insulin resistant children the supplementation
with 900 mg  per day of -3 FA for 1 month decreased fasting insulin
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and  HOMA-IR, also after adjustment for pubertal status and weight
loss [63]. Accordingly, a  recent trial showed a  reduction of glucose
and insulin levels while reducing HOMA-IR after 12 weeks of 1.8 g
of -3 supplementation in 201 obese and insulin resistant children,
also after adjustment for sex, age and change in BMI [55].
There is also increasing interest on the use of -3 supplements in
the treatment of non-alcoholic fatty liver disease (NAFLD), which
is  pathogenically linked to insulin resistance and metabolic syn-
drome. According to the evidence of a  positive effect of EPA and
DHA supplements on liver steatosis in adults, also the few clini-
cal trials available in children support the hypothesis that DHA can
decrease liver fat  content in children with NAFLD [64,65].
Animal models show positive results encouraging the use of -3
FA to prevent diet-induced obesity [66] and some trials in  over-
weight adults and in obese diabetic women have also reported a
beneficial effect in fat mass reduction [67,68].  Nowadays, there is
no clear evidence in children and the attention is mainly focused on
the  possible programming effect of -3 fatty acids in breast milk on
later infant and young children body composition. The results from
the available studies are  divergent: some studies show an inverse
correlation between maternal -3 FA intake and -3 FA content
in formula milk and later body composition [69–71], others show a
direct correlation [72–74],  finally in some studies no  significant cor-
relation was found [48,75–77].  A  recent study on 201 obese children
and adolescents indicates a  beneficial effect of -3 supplements
(1.8 g EPA and DHA for 12 weeks), without other lifestyle interven-
tions, on weight reduction [55].  In contrast Nobili reported no effect
on BMI  after 6 months DHA supplements in children compared with
placebo, but the doses of DHA  were low (250–500 mg/day) [64].
5.  Adverse effects
Omega-3 supplement are  generally considered safe and, where
reported, the tolerability of -3 FA in clinical trials, in children
as well in adults, was good with no major adverse reactions. An
adverse effect of -3 FA supplements is the increased risk of
bleeding, due to the potential antithrombotic effect, however the
evidence available does not support a  clinical relevant increased
bleeding, even when -3 FA supplements were concomitant with
antiplatelet or anticoagulant therapy [78].  Another potential safety
concern is the presence of contaminants, especially mercury and
dioxins, in fish and fish oil, which has direct implications for dietary
recommendation, in  particular for some population such as preg-
nant women and infants [79].
6.  Conclusion and perspectives
In summary, the clinical effect of -3 FA on cardiovascular risk
factors in children is not univocal. Actual evidence supports a  ben-
eficial effect of -3 FA supplements on insulin sensitivity and a
possible positive effect on blood pressure control whereas they are
not yet conclusive concerning the effect on plasma lipids and body
composition. Anyhow, there were few clinical trials in  children and
most of the evidence comes from epidemiological studies, some-
times with limited sample size. Moreover, doses of supplements
varies largely as well as the duration of the interventions, and it is
not easy to detect a  dose-response effect among different studies.
In humans, different CYP isoforms are  responsible for -3 or -6
metabolism, whereas other enzymes, such as the soluble epoxide
hydrolase (EPHX2), convert these metabolites to mostly inactive
compounds. Polymorphisms in  these genes have  been tested to
evaluate their effects especially in blood pressure homeostasis with
some encouraging results [80–88] and it is possible that also pref-
erential dietary intake of -3 vs.  -6 could influence their effect.
Thus, a suggestive hypothesis is  that the beneficial effect of -3
FA is not only dependent on their intake and content, but also on
the complex interaction between different nutrients and polymor-
phisms in  genes involved in -3 FA metabolism [89–97].  These
complex interaction has seldom been explored in children and ado-
lescents [95].  Further studies are needed to investigate all these
points in order to  find a  better collocation of -3 FA on the available
armamentarium for preventive, possibly individualized, medicine.
References
[1]  Vannice G, Rasmussen H. Position of the academy of nutrition and dietet-
ics:  dietary fatty acids for healthy adults. J  Acad Nutr Diet 2014;114(January
(1)):136–53.
[2] De Caterina R. n-3  fatty acids in cardiovascular disease. N Engl J  Med
2011;364(June (25)):2439–50.
[3] Harris WS,  Miller M,  Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty
acids and coronary heart disease risk: clinical and mechanistic perspectives.
Atherosclerosis 2008;197(March (1)):12–24.
[4] Lane K,  Derbyshire E, Li W,  Brennan C. Bioavailability and potential uses of
vegetarian sources of omega-3 fatty acids: a review of the literature. Crit Rev
Food Sci Nutr 2014;54(5):572–9.
[5] Ulven SM,  Kirkhus B,  Lamglait A, et al. Metabolic effects of krill oil are essen-
tially similar to  those of fish oil but at  lower dose  of EPA and DHA, in healthy
volunteers. Lipids 2011;46(January (1)):37–46.
[6] Dyerberg J,  Madsen P, Moller JM,  Aardestrup I, Schmidt EB. Bioavailability of
marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids
2010;83(September (3)):137–41.
[7] Schuchardt JP, Schneider I, Meyer H, Neubronner J, von SC, Hahn A.  Incor-
poration of EPA and DHA into plasma phospholipids in response to different
omega-3 fatty acid formulations – a  comparative bioavailability study of fish
oil vs. krill oil. Lipids Health Dis 2011;10:145.
[8] Ramprasath VR, Eyal I,  Zchut S, Jones PJ. Enhanced increase of omega-3 index
in healthy individuals with response to  4-week n-3 fatty acid supplementation
from  krill  oil versus fish oil. Lipids Health Dis 2013;12:178.
[9] Barcelo-Coblijn G, Murphy EJ, Othman R, Moghadasian MH, Kashour T, Friel JK.
Flaxseed oil and fish-oil capsule consumption alters human red blood cell n-3
fatty acid composition: a multiple-dosing trial comparing 2 sources of n-3 fatty
acid.  Am J  Clin Nutr 2008;88(September (3)):801–9.
[10] Cao J, Schwichtenberg KA,  Hanson NQ, Tsai MY.  Incorporation and clearance of
omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin
Chem 2006;52(December (12)):2265–72.
[11] Harper CR, Edwards MJ, DeFilippis AP, Jacobson TA. Flaxseed oil increases the
plasma  concentrations of cardioprotective (n-3) fatty acids in humans. J  Nutr
2006;136(January (1)):83–7.
[12] Kaul N, Kreml R, Austria JA, et al. A comparison of fish oil, flaxseed oil and
hempseed oil supplementation on selected parameters of cardiovascular health
in  healthy volunteers. J  Am  Coll Nutr 2008;27(February (1)):51–8.
[13] Tur JA, Bibiloni MM,  Sureda A,  Pons A. Dietary sources of omega 3 fatty acids:
public health risks and benefits. Br J Nutr 2012;107(June (Suppl. 2)):S23–52.
[14] Bao Y, Han J, Hu FB, et al. Association of nut  consumption with total and cause-
specific mortality. N Engl J Med  2013;369(November (21)):2001–11.
[15] Kris-Etherton PM, Hu  FB, Ros E, Sabate J.  The role of tree nuts and peanuts in the
prevention of coronary heart disease: multiple potential mechanisms. J Nutr
2008;138(September (9)):1746S–51S.
[16] Sabate J, Oda K, Ros E. Nut consumption and blood lipid levels: a pooled analysis
of 25 intervention trials. Arch Intern Med  2010;170(May (9)):821–7.
[17] Almario RU, Vonghavaravat V, Wong R, Kasim-Karakas SE. Effects of walnut
consumption on  plasma fatty acids and lipoproteins in  combined hyperlipi-
demia.  Am J  Clin Nutr 2001;74(July (1)):72–9.
[18] Westphal C, Konkel A, Schunck WH.  CYP-eicosanoids – a  new link between
omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat
2011;96(November (1–4)):99–108.
[19] Wada M, DeLong CJ,  Hong YH, et al. Enzymes and receptors of prostaglandin
pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived
substrates and products. J  Biol Chem 2007;282(August (31)):22254–66.
[20] De Caterina CR, Madonna R, Zucchi R, La  Rovere MT.  Antiarrhythmic
effects of omega-3 fatty acids: from epidemiology to  bedside. Am Heart J
2003;146(September (3)):420–30.
[21] Oh DY, Talukdar S, Bae EJ, et al.  GPR120 is an omega-3 fatty acid recep-
tor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell
2010;142(September (5)):687–98.
[22] Arnold C, Konkel A, Fischer R, Schunck WH. Cytochrome P450-dependent
metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids.
Pharmacol Rep 2010;62(May (3)):536–47.
[23] Lee HN, Surh YJ. Therapeutic potential of resolvins in the prevention and
treatment of inflammatory disorders. Biochem Pharmacol 2012;84(November
(10)):1340–50.
[24] Fischer R, Konkel A, Mehling H, et al. Dietary omega-3 fatty acids modulate the
eicosanoid profile in man  primarily via the CYP-epoxygenase pathway. J  Lipid
Res 2014;55(March (6)):1150–64.
[25] Lauterbach B, Barbosa-Sicard E, Wang MH, et al. Cytochrome P450-dependent
eicosapentaenoic acid metabolites are novel BK channel activators. Hyperten-
sion  2002;39(February (2 (Pt 2))):609–13.
[26] Ye D, Zhang D, Oltman C,  Dellsperger K,  Lee HC, VanRollins M. Cytochrome
p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary
78 S. Bonafini et al. / Prostaglandins & other Lipid Mediators 120 (2015) 72–79
arterioles by activating large-conductance calcium-activated potassium chan-
nels.  J Pharmacol Exp Ther 2002;303(November (2)):768–76.
[27] Ulu A, Stephen Lee KS, Miyabe C,  et  al. An  omega-3 epoxide of docosahex-
aenoic acid lowers blood pressure in angiotensin-II-dependent hypertension.
J  Cardiovasc Pharmacol 2014;64(July (1)):87–99.
[28] Morin C, Sirois M,  Echave V, Albadine R, Rousseau E. 17,18-
epoxyeicosatetraenoic acid targets PPARgamma and p38 mitogen-activated
protein kinase to mediate its anti-inflammatory effects in the lung: role of
soluble epoxide hydrolase. Am J  Respir Cell Mol  Biol 2010;43(November
(5)):564–75.
[29] Arnold C, Markovic M,  Blossey K, et al. Arachidonic acid-metabolizing
cytochrome P450 enzymes are targets of {omega}-3 fatty acids. J Biol Chem
2010;285(October (43)):32720–33.
[30] Caligiuri SP, Aukema HM,  Ravandi A,  Guzman R,  Dibrov E, Pierce GN. Flaxseed
consumption reduces blood pressure in patients with hypertension by altering
circulating oxylipins via an alpha-linolenic acid-induced inhibition of soluble
epoxide hydrolase. Hypertension 2014;64(July (1)):53–9.
[31] Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin
E  after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet
1999;354(August (9177)):447–55.
[32] Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evalu-
ating the risks and the  benefits. JAMA 2006;296(October (15)):1885–99.
[33] Harris WS.  Fish oils and plasma lipid and lipoprotein metabolism in humans:
a  critical review. J Lipid Res 1989;30(June (6)):785–807.
[34] Park Y, Harris WS.  Omega-3 fatty acid supplementation accelerates chylomi-
cron triglyceride clearance. J  Lipid Res 2003;44(March (3)):455–63.
[35] Brouwer IA, Raitt MH,  Dullemeijer C, et  al. Effect of fish oil on ventricular
tachyarrhythmia in three studies in patients with implantable cardioverter
defibrillators. Eur Heart J  2009;30(April (7)):820–6.
[36] Leaf A, Albert CM, Josephson M,  et al. Prevention of fatal arrhythmias in high-
risk subjects by fish oil n-3 fatty acid intake. Circulation 2005;112(November
(18)):2762–8.
[37] Raitt MH,  Connor WE,  Morris C,  et al. Fish  oil supplementation and
risk of ventricular tachycardia and ventricular fibrillation in patients with
implantable defibrillators: a randomized controlled trial. JAMA 2005;293(June
(23)):2884–91.
[38] Kris-Etherton PM,  Harris WS,  Appel LJ.  Fish consumption, fish oil, omega-
3  fatty acids, and cardiovascular disease. Circulation 2002;106(November
(21)):2747–57.
[39] Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascu-
lar risk in children: an American Heart Association scientific statement from the
Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council
on Cardiovascular Disease in the Young) and the Diabetes Committee (Council
on Nutrition, Physical Activity, and Metabolism). Circulation 2003;107(March
(10)):1448–53.
[40] Damsgaard CT, Stark KD, Hjorth MF,  et al. n-3 PUFA  status in school children is
associated with beneficial lipid profile, reduced physical activity and increased
blood pressure in boys. Br J Nutr 2013;110(October (7)):1304–12.
[41] Damsgaard CT, Schack-Nielsen L,  Michaelsen KF, Fruekilde MB,  Hels O, Lau-
ritzen  L. Fish oil affects blood pressure and the plasma lipid profile in healthy
Danish infants. J Nutr 2006;136(January (1)):94–9.
[42] Pedersen MH,  Molgaard C,  Hellgren LI, Lauritzen L.  Effects of fish oil supplemen-
tation on markers of the metabolic syndrome. J  Pediatr 2010;157(September
(3)):395–400.
[43] Lauritzen L, Harslof LB, Hellgren LI,  Pedersen MH, Molgaard C, Michaelsen KF.
Fish  intake, erythrocyte n-3  fatty acid status and metabolic health in Danish
adolescent girls and boys.  Br J  Nutr 2012;107(March (5)):697–704.
[44] Skilton MR,  Raitakari OT, Celermajer DS. High intake of dietary long-chain
omega-3 fatty acids is  associated with lower blood pressure in children
born with low birth weight: NHANES 2003–2008. Hypertension 2013;61(May
(5)):972–6.
[45] Skilton MR,  Mikkila V, Wurtz P, et al. Fetal growth, omega-3 (n-3) fatty
acids, and progression of subclinical atherosclerosis: preventing fetal origins
of  disease? The Cardiovascular Risk in Young Finns Study. Am J  Clin Nutr
2013;97(January (1)):58–65.
[46] Huxley R, Owen CG, Whincup PH, et al. Is birth weight a risk factor for ischemic
heart disease in  later life? Am J  Clin Nutr 2007;85(May (5)):1244–50.
[47] O’Sullivan TA, Bremner AP, Beilin LJ, et al. Polyunsaturated fatty acid intake and
blood pressure in adolescents. J  Hum Hypertens 2012;26(March (3)):178–87.
[48] Asserhoj M, Nehammer S, Matthiessen J,  Michaelsen KF, Lauritzen L.  Mater-
nal fish oil supplementation during lactation may  adversely affect long-term
blood pressure, energy intake, and physical activity of 7-year-old boys. J Nutr
2009;139(February (2)):298–304.
[49] Martin RM, Gunnell D, Smith GD. Breastfeeding in infancy and blood pres-
sure in later life: systematic review and meta-analysis. Am J  Epidemiol
2005;161(January (1)):15–26.
[50] Owen CG, Whincup PH, Gilg JA, Cook DG. Effect of breast feeding in  infancy
on  blood pressure in later life: systematic review and meta-analysis. BMJ
2003;327(November (7425)):1189–95.
[51] van RL, Wijga AH, de Jongste JC, et al. Blood pressure in 12-year-old children is
associated with fatty acid composition of human milk: the prevention and inci-
dence  of asthma and mite allergy birth cohort. Hypertension 2012;60(October
(4)):1055–60.
[52] Ayer JG, Harmer JA, Xuan W,  et  al. Dietary supplementation with n-3 polyun-
saturated fatty acids in early childhood: effects on blood pressure and arterial
structure and function at age 8 y. Am J Clin Nutr 2009;90(August (2)):
438–46.
[53] Chahal N, Manlhiot C,  Wong H, McCrindle BW.  Effectiveness of omega-3
polysaturated fatty acids (fish oil) supplementation for treating hypertriglyc-
eridemia in children and adolescents. Clin  Pediatr (Phila) 2014;53(March
(7)):645–51.
[54] de Ferranti SD, Milliren CE, Denhoff ER, et  al. Using high-dose omega-3 fatty
acid supplements to  lower triglyceride levels in 10- to 19-year-olds. Clin Pediatr
(Phila) 2014;53(May (5)):428–38.
[55] Juarez-Lopez C,  Klunder-Klunder M,  Madrigal-Azcarate A, Flores-Huerta S.
Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglyc-
erides in obese children and adolescents. Pediatr Diabetes 2013;14(August
(5)):377–83.
[56] Feskens EJ, Loeber JG, Kromhout D. Diet and physical activity as deter-
minants of hyperinsulinemia: the Zutphen Elderly Study. Am J Epidemiol
1994;140(August (4)):350–60.
[57] Thorsdottir I, Hill J, Ramel A.  Omega-3 fatty acid supply from milk associates
with lower type 2 diabetes in men and coronary heart disease in women. Prev
Med  2004;39(September (3)):630–4.
[58] Friedberg CE, Janssen MJ,  Heine RJ, Grobbee DE. Fish oil and glycemic control
in diabetes. A meta-analysis. Diabetes Care 1998;21(April (4)):494–500.
[59] Roche HM.  Fatty acids and the metabolic syndrome. Proc Nutr Soc
2005;64(February (1)):23–9.
[60] Burrows T, Collins CE, Garg ML.  Omega-3 index, obesity and insulin resistance
in  children. Int J  Pediatr Obes 2011;6(June (2–2)):e532–9.
[61] Decsi T, Minda H, Hermann R, et al. Polyunsaturated fatty acids in plasma and
erythrocyte membrane lipids of diabetic children. Prostaglandins Leukot Essent
Fatty  Acids 2002;67(October (4)):203–10.
[62] Miller MR, Yin X, Seifert J, et  al. Erythrocyte membrane omega-3 fatty acid
levels and omega-3 fatty acid intake are not associated with conversion to
type 1 diabetes in children with islet autoimmunity: the Diabetes Autoim-
munity Study in  the Young (DAISY). Pediatr Diabetes 2011;12(December (8)):
669–75.
[63] Lopez-Alarcon M,  Martinez-Coronado A,  Velarde-Castro O,  Rendon-Macias E,
Fernandez J. Supplementation of n3 long-chain polyunsaturated fatty acid syn-
ergistically decreases insulin resistance with weight loss  of obese prepubertal
and  pubertal children. Arch Med  Res 2011;42(August (6)):502–8.
[64] Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation
decreases liver fat content in children with non-alcoholic fatty liver disease:
double-blind randomised controlled clinical trial. Arch Dis Child 2011;96(April
(4)):350–3.
[65] Nobili V, Alisi A, Della CC, et  al. Docosahexaenoic acid for the treatment of
fatty  liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis
2013;23(November (11)):1066–70.
[66] Jang IS, Hwang DY, Chae KR, et al. Role of dietary fat type in the development
of adiposity from dietary obesity-susceptible Sprague-Dawley rats. Br J  Nutr
2003;89(March (3)):429–38.
[67] Hill AM,  Buckley JD,  Murphy KJ, Howe PR. Combining fish-oil supplements
with regular aerobic exercise improves body composition and cardiovascular
disease risk factors. Am J  Clin Nutr 2007;85(May (5)):1267–74.
[68] Kabir M,  Skurnik G, Naour N, et al. Treatment for 2  mo  with n 3  polyunsat-
urated fatty acids reduces adiposity and some atherogenic factors but does
not  improve insulin sensitivity in women with type 2 diabetes: a  randomized
controlled study. Am J  Clin Nutr 2007;86(December (6)):1670–9.
[69] Donahue SM, Rifas-Shiman SL, Gold DR, Jouni ZE, Gillman MW,  Oken E. Prenatal
fatty acid status and child adiposity at age 3 years: results from a  US  pregnancy
cohort. Am J  Clin Nutr 2011;93(April (4)):780–8.
[70] Groh-Wargo S, Jacobs J, Auestad N,  O’Connor DL, Moore JJ, Lerner E. Body com-
position in preterm infants who  are fed long-chain polyunsaturated fatty acids:
a  prospective, randomized, controlled trial. Pediatr Res 2005;57(May (5 (Pt
1))):712–8.
[71] Ryan AS, Montalto MB, Groh-Wargo S, et  al. Effect of DHA-containing formula
on  growth of preterm infants to  59 weeks postmenstrual age. Am J Hum Biol
1999;11(4):457–67.
[72] Helland IB, Smith L, Blomen B, Saarem K,  Saugstad OD, Drevon CA. Effect
of supplementing pregnant and lactating mothers with n-3 very-long-chain
fatty acids on children’s IQ  and body mass index at 7 years of age. Pediatrics
2008;122(August (2)):e472–9.
[73] Innis SM, Adamkin DH,  Hall RT, et  al. Docosahexaenoic acid and arachidonic
acid enhance growth with no adverse effects in  preterm infants fed formula. J
Pediatr 2002;140(May (5)):547–54.
[74] Kennedy K, Ross S, Isaacs EB, et al. The 10-year follow-up of a randomised
trial of long-chain polyunsaturated fatty acid supplementation in preterm
infants: effects on  growth and blood pressure. Arch Dis Child 2010;95(August
(8)):588–95.
[75] de Jong C, Boehm G, Kikkert HK,  Hadders-Algra M.  The Groningen LCPUFA
study: no effect of short-term postnatal long-chain polyunsaturated fatty acids
in  healthy term infants on cardiovascular and anthropometric development at
9  years. Pediatr Res 2011;70(October (4)):411–6.
[76] Hauner H, Much D, Vollhardt C, et al. Effect of reducing the n-6:n-3 long-chain
PUFA  ratio during pregnancy and lactation on  infant adipose tissue growth
within the first year of life: an open-label randomized controlled trial. Am J
Clin  Nutr 2012;95(February (2)):383–94.
[77] Scholtens S, Wijga AH, Smit HA, et al. Long-chain polyunsaturated fatty
acids  in  breast milk and early weight gain in breast-fed infants. Br J  Nutr
2009;101(January (1)):116–21.
S. Bonafini et al. / Prostaglandins &  other Lipid Mediators 120 (2015) 72–79 79
[78] Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol
2007;99(March (6A)):35C–43C.
[79] Mozaffarian D. Fish, mercury, selenium and cardiovascular risk: current evi-
dence and unanswered questions. Int  J Environ Res Public Health 2009;6(June
(6)):1894–916.
[80] Ward NC, Tsai IJ, Barden A, et al. A single nucleotide polymorphism in the
CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion
and  blood pressure. Hypertension 2008;51(May (5)):1393–8.
[81] Dreisbach AW,  Japa S, Sigel  A, et al. The Prevalence of CYP2C8, 2C9, 2J2, and solu-
ble  epoxide hydrolase polymorphisms in African Americans with hypertension.
Am  J Hypertens 2005;18(October (10)):1276–81.
[82] Fava C, Montagnana M,  Almgren P, et al. The V433M variant of the CYP4F2
is associated with ischemic stroke in male Swedes beyond its effect on blood
pressure. Hypertension 2008;52(August (2)):373–80.
[83] Fava C, Montagnana M,  Danese E, et  al. Homozygosity for the EPHX2 K55R
polymorphism increases the long-term risk of ischemic stroke in men: a study
in  Swedes. Pharmacogenet Genomics 2010;20(February (2)):94–103.
[84] Fava C, Montagnana M,  Almgren P, et  al. The common functional
polymorphism-50G>T of the CYP2J2 gene is  not associated with ischemic
coronary and cerebrovascular events in an urban-based sample of Swedes. J
Hypertens 2010;28(February (2)):294–9.
[85] Fava C, Montagnana M,  Danese E, et al. The functional variant V433M of the
CYP4F2 and the metabolic syndrome in Swedes. Prostaglandins Other Lipid
Mediat 2012;98(May (1–2)):31–6.
[86] Gainer JV, Bellamine A, Dawson EP, et  al. Functional variant of CYP4A11
20-hydroxyeicosatetraenoic acid synthase is associated with essential hyper-
tension. Circulation 2005;111(January (1)):63–9.
[87] King LM,  Gainer JV, David GL, et al. Single nucleotide polymorphisms in
the  CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet
Genomics 2005;15(January (1)):7–13.
[88] Spiecker M, Darius H, Hankeln T,  et al. Risk of coronary artery disease associated
with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation
2004;110(October (15)):2132–6.
[89] Bouchard-Mercier A, Rudkowska I,  Lemieux S, Couture P,  Vohl MC.  Polymor-
phisms in genes involved in fatty acid beta-oxidation interact with dietary fat
intakes to modulate the plasma TG response to  a fish oil supplementation.
Nutrients 2014;6(3):1145–63.
[90] AlSaleh A, Maniou Z, Lewis FJ, Hall WL, Sanders TA, O’Dell SD. Interaction
between a CSK gene variant and fish oil intake influences blood pressure in
healthy adults. J  Nutr 2014;144(March (3)):267–72.
[91] Ouellette C, Cormier H, Rudkowska I,  et al. Polymorphisms in genes involved
in  the triglyceride synthesis pathway and marine omega-3 polyunsaturated
fatty acid supplementation modulate plasma triglyceride levels. J Nutrigenet
Nutrigenomics 2013;6(4–5):268–80.
[92] Cormier H, Rudkowska I, Thifault E, Lemieux S, Couture P, Vohl MC.  Poly-
morphisms in fatty acid desaturase (FADS) gene cluster: effects on glycemic
controls following an omega-3 polyunsaturated fatty acids (PUFA) supplemen-
tation. Genes (Basel) 2013;4(3):485–98.
[93] Cormier H, Rudkowska I,  Paradis AM,  et  al. Association between polymorphisms
in  the fatty acid desaturase gene cluster and the plasma triacylglycerol response
to  an n-3 PUFA supplementation. Nutrients 2012;4(August (8)):1026–41.
[94] Hellstrand S, Sonestedt E, Ericson U,  et al. Intake levels of dietary long-chain
PUFAs modify the association between genetic variation in FADS and LDL-C. J
Lipid Res 2012;53(June (6)):1183–9.
[95] Dumont J, Huybrechts I, Spinneker A, et al. FADS1 genetic variability interacts
with dietary alpha-linolenic acid intake to affect serum non-HDL-cholesterol
concentrations in European adolescents. J  Nutr 2011;141(July (7)):1247–53.
[96] Lu Y,  Feskens EJ, Dolle ME,  et  al. Dietary n-3 and n-6 polyunsaturated fatty
acid intake interacts with FADS1 genetic variation to  affect total and HDL-
cholesterol concentrations in the Doetinchem Cohort Study. Am J  Clin Nutr
2010;92(July (1)):258–65.
[97] Volcik KA, Nettleton JA, Ballantyne CM,  Boerwinkle E. Peroxisome proliferator-
activated receptor [alpha] genetic variation interacts with n-6 and long-chain
n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concen-
trations in the Atherosclerosis Risk in Communities Study. Am J  Clin Nutr
2008;87(June (6)):1926–31.
Prostaglandins &  other Lipid Mediators 128–129 (2017) 34–42
Contents lists available at ScienceDirect
Prostaglandins and  Other  Lipid  Mediators
Review
Omega-3  fatty  acids  and  cytochrome  P450-derived  eicosanoids  in
cardiovascular  diseases:  Which  actions  and  interactions  modulate
hemodynamics?
Sara  Bonafini,  Cristiano  Fava ∗
University of Verona, Department of Medicine, General Medicine and Hypertension Unit, Italy
a  r t i  c  l e  i  n f o
Article history:
Received 11 July 2016
Received in revised form 5 January 2017
Accepted 18 January 2017
Available online 3 February 2017
Keywords:
Omega-3 fatty acids
Cytochrome P450 eicosanoids
Hemodynamics
Cardiovascular disease
a  b  s  t  r a  c t
Increasing interest  is  focused  on omega-3  fatty acids (FA)  because  of their  potential  beneficial  effects,
particularly  in cardiovascular disease  prevention. Eicosapentaenoic  acid (EPA)  and  docosahexaenoic  acid
(DHA), two  major omega-3  FA, are mainly  consumed  through  diet,  particularly  from fish and  seafood
intake, whereas alpha-linolenic  acid  (ALA)  is  present  in high  amounts in leafy green  vegetables,  nuts  and
seeds.  The hypothesis of a cardiovascular protective  action  of omega-3  FA  derives  mainly  from  observa-
tional  studies, whereas  the evidence from  interventional  studies  is  not always  consistent.  Nonetheless,
clinical  trials  and meta-analyses  indicate  a  positive  action,  at  minimum  on blood  pressure  (BP).  Omega-
3 FA may  act  through  different biological  pathways;  however,  in our review,  we seek to revisit,  most
notably,  the  role  of their metabolites  via  cytochrome  P450  (CYP450)  in hemodynamic  modulation. We
emphasize  that  the  effect of omega-3  FA may  depend  on  their  balance with  other  dietary  compounds,
particularly  omega-6  FA,  which  compete  for  the  same  pathways, thus  modulating  the production of
metabolites.  Furthermore,  the  biological activity  of omega-3  FA might be  better  explained by  the  com-
plex  balance and interactions  between a variety  of nutrients and  polymorphisms  of genes  implicated  in
specific  metabolic  pathways.
©  2017  Elsevier Inc.  All  rights  reserved.
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1.  Introduction
Fatty acids (FA) constitute a  broad family of compounds, subdi-
vided in different classes on the basis of biochemical structure. The
main families with biological and clinical relevance are saturated
and cis-unsaturated FA, the latter further divided into monounsat-
urated and polyunsaturated fatty acids according to the number of
carbon–carbon double bonds and their trans- analogues.
In the last few decades, increasing attention was  paid to
polyunsaturated FA because of their potential beneficial effects,
particularly regarding cardiovascular disease [1].
Whereas the sources of saturated FA are mainly meat and animal
products, most polyunsaturated FA derive from vegetable and seed
oils. The main sources of omega-6 FA, such as linoleic acid (LA), are
vegetable oils, such as safflower oil, sunflower oil and cottonseed
oil. Soybean oil  and canola oil are contrarily rich in omega-3 FA,
notably in alpha-linolenic acid (ALA) [1].  Moreover, nuts are rich
in LA and some of them, walnuts in particular, are good sources of
ALA [2]. LA and ALA are  essential FA whereas eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) are long-chain omega-3 FA
which may  be synthesized from ALA. However, the efficiency of
this process in human is  generally low. Therefore, they are mainly
consumed through diet and occur in seafood as follows: fatty fish,
such as salmon, tuna fish and herring, have a high content of these
compounds [1].
The mechanisms of action and the biological and clinical effects
of omega-3 FA are not completely understood currently and they
remain an active area of research.
In this review, we  seek to revisit the biological effects of omega-
3  FA and those of their metabolites via Cytochrome P450 (CYP450)
and explore their possible interactions with other compounds, in
particular omega-6 FA. We  are interested specifically in probing the
effects on blood pressure (BP) and vascular hemodynamics, which
may  be mediated through this pathway (Fig. 1).
2. Clinical effects of omega-3 FA
Omega-3 FA  have a  wide range of actions as follows: they may
act on the vessels by improving the endothelial function and elas-
tic properties of the arteries [3], exerting a favorable effect on the
autonomic system and reducing platelet aggregation [4], exerting
anti-arrhythmic action by increasing the arrhythmic thresholds [5]
and playing an important role in  the modulation of the inflamma-
tory response [6].  Finally, they may  improve the serum lipid profile
[7]. In summary, the rising interest in Omega-3 FA  is  due to their
pleiotrophic effects and to  the possible eventual protective effect on
cardiovascular disease, although the available data are not always
consistent. In fact, despite observational studies that have mostly
shown a protective effect, the results from randomized controlled
trials (RCT) have not always been uniform and successive meta-
analyses have questioned the presence of a  large omega-3-FA effect
in at-risk populations.
For example, a  recent large prospective study conducted on
healthy older adults investigated the role of omega-3 FA consumed
through the typical diet in  primary prevention. The results showed
that plasma omega-3 FA, considered as single FA (EPA, DHA and
DPA) and total Omega-3 FA, were associated with lower total mor-
tality, largely dependent on fewer cardiovascular deaths and in
particular fewer arrhythmic deaths [8].  Moreover, total mortality
was inversely associated with EPA and DHA in a linear fashion,
whereas the inverse association with total omega-3 FA was not
linear, in accord with previous studies [9].  However, it should be
considered that circulating FA are influenced by short-term fluctu-
ations in dietary FA consumption, which probably affects the true
relationship between plasma FA and mortality.
Additionally, some large interventional trials supported the
beneficial effect of omega-3 FA in cardiovascular disease as fol-
lows: in the GISSI-Prevenzione trial, the treatment by omega-3
FA lowered the risks of death, non-fatal myocardial infarction and
stroke in a  sample of 11,324 patients surviving a recent myocar-
dial infarction [10]. Another trial, investigating the effect of  EPA
supplementation in primary prevention in  14,981 hypercholes-
terolemic subjects on statin therapy, indicated a  reduction in the
incidence of coronary artery disease, particularly in the patients
with a  high-risk dyslipidemic pattern (high triglyceride level and
low HDL-cholesterol level) [11]. Regardless, recent meta-analyses,
including a  large number of primary studies, have not demon-
strated unequivocal results concerning cardiovascular risk [12–14].
In a systematic review and meta-analysis, including 20 studies
with a total of 68,680 patients, omega-3 FA supplements were
not associated with a  lower risk of all-cause mortality, cardiac
or sudden death, myocardial infarction or stroke [12]. Another
meta-analysis, including 14 randomized placebo-controlled trials
involving 20,485 patients with a history of cardiovascular disease,
reported insufficient evidence of a  beneficial effect of omega-
3 FA supplements in secondary cardiovascular prevention [14].
However, it is  worth considering that the trials included in  the
meta-analysis had a short follow-up period (2 years or less) and
that the above-mentioned large trials [10,11] with positive find-
ings were excluded from some meta-analyses because they were
not placebo-controlled, suggesting a  cautious interpretation of the
results. The most recent meta-analysis on the same topics arrived
at the same conclusion when considering the association between
coronary risk and fatty acids from dietary intake, assessed by ques-
tionnaire or  using dietary records, or by circulating levels of  fatty
acids. Comparing the participants in  the top third to  those in the
bottom third, dietary long-chain omega-3 FA and plasma levels of
EPA and DHA were associated with a nearly 13% lower coronary
risk [15].  When assessing the effect of omega-3 FA  supplements in
RCT, no significant reduction in coronary risk was found [15].
Uncertainty also remains regarding the relationship between
fish or omega-3 FA consumption and cerebrovascular disease. A
systematic review and meta-analysis of 26 prospective cohort stud-
ies and 12 RCT, which investigated the relation between the risk of
cerebrovascular disease and omega-3 FA and fish consumption in
primary and secondary prevention, showed the presence of  a mod-
erate, inverse association [16].  The analysis of the prospective trials
indicated a protective effect of fish  intake with regard to  the risk of
cerebrovascular disease in the general population and showed that
an increment of fish intake (at least 2 servings per week) reduced
cerebrovascular risk by 4%. Interestingly, the analysis of the dif-
ferent type of fish consumed showed a  possible favorable effect of
fatty fish, whereas such findings were not  significant for white fish.
Conversely, the RCT analysis of omega-3 FA supplementation did
not indicate any significant correlation with cerebrovascular risk
[16].
The evidence concerning the beneficial effect of EPA/DHA on
BP appears clear as follows: many interventional studies with fish
oil have suggested a  beneficial effect of omega-3 supplements
on BP control, particularly in  hypertensive subjects, with a pos-
sible threshold effect. The first meta-analysis to show a  positive
antihypertensive action of omega-3 FA in hypertensive patients,
compared to normotensive subjects, was  reported by Morris et al.
in  1993 [17].
These results were consistent with a  subsequent meta-analysis
of 36 studies evaluating a total sample of 2114 subjects receiv-
ing high doses of fish  oil (mean dose 4.1 g/day) as follows: fish
oil significantly reduced BP  (SBP–2.1 mmHg  and DBP–1.6 mmHg),
with a  stronger effect in  hypertensive and older (>45 years) sub-
jects. Interestingly, no dose-response relationship was observed
and the effect of low doses (<500 mg/day) of omega-3 supplements
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Fig. 1. Our hypothesis: omega-3 FA may  positively affect the vascular function determining blood pressure reduction.
In  particular, omega-3 FA  act as vasodilators, improve endothelial function and reduce arterial stiffness and calcification in part through their incorporation into cell  membranes
and  extra- and intra-cellular signaling and partly through their CYP/sEH metabolites. EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid;  eNOS: endothelial Nitric Oxide
Synthase;  PPAR: Peroxisome proliferator-activated receptor; GPR120: G protein-coupled receptor 120; EDHF: Endothelium-Derived Hyperpolarizing Factor.
remains unclear [18]. They observed a  dose-response effect when
the studies were grouped by Omega-3 FA dose; however, it should
be emphasized that the omega-3 dose was relatively high in  the
group receiving the lowest dose (up to 3 g/day).
The most recent meta-analysis examined 70 randomized con-
trolled trials with EPA +  DHA supplements in  hypertensive and
normotensive subjects [19].  The mean dose of EPA and DHA was
3.8 g/day, deriving mostly from fish oil  and also from EPA- and
DHA-fortified foods, seafood and algal oil. Omega-3 supplements
provided a reduction in systolic BP  (SBP) of 1.52 mmHg  and dias-
tolic BP (DBP) of 0.99 mmHg  in the meta-analysis of all studies with
hypertensive and normotensive subjects, compared with placebo
(mostly olive oil and other vegetable oils). The analysis of untreated
hypertensive subjects showed the strongest effect for EPA +  DHA in
lowering BP, compared to normotensive subjects [19].
Prospective cohort studies have also examined the impact of the
omega-3 FA dietary content on the development of hypertension
in normotensive subjects, with some finding an inverse association
[20,21] and others no association [22,23]. A meta-analysis, includ-
ing 8  of these studies with approximately 56,000 subjects followed
up for 3–20 years, showed that the subjects with the highest dietary
consumption of omega-3 FA, as determined by plasma or erythro-
cyte fatty acid content, had a  lower risk of developing hypertension
compared to subjects with the lowest intake [24]. Interestingly, this
finding supports the hypothesis of a stronger protective effect for
DHA in primary prevention.
A recent study on 312 subjects, evaluating the impact on BP of
lower doses of EPA +  DHA (0.7 and 1.8 g/day, respectively), which
are more easily achievable through dietary modification, showed
that only patients with isolated systolic hypertension exhibited a
significant reduction in SBP (- 5 mmHg) [25].
Current guidelines by the American Heart Association Nutri-
tion Committee suggest the consumption of at least 2 servings of
fish per week for primary cardiovascular prevention and Omega-
3 supplements for secondary prevention [26,27].  Regarding BP,
the European Society of Hypertension (ESH) and of the European
Society of Cardiology (ESC) guidelines published in 2013 recom-
mend that patients with hypertension eat fish at least twice a  week
[28],  without specifying the type of fish, whereas the 7th and 8th
Joint National Project reports mention neither fish nor omega-3 FA
[29,30].
Recently, increasing attention was directed to  the possible pro-
tective effect of omega-3 FA on the development of hypertension in
children, who might comprise an interesting population because of
the lack of many confounders present in adults. Thus, some obser-
vational studies and a  few interventional studies support a  positive
effect of omega-3 FA on BP  control in childhood as well [31–33].
In addition to the actions of EPA and DHA, recent studies found
a  BP-lowering effect of flaxseed oil, which is rich in  ALA as follows:
in a  double-blind, placebo-controlled RCT (FlexPAD trial) in  110
patients with peripheral artery disease (PAD), the treated group
(30 g/day of flaxseed) showed an increase in  plasma ALA, which
was inversely associated with BP, and they exhibited a  decrease in
SBP and DBP after 6 months that was  significant in  hypertensive
patients [34]. A subsequent study on the same population in  the
FlexPAD trial moreover displayed a  reduction in central SBP and
DBP after flaxseed supplementation [35].
The possible stronger effect of dietary fish on BP, compared
to EPA/DHA supplementation, raises some unanswered questions.
First, it warrants consideration that the biological role of single
nutrients probably cannot be separated from the wide range of
other substances contained in a food. For example, fish is  rich in
vitamins [36],  amino acids [37] and some trace elements [38] that
may  also exert favorable vascular effects. Second, the intake of  cer-
tain foods should be  assessed in the context of the whole diet,
considering the balance between the different nutrients that may
exert a  variety of actions and interactions.
2.1. Vascular effects of omega-3 FA
A  clinically relevant action of omega-3 FA is  the BP-lowering
effect, which is believed to derive from reduced systemic vascu-
lar resistance and improved endothelial function, thus interfering
with the atherosclerotic process [39].  The modulation of  vascular
functions remains, in  our opinion, one of the key aspects of cardio-
vascular protection by omega-3 FA.
Studies on animal models suggest that EPA, but probably
not  DHA and DPA, may  induce Ca++-independent activation and
translocation of endothelial nitric oxide synthase (eNOS) with con-
sequent endothelium-dependent vasodilation [40].  In vivo, EPA
induces an increase in  eNOS phosphorylation via the up-regulation
of uncoupling protein-2 (UCP-2) and activation of AMP-activated
protein kinase [41].  In the past few decades, dozens of stud-
ies in humans were conducted with divergent results concerning
the effect of omega-3 FA on endothelium-dependent vasodilation,
whereas no effect was consistently observed regarding omega-
3 FA  supplements on endothelium-independent dilation. Two
meta-analysis, including 16 clinical trials, show improvement in
endothelial function after omega-3 FA supplementation [42,43].
However, this result warrants a  careful evaluation as follows: first,
in the meta-analysis conducted by Wang and colleagues, in  addition
to  trials with EPA + DHA, studies with ALA supplements were also
included, whereas Xin and colleagues considered only EPA +  DHA
supplementation for the analysis. Moreover, the sample size  in
most of the primary studies was  low, and the significance of the
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results appeared mainly dependent on the contribution of the low-
quality studies [44,45].  Regardless, both meta-analyses included
a high-quality randomized double-blind trial  in 312 healthy non-
smoking subjects with increasing doses of EPA +  DHA (0.45, 0.9 and
1.8 g/day) [46]. Compliance with the intervention was verified by
a  significant increase in  the EPA and DHA content of red blood cell
membranes; however, endothelial function, as measured by Flow
Mediated Dilation (FMD), was not related to  EPA +  DHA intake [46].
Thus, further studies and large-scale RCT remain required to
define the role of omega-3 FA on endothelial function. More-
over, the evidence concerning the effect of EPA and/or DHA on
arterial stiffness suggests a  possible protective effect, though the
clinical significance remains to be clarified. The largest observa-
tional study was conducted in a subcohort of the Framingham
study, including 3055 subjects as follows: a  moderate associ-
ation between red blood cell omega-3 FA content and several
measures of arterial stiffness was observed, in particular, the
carotid-femoral pulse wave velocity, which is considered the gold
standard index of aortic stiffness. However, after multivariable
adjustment, only a  modest correlation between higher omega-3
content in red blood cell membranes and lower aortic stiffness
remained [47]. A recent small interventional study on 29 subjects
receiving EPA +  DHA supplements (2 g/day) reported a  significant
improvement not only in flow-mediated dilation but also in pulse
wave velocity, a measure of aortic stiffness [48]. Despite the scarce
and mostly underpowered RCT in humans, a recent meta-analysis
appears to confirm the association between omega-3 FA supple-
ments and arterial stiffness and arterial compliance; interestingly,
the results were not affected by BP changes, indicating a pos-
sible BP-independent effect of omega-3 FA on arterial function
[49].
Moreover, epidemiological and experimental studies suggest
that EPA and DHA are associated with less vascular calcifica-
tion, probably due to  their preventive effect on tissue remodeling
[50–52].
A population-based observational study on 1570 subjects in
the Netherlands investigated the correlation between fish and
EPA + DHA intake, assessed using a  170-item semiquantitative
food-frequency questionnaire and coronary calcification measures
determined by CT  scanning according to Agatston’s method. The
investigators found that subjects with a  higher fish intake had a
significantly lower prevalence of mild to  moderate coronary calci-
fication compared to subjects who did  not  consume fish, whereas
EPA + DHA intake showed no significant association [53].  No inter-
ventional trials on humans are available to date to determine the
effect of EPA and DHA on vascular calcifications.
3. Mechanisms of action of omega-3 FA
EPA and DHA exert their biological effects mainly through three
classes of mechanisms, although their relative importance concern-
ing the cardiovascular effects is not yet completely understood
as follows: first, they may  directly interact with ion channels
and other cellular components; second, they may  be incorpo-
rated into cell membranes; and finally, the factor that we consider
the most mechanistically relevant, at least for BP homeostasis,
is that they are the precursors of a  wide family of bioactive
lipid mediators [1]. Free omega-3 FA may  interfere directly with
ion channels without incorporation into cell membranes, thus
modulating different actions such as anti-arrhythmic effects [54].
When incorporated into cell membranes, they alter the phos-
pholipid composition, thus modifying the properties of lipid rafts
and caveolae and contributing to membrane fluidity [1,6,55].
The incorporation into membrane phospholipids affects the func-
tions of hormone-receptor and membrane-associated proteins
as  follows: the activation of the pro-inflammatory transcrip-
tion factor nuclear factor-kappa B is  inhibited and the signaling
pathway via G protein-coupled receptor GPR120 is  activated
[6].
However, as the principal mechanism, omega-3 FA, and in par-
ticular EPA and DHA, are the precursors of a  substantial number of
bioactive compounds through the following three main metabolic
pathways: the cyclo-oxygenase (COX) pathway, the lipoxygenase
(LOX) pathway and the so-called third branch via Cytochrome P450
(CYP450) [56]. These metabolic chains also metabolize arachidonic
acid (AA), an omega-6 FA, which competes with EPA and DHA for
the binding with these enzymes [57,58].
3.1. CYP450-derived metabolites of AA
The metabolites of AA generated through the three pathways
and their clinical and biological effects are better understood com-
pared to those derived from EPA and DHA. In this paragraph, we
briefly review the evidence concerning the AA-derived metabo-
lites via CYP450, which have well known hemodynamic effects and,
notably, may  interfere with the formation of the eicosanoids of EPA
and DHA.
COX and LOX metabolize AA leading to the production
of prostaglandins, prostacyclin, thromboxane and leukotrienes,
which are involved in  the modulation of pulmonary and renal func-
tion, and in  vascular tone and inflammation [56]. Less attention
was directed to the third metabolic pathway, the cascade lead-
ing to the formation of CYP-derived AA metabolites. In fact, CYP
epoxygenase catalyzes the formation of epoxyeicosatrienoic acids
(EETs), whereas CYP hydroxygenase leads to  the biosynthesis of 20-
hydroxyeicosatetraenoic acid (20-HETE) [59].  EETs are generally
involved in  protective mechanisms and exert an antihyperten-
sive effect as follows: in most vascular beds, they act mainly as
endothelium-derived hyperpolarizing factor (EDHF) and may also
activate eNOS, leading to a  vasodilatory effect [60].  Moreover, they
exert a Na+-excreting action [56].  At the renal level, 20-HETE shares
the Na+-excreting effect with EETs; conversely, in  the vascular
system, 20-HETE constricts renal, cerebral, mesenteric and skele-
tal muscle arterioles [56].  Consequently, 20-HETE acts in  opposite
directions, eliciting both pro- and anti-hypertensive effects.
Furthermore, EETs mediate anti-inflammatory actions [61]
and their less potent metabolites dihydroxyeicosatrienoic acids
(DHETs), produced by the soluble Epoxide-Hydrolase (sEH), have
antithrombotic effects and may  be involved in  the inflam-
matory process, with some reports suggesting them to be
pro-inflammatory [62].  Whereas a  number of studies in animal
models recognized a role of 20-HETE and/or EETs in the develop-
ment of hypertension [63,64], to  date a  small number of  human
studies are available. In renovascular hypertension in particular,
some clues were unveiled regarding the involvement of  CYP-
derived metabolites of AA, notably 20-HETE [65].  Two studies
indicated the involvement of CYP-derived metabolites of  AA in
the regulation of the maternal circulation during pregnancy and a
possible contribution to  pre-eclampsia, although their pathophys-
iological role is not defined to  date [66,67].
Previous studies in  animal models showed the possible modu-
lation of BP  by EETs in pregnancy [68,69],  some of them suggesting
instead their protective role against pregnancy-induced hyperten-
sion [69]. In pregnant women, high levels of EETs were found in
the fetoplacental circulation compared to that of the maternal cir-
culation [67] and within intrauterine tissues [70,71,69] and some
studies support the hypothesis that EETs play a  role in BP regulation
in  pre-eclamptic pregnancies [66,68,72].
Additionally, genetic studies provided some clues concerning
the possible role of these compounds in  BP regulation and cardio-
vascular risk. In fact, human genes encoding for the major CYP
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isoforms codifying for the enzymes that form EETs along with
EPHX2, the sEH gene, are highly polymorphic and a  number of stud-
ies have shown that some variants are associated with a higher risk
of hypertension, stroke or  other major cardiovascular endpoints
[73] with a possible gender-specific effect [74,75].
Thus, a suggestive hypothesis is  that omega-3 FA may  addi-
tionally exert their action through the complex interaction with
polymorphisms in genes encoding for CYP enzymes as was  simi-
larly hypothesized in a  recent study, in which a  stronger overtime
reduction in BP was significantly associated with a higher -3 PUFA
intake, but only in  subjects carrying the CYP4F2 433VV genotype
[76].  In fact, the analyzed genotype did not  show an association
with BP by itself in  the whole population; but a significant cor-
relation was found only when considering the interaction with
-3 PUFA intake, thus suggesting that -3 PUFA can exert their
protective effect on BP only in  people carrying selected genotypes.
3.2. CYP450-derived metabolites of EPA and DHA
As previously stated, not only AA but also EPA and DHA are
metabolized by COX and LOX, but particularly by  CYP450 leading to
the biosynthesis of a  wide range of compounds that are currently
attracting active research. The EPA-derived counterparts of EETs
through the metabolism of CYP-epoxygenase are epoxyeicosate-
traenoic acids (EEQs), whereas the DHA-derived counterparts are
epoxydocosapentaenoic acids (EDPs). CYP-hydroxylase converts
EPA to 19- and 20-hydroxyeicosapentaenoic acid (19- and 20-
HEPE) and DHA to  22-hydroxydocosahexaenoic acid (22-HDoHe),
which are the counterparts of 20-HETE [77] (Fig. 2).
Epoxy metabolites of AA, EPA and DHA are further metabolized
by the sEH, generating dihydroxy-fatty acids, or diols, which are the
DHETs dihydroxyeicosatetraenoic acids (DiHETE) and dihydroxy-
docosapentaenoic acids (DHDP), respectively. This metabolic step
is moreover the object of competition between AA and DHA/EPA
for enzymatic binding [78].
The biological properties of the epoxides and diols derived from
EPA and DHA are not yet completely understood, although sub-
stantial interest has been raised recently. In fact, the EPA and DHA
epoxides have at least similar but often stronger effects than EETs,
in particular concerning their vasodilator [79],anti-inflammatory
[78,80,81] and analgesic actions [78].
Animal models using canine and porcine coronary microvessels
[79,82] and in rat cerebral artery [83] support the hypothesis that
EEQs and EDPs act as endothelium-derived hyperpolarizing factor
(EDHF) by activating Ca++-activated K+ channels and that they have
a greater vasodilatory action with respect to  EETs, which might be
the mechanism, or  at least one of the mechanisms, responsible for
the BP-lowering effect of omega-3 PUFA.
Other studies in  animal models stress the role of omega-3
epoxides in BP control as follows: in Angiotensin II-dependent
hypertensive mice, an omega-3 rich diet in combination with the
sEH inhibitor lowered BP, suggesting that omega-3 epoxides con-
tribute to BP lowering [84].  Moreover, the same group focused
attention on DHA-derived epoxides and provided some particular
clues regarding 19,20-EDP as a mediator of the anti-hypertensive
effect of DHA [85]. Additionally, in CYP1A1 knockout mice, the
involvement of 17,18-EEQ and 19,20-EDP in BP control has been
shown, suggesting vasodilation via increases in nitric oxide as a
pathophysiological mechanism [86].
Moreover, the CYP/sEH-derived metabolites of omega 3 PUFA
are involved in angiogenesis regulation, at minimum in retinal and
tumoral vascularization as follows: omega-3 epoxide have anti-
angiogenic properties [87–89],  whereas sEH-derived diols may
exert pro-angiogenic action [90].  Contrarily, several studies on ani-
mal  models revealed that EETs were linked to angiogenesis [91–93].
Finally, EPA and DHA epoxides, along with EETs, exert anti-
inflammatory actions [78,80,94]. Thus, our hypothesis maintains
that the cardioprotective effects of Omega-3 FA may be explained,
at least partially, by the replacement of AA-derived EETs by the
more effective EPA- and DHA-derived EEQs and EDPs.
Because no reports are available concerning the biological role of
20-HEPE and 22-HDoHE in  hemodynamic modulation in  humans,
the question of whether they share or perhaps antagonize the vaso-
constrictor action of 20-HETE remains unanswered.
4. Metabolic interactions between omega-3 and omega-6
PUFA
The wide range of the metabolic pathways and biological effects
of omega-3 FA makes it difficult to completely understand the clini-
cal role of omega-3 FA and their metabolites, which remain a matter
of debate. The overall picture is  complicated by the possible inter-
actions with other nutrients and dietary compounds that are far
from being completely elucidated.
First, consideration should be given to  the competition of
omega-3 FA with omega-6 FA for the binding with several enzymes.
ALA competes with LA for metabolism by delta-6 desaturase and
the subsequent enzymes of the pathway, leading to the forma-
tion of EPA and AA, respectively [1]. The COX pathway catalyzes
the production of prostanoids, such as the pro-thrombotic TXA2
and the anti-thrombotic PGI2, starting from AA. The counter-
parts derived from EPA exert more potent antiaggregatory (TXA3
and PGI3) and weaker pro-inflammatory actions (LTB5) [59]. The
anti-inflammatory effect of omega-3 is further explained by  a
novel family of compounds, the so-called protectins, resolvins and
maresins [95].
Indeed, previous studies have demonstrated that many iso-
forms of CYP enzymes convert EPA and DHA with equal or even
higher metabolic capacities compared to  AA and notably, they show
largely different regioselectivity [77].  In animal models, EPA and
DHA have been demonstrated to  replace AA in  membrane phospho-
lipids and concomitantly, clear modification exists in  the balance
of their metabolites with a tissue-specific effect. In rats fed with
EPA +  DHA supplements, the endogenous formation of EETs, EEQs
and EDPs was  shifted in favor of EPA and DHA metabolites with
different rates in  the various tissues, e.g., in  the heart, the EET:
EEQ: EDP ratio shifted from 87:0:13 to  27:18:55, whereas the
modification was in  the same direction but with different rates
in other tissues, like kidney and liver; only in brain the changes
were slight [96].  Additionally, 20-HETE decreased after EPA +  DHA
supplementation with a  concomitant increase in 20-HEPE and 22-
HDoHE [96]. An interventional study in humans tested the effect
of EPA + DHA supplements on the Omega-3 Index and on the bal-
ance of metabolite production. The results were consistent with
the previous study on rats as follows: after increasing doses of
omega-3 FA supplements for 8 weeks in 20 healthy volunteers,
the Omega-3 Index increased in a  time- and dose-dependent man-
ner and a  large increase was also observed in  the EPA-derived
metabolites via CYP epoxygenase. In particular, the ratio between
the metabolites and precursors of fatty acids indicated that CYP
epoxygenase was 8.6 times more efficient in EPA metabolism and
2.2  times more efficient in DHA metabolism compared to AA.
Regarding the CYP-hydroxygenase pathway, no modification in  20-
HETE and 22-HDoHE were observed, whereas the concentration
of 20-HEPE increased 3-fold. Notably, the effect on COX and LOX
remained rather weak with respect to  that on the CYP epoxyge-
nases, indicating that CYP-dependent metabolites of EPA and DHA
are the putative mediators of the cardiovascular protective effects
of omega-3 FA [97].
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Fig. 2. Main AA, EPA and DHA metabolites via CYP450/sEH and their principal actions [113–118].
The  metabolites of AA, EPA and DHA are constituted by  different isomers, which are listed in  the figure; the illustrated structure refers to the underlined isomer.
AA:  Arachidonic acid; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; EETs: Epoxyeicosatrienoic acids; 20-HETE: hydroxyeicosatetraenoic acid; EEQs:
epoxyeicosatetraenoic acids; 20-HEPE: 20-hydroxyeicosapentaenoic acids; EDPs: epoxydocosapentaenoic acids; DHET: dihydroxyeicosatrienoic acid; DiHETE: dihydrox-
yeicosatetraenoic acid; DHDP: dihydroxydocosapentaenoic acid; 22-HDoHE: 22-hydroxydocosahexaenoic acid.
5. Possible confounders when evaluating the clinical effect
of omega-3 FA
Notwithstanding the understanding of the biological mecha-
nisms of action of EPA, DHA and their metabolites, uncertainty
remains about their clinical efficacy. In  particular, as stated pre-
viously, a discrepancy between observational and interventional
studies is often evident. A  possible confounder is the use of vegeta-
bles oils as controls, and often olive oil, which may  in turn exert
protective actions [98–100], thus partially blurring the positive
effect of omega-3 FA.
Moreover, the protective effect was  reported in trials using
fish as the source of omega-3 FA compared to EPA + DHA supple-
ments, although supplementation may  easily provide higher doses
of omega-3 FA than those supplied by fish in the diet. In our opinion,
further investigation is warranted to elucidate this complex issue,
that is, whether a favorable effect of omega-3 FA  should be  traced to
these dietary fatty acids alone or  to the overall sources of these com-
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pounds. Fish in particular is rich in many macro and micronutrients
[101], such as vitamin D, branched chain amino acids, potassium
and magnesium, that may  act independently or even synergistically
with omega-3 FA [102–104].  Furthermore, the intake of each indi-
vidual nutrient should be considered in  assessing the whole dietary
pattern as follows: the intake of fish  may  be generally assumed
to indicate healthier dietary habits and in particular, higher fish
consumption is usually associated with higher vegetable and fruit
intake and lower intake of meat, which are  altogether often related
to a higher socioeconomical status [105,106].Thus, the effects of
Omega-3 FA may  indeed derive from the interaction with other
nutrients, such as fiber, olive oil  or  antioxidants, which are consid-
ered to play a role in  cardiovascular risk reduction [107]. Indeed,
some recent studies and meta-analyses have called attention to  the
role of dietary models rather than single nutrients with respect to
cardiovascular risk. A systematic review of prospective studies or
RCT investigating the relationship between dietary exposure and
coronary heart disease identified vegetables, nuts, fish and marine
Omega-3 FA, fruit, fiber and the “Mediterranean diet” as protec-
tive factors, whereas trans fatty acids and foods with high glycemic
indexes were recognized as harmful factors [108,110]. A recent RCT
showed that a Mediterranean diet supplemented with olive oil or
nuts, which are rich in omega-6, reduced the incidence of major
cardiovascular events (myocardial infarction, stroke or death from
cardiovascular causes) in primary prevention [109].
In our opinion, greater attention should be directed addition-
ally to the balance between the different types of fatty acids.
Undeniably, consideration should be given to the profound change
in dietary patterns during the last century in  Western countries
whereby the omega-6: omega-3 FA balance shifted from a  ratio of
1–2:1 in the Paleolithic era to the current 15–20:1 ratio [111]. This
unbalance and the changes in the dietary intake of vegetables, fiber,
nuts and berries are considered key factors in the development of
cardiovascular disease.
Finally, the response to omega-3 FA supplements, in  terms of
modifications of their metabolite profile, appears to show a  high
grade of inter-individual variability [112], which may  consequently
obscure the clinical effect of omega-3 supplementation in large
clinical trials.
6. Conclusion
In conclusion, evidence from observational studies, in particular,
support the recommendation to enhance the intake of omega-
3 FA, primarily from seafood, to reduce cardiovascular risk. We
believe that their protective effects are probably mediated by an
improvement in  vascular function with a consequent antihyper-
tensive effect due to  the shift of CYP-derived metabolites to  more
potent vasodilatory agents. Persistent debate remains concerning
the best source of omega-3 FA and whether the beneficial effects
may  be explained only by their specific biological actions or rather
by their complex balance and interactions with a  variety of nutri-
ents and polymorphisms of genes implicated in  their metabolic
pathways.
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